

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
7 November 2002 (07.11.2002)

PCT

(10) International Publication Number
WO 02/088095 A1(51) International Patent Classification⁷: **C07D 239/70**,
A61K 31/517, C07D 487/04, 471/04, A61K 31/519, A61P
25/00

(21) International Application Number: PCT/GB02/02029

(22) International Filing Date: 30 April 2002 (30.04.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0110569.1	30 April 2001 (30.04.2001)	GB
0110567.5	30 April 2001 (30.04.2001)	GB
0110570.9	30 April 2001 (30.04.2001)	GB
0117399.6	17 July 2001 (17.07.2001)	GB
0117420.0	17 July 2001 (17.07.2001)	GB
0117401.0	17 July 2001 (17.07.2001)	GB
0203201.9	11 February 2002 (11.02.2002)	GB
0206834.4	22 March 2002 (22.03.2002)	GB

(71) Applicants (*for all designated States except US*): **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB). **DI FABIO, Romano** [IT/IT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37100 Verona (IT).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): **CAPELLI, Anna, Maria** [IT/IT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37100 Verona (IT). **MARCHIONNI, Chiara** [IT/IT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37100 Verona (IT). **MICHELI, Fabrizio**[IT/IT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37100 Verona (IT). **PASQUARELLO, Alessandra** [IT/IT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37100 Verona (IT). **PERINI, Benedetta** [IT/IT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37100 Verona (IT). **ST-DENIS, Yves** [CA/IT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37100 Verona (IT).(74) Agent: **GIDDINGS, Peter, John**; GlaxoSmithKline, Corporate Intellectual Property (CN925.1), 980 Great West Road, Brentford, Middlesex TW8 9GS (GB).(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: FUSED PYRIMIDINES AS ANTAGONISTS OF THE CORTICOTROPIN RELEASING FACTOR (CRF)



(I)

(57) Abstract: The present invention provides compounds of formula (I) including stereoisomers, prodrugs and pharmaceutically acceptable salts or solvates thereof wherein the variables are as defined in the description, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions mediated by corticotropin-releasing factor (CRF).

FUSED PYRIMIDINES AS ANTAGONISTS OF THE CORTICOTROPIN RELEASING FACTOR (CRF)

The present invention relates to bicyclic derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their use in therapy.

5

The first corticotropin-releasing factor (CRF) was isolated from ovine hypothalami and identified as a 41-amino acid peptide (Vale et al., Science 213: 1394-1397,1981).

CRF has been found to produce profound alterations in endocrine, nervous and immune system function. CRF is believed to be the major physiological regulator of the basal and stress-release of adrenocorticotrophic hormone ("ACTH"), Bendorphin and other proopiomelanocortin ("POMC")-derived peptides from the anterior pituitary (Vale et al., Science 213: 1394-1397,1981).

10

In addition to its role in stimulating the production of ACTH and POMC, CRF appears to be one of the pivotal central nervous system neurotransmitters and plays a crucial role in integrating the body's overall response to stress.

15

Administration of CRF directly to the brain elicits behavioral, physiological and endocrine responses identical to those observed for an animal exposed to a stressful environment.

Accordingly, clinical data suggests that CRF receptor antagonists may represent novel antidepressant and/or anxiolytic drugs that may be useful in the treatment of the neuropsychiatric disorders manifesting hypersecretion of CRF.


20

The first CRF receptor antagonists were peptides (see, e.g., Rivier et al., U.S. Patent No. 4,605,642; Rivier et al., Science 224: 889,1984). While these peptides established that CRF receptor antagonists can attenuate the pharmacological responses to CRF, peptide CRF receptor antagonists suffer from the usual drawbacks of peptide therapeutics including lack of stability and limited oral activity. More recently, small molecule CRF receptor antagonists have been reported.

25

WO 95/10506 describes inter alia compounds of general formula (A) with general CRF antagonist activity


30



wherein Y may be CR29; V and Z may be nitrogen and carbon, R3 may correspond to an amine derivative and R4 may be taken together with R29 to form a 5-membered ring and is -CH(R28) when R29 is-CH(R30). There are no specific disclosures of compounds corresponding to this definition.

35


WO 95/33750 also describes compounds of general formula (B) having CRF antagonistic activity,



in which A and Y may be nitrogen and carbon and B may correspond to an amine derivative.

- 5 The compounds comprised in general formula (B), whose preparation is included in the Experimental Part of WO 95/33750, are characterized by having always at least one substituent other than hydrogen on the atoms different from Y in the 5-membered ring, when saturated.

- 10 WO 98/08846 describes compounds of general formula (C) having CRF antagonistic activity,



wherein A may be nitrogen, G may be nitrogen or carbon, B may be an amino derivative and the other groups have the meanings as defined.


- 15 The compounds comprised in general formula (C), in which A may be nitrogen and B may be an amino derivative, whose preparation is included in the Experimental Part WO 98/08846, are characterized by having always at least a substituent other than hydrogen on the atoms different from G in the 6-membered ring, when saturated.

- 20 Due to the physiological significance of CRF, the development of biologically-active small molecules having significant CRF receptor binding activity and which are capable of antagonizing the CRF receptor remains a desirable goal. Such CRF receptor antagonists would be useful in the treatment of endocrine, psychiatric and neurologic conditions or illnesses, including stress-related disorders in general.

- 25 While significant strides have been made toward achieving CRF regulation through administration of CRF receptor antagonists, there remains a need in the art for effective small molecule CRF receptor antagonists. There is also a need for pharmaceutical compositions containing such CRF receptor antagonists, as well as methods relating to the use thereof to treat, for example, stress-related disorders. The present invention fulfills these needs, and
- 30 provides other related advantages.

In particular the invention relates to novel compounds which are potent and specific antagonists of corticotropin-releasing factor (CRF) receptors.

- 35 The present invention provides compounds of formula (I) including stereoisomers, prodrugs and pharmaceutically acceptable salts or solvates thereof



wherein

- | | | |
|----|-----------------------------------|---|
| 5 | R | is aryl or heteroaryl, each of which may be substituted by 1 to 4 groups selected from:
halogen, C1-C6 alkyl, C1-C6 alkoxy, halo C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halo C1-C6 alkoxy, -COR ₄ , nitro, -NR ₉ R ₁₀ cyano, and a group R ₅ ; |
| 10 | R ₁ | is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halo C1-C6 alkyl, halo C1-C6 alkoxy, halogen, NR ₉ R ₁₀ or cyano; |
| | R ₂ | is hydrogen, C3-C7 cycloalkyl, or a group R ₆ ; |
| | R ₃ | has the same meanings as R ₂ , but R ₂ and R ₃ may not be simultaneously hydrogen; or |
| 15 | R ₂ and R ₃ | together with N form a saturated or unsaturated heterocycle, which may be substituted by 1 to 3 R ₇ groups; or |
| | R ₂ and R ₃ | together with N form a 5-10 membered heteroaryl group, in which the 5-membered heteroaryl group contains at least one heteroatom selected from oxygen, sulphur or nitrogen and the 6-10 membered heteroaryl group contains from 1 to 3 nitrogen atoms and wherein said 5-10 membered heteroaryl may be substituted by 1 to 3 R ₇ groups; |
| 20 | R ₄ | is a C1-C4 alkyl, -OR ₉ or -NR ₉ R ₁₀ ; |
| | R ₅ | is a 5-6 membered heterocycle, which may be saturated or may contain one to three double bonds, and which may be substituted by 1 or more R ₈ groups; |
| 25 | R ₆ | is a C1-C6 alkyl that may be substituted by one or more groups selected from: C3-C7 cycloalkyl, C1-C6 alkoxy, haloC1-C6 alkoxy, hydroxy, haloC1-C6 alkyl; |
| 30 | R ₇ | is a group R ₅ , a group R ₆ , C3-C7 cycloalkyl, C1-C6 alkoxy, hydroxy, halogen, nitro, cyano, C(O)NR ₉ R ₁₀ , phenyl which may be substituted by 1 to 4 R ₈ groups; |
| | R ₈ | is C1-C6 alkyl, halo C1-C2 alkyl, halogen, nitro, C1-C6 alkoxy or cyano; |
| 35 | R ₉ | is hydrogen or C1-C6 alkyl; |
| | R ₁₀ | independently from R ₉ , has the same meanings; |
| | X | is carbon or nitrogen; |
| | n | is 1 or 2. |

Acid addition salts of the free base amino compounds of the present invention may be prepared by methods well known in the art, and may be formed from organic and inorganic acids. Suitable organic acids include maleic, malic, fumaric, benzoic, ascorbic, succinic, methanesulfonic, p-toluensulfonic, acetic, oxalic, propionic, tartaric, salicylic, citric, gluconic, lactic, mandelic, cinnamic, aspartic, stearic, palmitic, glycolic, glutamic, and benzenesulfonic acids. Suitable inorganic acids include hydrochloric, hydrobromic, sulfuric, phosphoric, and nitric acids. Thus, the term "pharmaceutically acceptable salt" of structure (I) is intended to encompass any and all acceptable salt forms.

10 The solvates may, for example, be hydrates.

References hereinafter to a compound according to the invention include both compounds of formula (I) and their pharmaceutically acceptable acid addition salts together with pharmaceutically acceptable solvates.

15

In addition, prodrugs are also included within the context of this invention. Prodrugs are any covalently bonded carriers that release a compound of structure (I) in vivo when such prodrug is administered to a patient. Prodrugs are generally prepared by modifying functional groups in a way such that the modification is cleaved, either by routine manipulation or in vivo, yielding the parent compound. Prodrugs include, for example, compounds of this invention wherein hydroxy, amine or sulfhydryl groups are bonded to any group that, when administered to a patient, cleaves to form the hydroxy, amine or sulfhydryl groups. Thus, representative examples of prodrugs include (but are not limited to) acetate, formate and benzoate derivatives of alcohol, sulfhydryl and amine functional groups of the compounds of structure (I). Further, in the case of a carboxylic acid (-COOH), esters may be employed, such as methyl esters, ethyl esters, and the like.

20

25

With regard to stereoisomers, the compounds of structure (I) may have chiral centers and may occur as recemates, racemic mixtures and as individual enantiomers or diastereomers. All such isomeric forms are included within the present invention, including mixtures thereof. Furthermore, some of the crystalline forms of the compounds of structure (I) may exist as polymorphs, which are included in the present invention.

30

The term C1-C6 alkyl as used herein as a group or a part of the group refers to a linear or branched alkyl group containing from 1 to 6 carbon atoms; examples of such groups include methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert butyl, pentyl or hexyl.

35

The term C3-C7 cycloalkyl group means a non aromatic monocyclic hydrocarbon ring of 3 to 7 carbon atom such as, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl; while unsaturated cycloalkyls include cyclopentenyl and cyclohexenyl, and the like.

40

The term halogen refers to a fluorine, chlorine, bromine or iodine atom.

The term halo C1-C6 alkyl, or halo C1-C2 alkyl means an alkyl group having one or more carbon atoms and wherein at least one hydrogen atom is replaced with halogen such as for example a trifluoromethyl group and the like.

5 The term C2-C6 alkenyl defines straight or branched chain hydrocarbon radicals containing one or more double bond and having from 2 to 6 carbon atoms such as, for example, ethenyl, 2-propenyl, 3-butenyl, 2-butenyl, 2-pentenyl, 3-pentenyl, 3-methyl-2-butenyl or 3-hexenyl and the like.

10 The term C1-C6 alkoxy group may be a linear or a branched chain alkoxy group, for example methoxy, ethoxy, propoxy, prop-2-oxy, butoxy, but-2-oxy or methylprop-2-oxy and the like.

The term halo C1-C6 alkoxy group may be a C1-C6 alkoxy group as defined before substituted with at least one halogen, preferably fluorine, such as OCHF₂, or OCF₃.

15 The term C2-C6 alkynyl defines straight or branched chain hydrocarbon radicals containing one or more triple bond and having from 2 to 6 carbon atoms including acetylenyl, propynyl, 1-butylnyl, 1-pentynyl, 3-methyl-1-butylnyl and the like.


20 The term aryl means an aromatic carbocyclic moiety such as phenyl, biphenyl or naphthyl.

The term heteroaryl means an aromatic heterocycle ring of 5 to 10 members and having at least one heteroatom selected from nitrogen, oxygen and sulfur, and containing at least 1 carbon atom, including both mono-and bicyclic ring systems.


25 Representative heteroaryls include (but are not limited to) furyl, benzofuranyl, thiophenyl, benzothiophenyl, pyrrolyl, indolyl, isoindolyl, azaindolyl, pyridyl, quinolynyl, isoquinolynyl, oxazolyl, isooxazolyl, benzoxazolyl, pyrazolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, cinnolynyl, phthalazinyl, triazolyl, tetrazolyl, and quinazolinyl.

35 The term heterocycle means a 5 to 7-membered monocyclic, or 7-to 14-membered polycyclic, heterocycle ring which is either saturated, unsaturated or aromatic, and which contains from 1 to 4 heteroatoms independently selected from nitrogen, oxygen and sulfur, and wherein the nitrogen and sulfur heteroatoms may be optionally oxidized, and the nitrogen heteroatom may be optionally quaternized, including bicyclic rings in which any of the above heterocycles are fused to a benzene ring as well as tricyclic (and higher) heterocyclic rings. The heterocycle may be attached via any heteroatom or carbon atom. Heterocycles include heteroaryls as defined above. Thus, in addition to the aromatic heteroaryls listed above,
40 heterocycles also include (but are not limited to) morpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyridinyl, tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, and the like.

The term 5-6 membered heterocycle means, according to the above definition, a 5-6 monocyclic heterocyclic ring which is either saturated, unsaturated or aromatic, and which contains from 1 to 4 heteroatoms independently selected from nitrogen, oxygen and sulfur, and wherein the nitrogen and sulfur heteroatoms may be optionally oxidized, and the nitrogen heteroatom may be optionally quaternized. Heterocycles include heteroaryls as defined above. The heterocycle may be attached via any heteroatom or carbon atom. Thus, the term include (but are not limited to) morpholinyl, pyridinyl, pyrazinyl, pyrazolyl, triazolyl, imidazolyl, oxadiazolyl, oxazolyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyridinyl, tetrahydroprimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, and the like.



(Ia)



(Ib)


In one preferred embodiment in which n is 1 according to the definition of the compounds of formula (I) above, the CRF receptor antagonists of this invention have structure (Ia), and, when n is 2, then the CRF receptor antagonists of this invention have structure (Ib), wherein R, R₁, R₂ and R₃ are defined as above.

Further representative compounds of this invention include compounds of general formula (I), (Ia) and (Ib), in which

R₂ and R₃ together with N form a saturated or unsaturated heterocycle, which may be substituted by 1 to 3 R₇ groups or

R₂ and R₃ together with N form a 5-10 membered heteroaryl group, in which the 5-membered heteroaryl group contains at least one heteroatom selected from oxygen, sulphur or nitrogen and the 6-10 membered heteroaryl group contains from 1 to 3 nitrogen atoms and wherein said 5-10 membered heteroaryl may be substituted by 1 to 3 R₇ groups, such R₇ groups are defined as above.

Depending upon the choice of X, the CRF receptor antagonists of this invention include compounds having the following structures (Ia-1), (Ia-2), (Ib-1), (Ib-2).



(Ia-1)


(Ia-2)

(Ib-1)

(Ib-2)

More specific embodiments of the invention include, but are not limited to, compounds of general formula (Ia-1), (Ia-2), (Ib-1), and (Ib-2), in which the group NR_2R_3 represents a secondary amine or a tertiary amine.


- 5 In particular compounds of formula (1-1), (1-2), (1-3), (1-4), (1-5), (2-1), (2-2), (2-3), (3-1), (3-2), (3-3), (4-1), (4-2) are preferred




- 10 in which R_1 , R_2 , R have the meanings as defined before. Examples of such compounds are reported in the Experimental Part.

- Further specific embodiments of the invention include, but are not limited to, compounds of the formula (Ia-1), (Ia-2), (Ib-1) and (Ib-2), in which the group NR_2R_3 represents a 5-6
- 15 membered heterocycle.

In particular compounds of formula (1-6), (1-7), (1-8), (1-9), (1-10), (1-11), (1-12), (2-4), (2-5) and (3-4) are preferred



8



in which R₁, R and R₇ have the meanings as defined before.

Examples of such compounds are reported in the Experimental Part.

5

Even more preferred embodiments of the invention include, but are not limited to, compounds of the formula (I); (Ia), (Ib), (Ic), (Id); (Ia-1), (Ia-2), (Ib-1), (Ib-2), (Ic-1), (Ic-2), (Id-1), (Id-2), (1-1), (1-2), (1-3), (1-4), (1-5), (1-6), (1-7), (1-8), (1-9), (1-10), (1-11), (1-12), (2-1), (2-2), (2-3), (2-4), (2-5), (3-1), (3-2), (3-3), (3-4), (4-1), and (4-2)

10

wherein:

- R₁ is C1-C3 alkyl group or halo C1-C3 alkyl group, preferably methyl or trifluoromethyl;
- R is an aryl group selected from: 2,4-dichlorophenyl, 2-chloro-4-methylphenyl, 2-chloro-4-trifluoromethyl, 2-chloro-4-methoxyphenyl, 2,4,5-trimethylphenyl, 2,4-dimethylphenyl, 2-methyl-4-methoxyphenyl, 2-methyl-4-chlorophenyl, 2-methyl-4-trifluoromethyl, 2,4-dimethoxyphenyl, 2-methoxy-4-trifluoromethylphenyl, 2-methoxy-4-chlorophenyl, 3-methoxy-4-chlorophenyl, 2,5-dimethoxy-4-chlorophenyl, 2-methoxy-4-isopropylphenyl, 2-methoxy-4-trifluoromethylphenyl, 2-methoxy-4-isopropylphenyl, 2-methoxy-4-methylphenyl, 2-trifluoromethyl-4-chlorophenyl, 2,4-trifluoromethylphenyl, 2-trifluoromethyl-4-methylphenyl, 2-trifluoromethyl-4-methoxyphenyl, 2-bromo-4-isopropylphenyl, 4-methyl-6-dimethylaminopyridin-3-yl, 3,5-dichloro-pyridin-2-yl, 2,6-bismethoxy-pyridin-3-yl and 3-chloro-5-trichloromethyl-pyridin-2-yl.

25

Preferred compounds according to the invention are:

[7-(2,4-dichlorophenyl)-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl]-(1-ethyl-propyl)amine (1-1-1);

[7-(2-bromo-4-isopropylphenyl)-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl]-(1-ethylpropyl)amine (1-1-2);

30

[7-(2,4-bis-trifluoromethylphenyl)-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl]-(1-propylbutyl)amine (1-1-3);

butyl-[7-(2,4-dichlorophenyl)-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]-pyrimidin-4-yl]ethylamine (1-2-1);

35

[7-(2-bromo-4-isopropylphenyl)-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl]-butylethylamine (1-2-2);

butyl-[7-(2-chloro-4-trifluoromethylphenyl)-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl]ethylamine (1-2-3);

- [7-(2,4-bis-trifluoromethylphenyl)-2-methyl-6,7-dihydro-5*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]-butylethylamine (1-2-4);
- [7-(2-chloro-4-trifluoromethylphenyl)-2-methyl-6,7-dihydro-5*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]cyclopropylmethylpropylamine (1-4-1);
- 5 [7-(2,4-bis-trifluoromethylphenyl)-2-methyl-6,7-dihydro-5*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]-cyclopropylmethylpropylamine (1-4-2);
- [7-(2-bromo-4-isopropylphenyl)-2-methyl-6,7-dihydro-5*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]-cyclopropylmethylpropylamine (1-4-3);
- cyclopropylmethyl[7-(2,4-dichlorophenyl)-2-methyl-6,7-dihydro-5*H*-pyrrolo[2,3-*d*]
- 10 pyrimidin-4-yl]propylamine (1-4-4);
- 7-(2,4-dichlorophenyl)-4-(2-ethyl-piperidin-1-yl)-2-methyl-6,7-dihydro-5*H*-pyrrolo[2,3-*d*]pyrimidine (1-6-3);
- 7-(2,4-dichlorophenyl)-4-[(2*R*,5*R*)-2,5-dimethylpyrrolidin-1-yl]-2-methyl-6,7-dihydro-5*H*-pyrrolo[2,3-*d*]pyrimidine (1-7-3);
- 15 7-(2,4-dichlorophenyl)-2-methyl-4-(3-thiazol-2-yl-pyrazol-1-yl)-6,7-dihydro-5*H*-pyrrolo[2,3-*d*]pyrimidine (1-10-1);
- 7-(2,4-bis-trifluoromethylphenyl)-2-methyl-4-(3-thiazol-2-yl-pyrazol-1-yl)-6,7-dihydro-5*H*-pyrrolo[2,3-*d*]pyrimidine (1-10-2);
- 7-(2-bromo-4-isopropylphenyl)-2-methyl-4-(3-trifluoromethyl-pyrazol-1-yl)-6,7-dihydro-5*H*-pyrrolo[2,3-*d*]pyrimidine (1-10-6);
- 20 7-(2,4-dichlorophenyl)-4-(5-isopropyl-3-trifluoromethyl-pyrazol-1-yl)-2-methyl-6,7-dihydro-5*H*-pyrrolo[2,3-*d*]pyrimidine and 7-(2,4-dichlorophenyl)-4-(3-isopropyl-5-trifluoromethyl-pyrazol-1-yl)-2-methyl-6,7-dihydro-5*H*-pyrrolo[2,3-*d*]pyrimidine (1-10-7);
- 7-(2,4-dichlorophenyl)-4-(3-ethyl-5-trifluoromethylpyrazol-1-yl)-2-methyl-6,7-dihydro-5*H*-pyrrolo[2,3-*d*]pyrimidine (1-10-9);
- 25 7-(2,4-dichlorophenyl)-4-(3,5-dimethylpyrazol-1-yl)-2-methyl-6,7-dihydro-5*H*-pyrrolo[2,3-*d*]pyrimidine (1-10-11);
- 7-(2,4-dichlorophenyl)-4-(3-dimethoxymethyl-pyrazol-1-yl)-2-methyl-6,7-dihydro-5*H*-pyrrolo[2,3-*d*]pyrimidine (1-10-15);
- 30 7-(2,4-dichlorophenyl)-4-(3-ethyl-5-trifluoromethylpyrazol-1-yl)-2-methyl-6,7-dihydro-5*H*-pyrrolo[2,3-*d*]pyrimidine (1-10-16);
- 4-(4-bromo-3-methyl-pyrazol-1-yl)-7-(2,4-dichlorophenyl)-2-methyl-6,7-dihydro-5*H*-pyrrolo[2,3-*d*]pyrimidine (1-10-18);
- 4-(4-bromopyrazol-1-yl)-7-(2,4-dichlorophenyl)-2-methyl-6,7-dihydro-5*H*-pyrrolo[2,3-*d*]pyrimidine (1-10-19);
- 35 7-(2,4-dichlorophenyl)-4-[3-(4-chlorophenyl)-pyrazol-1-yl]-2-methyl-6,7-dihydro-5*H*-pyrrolo[2,3-*d*]pyrimidine (1-10-23);
- 7-(2,4-dichlorophenyl)-4-[3-(2-nitrophenyl)-pyrazol-1-yl]-2-methyl-6,7-dihydro-5*H*-pyrrolo[2,3-*d*]pyrimidine (1-10-24);
- 40 7-(2,6-dimethoxy-pyridin-3-yl)-2-methyl-4-(3-thiazol-2-yl-pyrazol-1-yl)-6,7-dihydro-5*H*-pyrrolo[(2,3-*d*)]pyrimidine (1-10-30);
- 7-(2,4-bis-trifluoromethyl-phenyl)-2-methyl-4-(3-morpholyn-4-yl-pyrazol-1-yl)-6,7-dihydro-5*H*-pyrrolo[(2,3-*d*)]pyrimidine (1-10-31);

7-(2,4-bis-trifluoromethyl-phenyl)-2-methyl-4-(3-pyridin-3-yl-pyrazol-1-yl)-6,7-dihydro-5H-pyrrolo[(2,3-d)]pyrimidine (1-10-32);

7-(2,4-bis-trifluoromethyl-phenyl)-2-methyl-4-(3-pyrazin-2-yl-pyrazol-1-yl)-6,7-dihydro-5H-pyrrolo[(2,3-d)]pyrimidine (1-10-33);

5 7-(2,4-bis-trifluoromethyl-phenyl)-2-methyl-4-(3-oxazol-5-yl-pyrazol-1-yl)-6,7-dihydro-5H-pyrrolo[(2,3-d)]pyrimidine (1-10-40);

7-(2,4-dichlorophenyl)-2-methyl-4-(3-trifluoromethyl-(1,2,4)triazol-1-yl)-6,7-dihydro-5H-pyrrolo(2,3-d)pyrimidine (1-11-2);

10 butyl-[7-(2,4-dichlorophenyl)-2-methyl-6,7-dihydro-5H-cyclopentapyrimidin-4-yl]-ethyl-amine (2-2-5);

cyclopropylmethyl[7-(2,4-dimethoxyphenyl)-2-methyl-6,7-dihydro-5H-cyclopentapyrimidin-4-yl]-propyl-amine (2-3-5);

cyclopropylmethyl[7-(2,4-dichlorophenyl)-2-methyl-6,7-dihydro-5H-cyclopentapyrimidin-4-yl]-propylamine (2-3-6);

15 7-(2,4-dichlorophenyl)-4-[(2R,5R)-2,5-dimethylpyrrolidin-1-yl]-2-methyl-6,7-dihydro-5H-cyclopentapyrimidine (2-5-1);

7-(2,4-dichlorophenyl)-4-[(2R,5R)-2,5-dimethylpyrrolidin-1-yl]-2-methyl-6,7-dihydro-5H-cyclopentapyrimidine (2-5-2);

20 [8-(2,4-bis-trifluoromethylphenyl)-2-methyl-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-4-yl](1-propylbutyl)amine (3-1-1);

butyl-[8-(2,4-dichlorophenyl)-2-methyl-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-4-yl]-ethylamine (3-1-2);


cyclopropylmethyl[8-(2,4-dichlorophenyl)-2-methyl-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-4-yl]propylamine (3-1-3).

25

In general, the compounds of structure (I) may be made according to the organic synthesis techniques known to those skilled in this field, as well as by the representative methods set forth in the Examples.

30 Compounds of formula (I), and salts and solvates thereof, may be prepared by the general methods outlined hereinafter. In the following description, the groups R, R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈, R₉, R₁₀, and n have the meanings as previously defined for compounds of formula (I) unless otherwise stated.


35 Compounds of formula (I) may be prepared by reaction of a compound of formula (II), wherein L is a leaving group selected in a group consisting from halogens (preferably chlorine) or reactive residue of a sulphonic acid (e.g. mesylate, tosylate, triflate).



with the amino compound NHR_2R_3 (III). The reaction can be optionally carried out in an aprotic solvent such as NN-dimethylformamide in the presence, if desired, of a strong base such as sodium hydride and with heating.


Alternatively, when NR_2R_3 represents a cycle, compounds (II) may react with hydrazine to give the corresponding hydrazino derivatives and then they may be cyclised to the desired final compound (I).

Compounds of formula (II), wherein X is nitrogen are equivalent to compounds of formula (IIa), may be prepared by cyclisation of a compound of formula (IV), wherein p is 1 or 2 and Ra is a suitable protecting group for the amino group. The activation of the hydroxy group is performed by conversion into a suitable leaving group, such as mesylate. The deprotection of the amino protecting group can be performed, for example, using an acid, such as trifluoroacetic acid, in an aprotic solvent, like dichloromethane.



The cyclisation may take place in an aprotic solvent such as tetrahydrofuran and in the presence of a tertiary amine such as triethyl amine.


Compounds of formula (IV), wherein p is 1 are equivalent to compounds of formula (IVa), may be prepared by oxidation of a compound of formula (V) to the corresponding aldehyde of formula (VI), followed by reduction to alcohol.



The oxidation is carried out, for example, with ozone at low temperature, e.g. -78°C , in a solvent such as dichloromethane.

The reduction takes places using for example sodium borohydride in a solvent such as methanol.

Compounds of formula (IV), wherein p is 2, may be prepared by reduction of an aldehyde of formula (VII) with a suitable reducing agent, such as diisobutylaluminumhydride in usual conditions (aprotic solvent such as dichloromethane at low temperature, e.g. 0°C).



Compounds of formula (VII) may be prepared by Wittig reaction of a compound of formula (VIII) with a phosphorus ylide (IX), wherein R_6 is phenyl or a phenyl derivative, followed by hydrolysis with an acid (e.g. hydrochloric acid). The reaction is carried out in an aprotic solvent such as acetonitrile or an ether such as tetrahydrofuran.


5

Aldehydes (VIII) may be obtained by oxidation of a compound of formula (V).

The oxidation is carried out in the presence of ozone at low temperature, e.g. -78°C , in a solvent such as dichloromethane.

10

Alternatively compounds of formula (IVc) may be prepared by reaction of a compound of formula (IX) with amine (X), in which R_b is a suitable protecting group for the hydroxy group.




The reaction preferably takes place in an aprotic solvent such as dichloromethane or N,N -dimethyl formamide optionally in the presence of a tertiary amine (e.g. triethylamine).

15

Compounds (IVc) may be subjected to deprotection and then activation of the hydroxy group (e.g. mesylate) as described before followed by in situ cyclisation

Compounds of formula (IX) may be prepared by reduction of an ester of formula (XI), with a suitable reducing agent, such as diisobutylaluminumhydride.


20



Compounds of formula (XI) may be prepared from compounds of formula (XII) by conversion of the hydroxy groups in suitable leaving groups. For example, the halogenation reaction may be carried out using conventional methods known in the art. Thus, for example,

the reaction may be carried out by treatment with $\text{PO}(\text{Hal})_3$, wherein Hal is preferably chlorine.


- 5 Compounds of formula (V), may be prepared by reaction of a compound of formula (XIII) with amine (X), followed by protection of the amino group.



The reaction preferably takes place in an aprotic solvent such as tetrahydrofuran, dichloromethane or N,N-dimethylformamide in the presence of a strong base such sodium hydride and by heating.

10

Compounds of formula (II), wherein X is a carbon atom are equivalent to compounds of formula (IIb), may be prepared by conversion of the hydroxy group of compounds of formula (XIV) into a leaving group.



- 15 For example, the halogenation reaction may be carried out using conventional methods known in the art. Thus, e.g. the reaction may be carried out by treatment with $\text{PO}(\text{Hal})_3$, wherein Hal is preferably chlorine.

Compounds of formula (XIV) may be prepared by cyclisation of a compound of formula (XVI) with a salt (e.g. hydrochloride) of acetamidine (XV).

- 20 The reaction is carried out in the presence of an alkaline organic base C1-C4 (e.g. sodium methoxide) in a solvent such as methyl alcohol.


Compounds of formula (XVI) may be prepared by cyclisation of a compound of formula (XVII), in which R_{11} is a linear or branched C1-C4 alkyl and p is defined as above.

- 25 The cyclisation may be carried out in the presence of an organic alkaline C1-C4 alkoxyde (e.g. sodium methoxide) in an aprotic solvent such as N,N-dimethylformamide or toluene and at temperature ranging from 20° to 100°C.


Compounds of formula (XVII) can be prepared by reaction of a compound of formula (XVIII) with a compound of formula (XIX), wherein L is preferably a bromine or iodine atom.

The reaction is carried out in aprotic solvent such as an ether e.g. tetrahydrofuran at low temperature, e.g. -78°C , and in the presence of a strong base such as Lithium diisopropylamide.

Alternatively, compounds of formula (XVIa), corresponding to compounds of formula (XVI) when n is 2, may be prepared according to the following scheme from cyclohexanone. It can be converted to its reactive enol ether (such as a triflate, as in *Lai and McAllister; Synth. Commun.*; 29; 3; 1999; p 409), then coupled with an organic metallic derivative of R (such as a boronic acid derivative, as in *Suzuki, Akira; J.Org.Chem.*; 58; 8; 1993; p 2201) to give the substituted cyclohexene, which can be epoxidised, using for example chloroperoxybenzoic acid, and converted to a carbonyl group under acidic conditions (using, for example, sulfuric acid, as in *Crotti, P. et al; Tetrahedron*; 29; 1973; p 155). The ketone thus obtained can be carboxymethylated, using a strong base (such as lithium diisopropyl amide) and an acylating agent (such as ethyl cyanoformate).



In another alternative, compounds of formula (XVIb), corresponding to compounds of formula (XVI) when n is 1, may be prepared according to the following scheme from 2-chloro-cyclopentanone, by reaction with a suitable Grignard derivative of the group R and then carboxymethylated as described above.



Compounds of formula (XI), (XII), (XIII), (XVIII) and (XIX) are either known compounds or may be prepared by analogous methods to those described for known compounds.

Pharmaceutical acceptable salts may also be prepared from other salts, including other pharmaceutically acceptable salts, of the compound of formula (I) using conventional methods.

The compounds of formula (I) may readily be isolated in association with solvent molecules by crystallisation or evaporation of an appropriate solvent to give the corresponding solvates.

When a specific enantiomer of a compound of general formula (I) is required, this may be obtained for example by resolution of a corresponding enantiomeric mixture of a compound of formula (I) using conventional methods. Thus the required enantiomer may be obtained from the racemic compound of formula (I) by use of chiral HPLC procedure.

The subject invention also includes isotopically-labeled compounds, which are identical to those recited in formulas I and following, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into

5 compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, iodine, and chlorine, such as ^3H , ^{11}C , ^{14}C , ^{18}F , ^{123}I and ^{125}I .

Compounds of the present invention and pharmaceutically acceptable salts of said compounds that contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of the present invention. Isotopically-labeled compounds of the present

10 invention, for example those into which radioactive isotopes such as ^3H , ^{14}C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., ^3H , and carbon-14, i.e., ^{14}C , isotopes are particularly preferred for their ease of preparation and detectability.

^{11}C and ^8F isotopes are particularly useful in PET (positron emission tomography), and ^{125}I isotopes are particularly useful in SPECT (single photon emission computerized

15 tomography), all useful in brain imaging. Further, substitution with heavier isotopes such as deuterium, i.e., ^2H , can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased *in vivo* half-life or reduced dosage requirements and, hence, may be preferred in some circumstances. Isotopically labeled compounds of formula I and following of this invention can generally be prepared by carrying out the procedures

20 disclosed in the Schemes and/or in the Examples below, by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.

The CRF receptor antagonists of the present invention demonstrate activity at the CRF receptor site including CRF 1 and CRF 2 receptors and may be used in the treatment of

25 conditions mediated by CRF or CRF receptors.

The effectiveness of a compound as a CRF receptor antagonist may be determined by various assay methods. Suitable CRF antagonists of this invention are capable of inhibiting the specific binding of CRF to its receptor and antagonizing activities associated with CRF. A

30 compound of structure (I) may be assessed for activity as a CRF antagonist by one or more generally accepted assays for this purpose, including (but not limited to) the assays disclosed by DeSouza et al. (J. Neuroscience 7: 88,1987) and Battaglia et al. (Synapse 1: 572,1987).

The CRF receptors-binding assay was performed by using the homogeneous technique of scintillation proximity (SPA). The ligand binds to recombinant membrane preparation expressing the CRF receptors which in turn bind to wheatgerm agglutinin coated SPA beads. In the Experimental Part will be disclosed the details of the experiments.

35

With reference to CRF receptor binding affinities, CRF receptor antagonists of this invention have a K_i less than 10 μM . In a preferred embodiment of this invention, a CRF receptor antagonist has a K_i comprised in a range from 0.1 nM and 10 μM .

40

In a more preferred embodiment the value of K_i is less than 1 μM and more preferably less than 0.1 μM . As set forth in greater detail below, the K_i values of representative compounds of this invention were assayed by the methods set forth in Example 5.

Preferred compounds having a K_i of less than 1 μm are compound numbers 1-10-9, 1-10-11, 1-10-16, 1-10-19, 1-10-23, 1-10-24, 1-10-31, 1-10-32, 1-10-33, 1-10-40, 1-11-2, 2-2-5, 2-3-5, 2-3-6 and 2-5-2.

5 More preferred compounds having a K_i less than 0.1 μm are compound numbers 1-1-1, 1-1-2, 1-1-3, 1-2-1, 1-2-2, 1-2-3, 1-2-4, 1-4-1, 1-4-2, 1-4-3, 1-4-4, 1-6-3, 1-7-3, 1-10-1, 1-10-2, 1-10-6, 1-10-7, 1-10-15, 1-10-18, 1-10-30, 2-5-1, 3-1-1, 3-2-1 and 3-3-1.

10 Compounds of the invention may be useful in the treatment of central nervous system disorders where CRF receptors are involved. In particular in the treatment or prevention of major depressive disorders including bipolar depression, unipolar depression, single or recurrent major depressive episodes with or without psychotic features, catatonic features, melancholic features, atypical features or postpartum onset, the treatment of anxiety and the treatment of panic disorders. Other mood disorders encompassed within the term major depressive disorders include dysthymic disorder with early or late onset and with or without atypical features, neurotic depression, post traumatic stress disorders and social phobia; 15 dementia of the Alzheimer's type, with early or late onset, with depressed mood; vascular dementia with depressed mood; mood disorders induced by alcohol, amphetamines, cocaine, hallucinogens, inhalants, opioids, phencyclidine, sedatives, hypnotics, anxiolytics and other substances; schizoaffective disorder of the depressed type; and adjustment disorder with depressed mood. Major depressive disorders may also result from a general medical condition including, but not limited to, myocardial infarction, diabetes, miscarriage or abortion, etc.

25 Compounds of the invention are useful as analgesics. In particular they are useful in the treatment of traumatic pain such as postoperative pain; traumatic avulsion pain such as brachial plexus; chronic pain such as arthritic pain such as occurring in osteo-, rheumatoid or psoriatic arthritis; neuropathic pain such as post-herpetic neuralgia, trigeminal neuralgia, segmental or intercostal neuralgia, fibromyalgia, causalgia, peripheral neuropathy, diabetic neuropathy, chemotherapy-induced neuropathy, AIDS related neuropathy, occipital neuralgia, geniculate neuralgia, glossopharyngeal neuralgia, reflex sympathetic dystrophy, phantom limb pain; various forms of headache such as migraine, acute or chronic tension headache, temporomandibular pain, maxillary sinus pain, cluster headache; odontalgia; cancer pain; pain of visceral origin; gastrointestinal pain; nerve entrapment pain; sport's injury pain; dysmenorrhoea; menstrual pain; meningitis; arachnoiditis; musculoskeletal pain; low back pain e.g. spinal stenosis; prolapsed disc; sciatica; angina; ankylosing 35 spondylitis; gout; burns; scar pain; itch; and thalamic pain such as post stroke thalamic pain.

40 Compounds of the invention are also useful for the treatment of dysfunction of appetite and food intake and in circumstances such as anorexia, anorexia nervosa and bulimia.

Compounds of the invention are also useful in the treatment of sleep disorders including dysomnia, insomnia, sleep apnea, narcolepsy, and circadian rhythmic disorders.

Compounds of the invention are also useful in the treatment or prevention of cognitive disorders. Cognitive disorders include dementia, amnesic disorders and cognitive disorders not otherwise specified.

- 5 Furthermore compounds of the invention are also useful as memory and/or cognition enhancers in healthy humans with no cognitive and/or memory deficit.

10 Compounds of the invention are also useful in the treatment of tolerance to and dependence on a number of substances. For example, they are useful in the treatment of dependence on nicotine, alcohol, caffeine, phencyclidine (phencyclidine like compounds), or in the treatment of tolerance to and dependence on opiates (e.g. cannabis, heroin, morphine) or benzodiazepines; in the treatment of cocaine, sedative ipnotic, amphetamine or amphetamine-related drugs (e.g. dextroamphetamine, methylamphetamine) addiction or a combination thereof.

15 Compounds of the invention are also useful as anti-inflammatory agents. In particular they are useful in the treatment of inflammation in asthma, influenza, chronic bronchitis and rheumatoid arthritis; in the treatment of inflammatory diseases of the gastrointestinal tract such as Crohn's disease, ulcerative colitis, inflammatory bowel disease (IBD) and non-steroidal anti-inflammatory drug induced damage; inflammatory diseases of the skin such as herpes and eczema; inflammatory diseases of the bladder such as cystitis and urge incontinence; and eye and dental inflammation.

20 Compounds of the invention are also useful in the treatment of allergic disorders, in particular allergic disorders of the skin such as urticaria, and allergic disorders of the airways such as rhinitis.

25 Compounds of the invention are also useful in the treatment of emesis, i.e. nausea, retching and vomiting. Emesis includes acute emesis, delayed emesis and anticipatory emesis. The compounds of the invention are useful in the treatment of emesis however induced. For example, emesis may be induced by drugs such as cancer chemotherapeutic agents such as alkylating agents, e.g. cyclophosphamide, carmustine, lomustine and chlorambucil; cytotoxic antibiotics, e.g. dactinomycin, doxorubicin, mitomycin-C and bleomycin; anti-metabolites, e.g. cytarabine, methotrexate and 5- fluorouracil; vinca alkaloids, e.g. etoposide, vinblastine and vincristine; and others such as cisplatin, dacarbazine, procarbazine and hydroxyurea; and combinations thereof; radiation sickness; radiation therapy, e.g. irradiation of the thorax or abdomen, such as in the treatment of cancer; poisons; toxins such as toxins caused by metabolic disorders or by infection, e.g. gastritis, or released during bacterial or viral gastrointestinal infection; pregnancy; vestibular disorders, such as motion sickness, vertigo, dizziness and Meniere's disease; post-operative sickness; gastrointestinal obstruction; reduced gastrointestinal motility; visceral pain, e.g. myocardial infarction or peritonitis; migraine; increased intracranial pressure; decreased intracranial pressure (e.g. altitude sickness); opioid analgesics, such as morphine; and gastro-oesophageal reflux disease, acid indigestion, over-indulgence of food or drink, acid stomach, sour stomach,

30
35
40

waterbrash/regurgitation, heartburn, such as episodic heartburn, nocturnal heartburn, and meal-induced heartburn and dyspepsia.

5 Compounds of the invention are of particular use in the treatment of gastrointestinal disorders such as irritable bowel syndrome (IBS); skin disorders such as psoriasis, pruritis and sunburn; vasospastic diseases such as angina, vascular headache and Reynaud's disease; cerebral ischaemia such as cerebral vasospasm following subarachnoid haemorrhage; fibrosing and collagen diseases such as scleroderma and eosinophilic fascioliasis; disorders related to immune enhancement or suppression such as systemic lupus erythematosus and
10 rheumatic diseases such as fibrositis; and cough.

Compounds of the invention are of particular use in the treatment of depressive states, in the treatment of anxiety and of panic disorders.

15 Depressive states include major depressive disorders including bipolar depression, unipolar depression, single or recurrent major depressive episodes with or without psychotic features, catatonic features, melancholic features, atypical features or postpartum onset, dysthymic disorder with early or late onset and with or without atypical features, neurotic depression and social phobia; dementia of the Alzheimer's type, with early or late onset, with depressed mood; vascular dementia with depressed mood; mood disorders induced by alcohol,
20 amphetamines, cocaine, hallucinogens, inhalants, opioids, phencyclidine, sedatives, hypnotics, anxiolytics and other substances; schizoaffective disorder of the depressed type.

Compounds of the invention are useful for the treatment of neurotoxic injury which follows cerebral stroke, thromboembolic stroke, hemorrhagic stroke, cerebral ischemia, cerebral
25 vasospasm, hypoglycemia, hypoxia, anoxia, perinatal asphyxia cardiac arrest.

The invention therefore provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof for use in therapy, in particular in human medicine.

30 There is also provided as a further aspect of the invention the use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof in the preparation of a medicament for use in the treatment of conditions mediated by CRF.

35 In an alternative or further aspect there is provided a method for the treatment of a mammal, including man, in particular in the treatment of condition mediated by CRF, comprising administration of an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or a solvate thereof.

40 It will be appreciated that reference to treatment is intended to include prophylaxis as well as the alleviation of established symptoms.

Compounds of formula (I) may be administered as the raw chemical but the active ingredient is preferably presented as a pharmaceutical formulation.

Accordingly, the invention also provides a pharmaceutical composition which comprises at least one compound of formula (I) or a pharmaceutically acceptable salt thereof and formulated for administration by any convenient route. Such compositions are preferably in a form adapted for use in medicine, in particular human medicine, and can conveniently be formulated in a conventional manner using one or more pharmaceutically acceptable carriers or excipients.

Thus compounds of formula (I) may be formulated for oral, buccal, parenteral, topical (including ophthalmic and nasal), depot or rectal administration or in a form suitable for administration by inhalation or insufflation (either through the mouth or nose).

For oral administration, the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium starch glycollate); or wetting agents (e.g. sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g. sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g. lecithin or acacia); non-aqueous vehicles (e.g. almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g. methyl or propyl-p-hydroxybenzoates or sorbic acid). The preparations may also contain buffer salts, flavouring, colouring and sweetening agents as appropriate.

Preparations for oral administration may be suitably formulated to give controlled release of the active compound.

For buccal administration the composition may take the form of tablets or formulated in conventional manner.

The compounds of the invention may be formulated for parenteral administration by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form e.g. in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use.

The compounds of the invention may be formulated for topical administration in the form of ointments, creams, gels, lotions, pessaries, aerosols or drops (e.g. eye, ear or nose drops). Ointments and creams may, for example, be formulated with an aqueous or oily base with the

addition of suitable thickening and/or gelling agents. Ointments for administration to the eye may be manufactured in a sterile manner using sterilised components.

5 Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents, thickening agents, or colouring agents. Drops may be formulated with an aqueous or non-aqueous base also comprising one or more dispersing agents, stabilising agents, solubilising agents or suspending agents. They may also contain a preservative.

10 The compounds of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, e.g. containing conventional suppository bases such as cocoa butter or other glycerides.

15 The compounds of the invention may also be formulated as depot preparations. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds of the invention may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

20 For intranasal administration, the compounds of the invention may be formulated as solutions for administration via a suitable metered or unitary dose device or alternatively as a powder mix with a suitable carrier for administration using a suitable delivery device.

25 A proposed dose of the compounds of the invention is 1 to about 1000mg per day. It will be appreciated that it may be necessary to make routine variations to the dosage, depending on the age and condition of the patient and the precise dosage will be ultimately at the discretion of the attendant physician or veterinarian. The dosage will also depend on the route of administration and the particular compound selected.

30 Thus for parenteral administration a daily dose will typically be in the range of 1 to about 100 mg, preferably 1 to 80 mg per day. For oral administration a daily dose will typically be within the range 1 to 300 mg e.g. 1 to 100 mg.

EXAMPLES

35 In the Intermediates and Examples unless otherwise stated:

40 Melting points (m.p.) were determined on a Gallenkamp m.p. apparatus and are uncorrected. All temperatures refers to °C. Infrared spectra were measured on a FT-IR instrument. Proton Magnetic Resonance (¹H-NMR) spectra were recorded at 400 MHz, chemical shifts are reported in ppm downfield (δ) from Me₄Si, used as internal standard, and are assigned as singlets (s), doublets (d), doublets of doublets (dd), triplets (t), quartets (q) or multiplets (m). Column chromatography was carried out over silica gel (Merck AG Darmstadt, Germany). The following abbreviations are used in text: EtOAc = ethyl acetate, cHex = cyclohexane,

CH₂Cl₂ = dichloromethane, Et₂O = diethyl ether, DMF = N,N'-dimethylformamide, DIPEA=N,N-diisopropylethylamine MeOH = methanol, Et₃N = triethylamine, TFA = trifluoroacetic acid, THF = tetrahydrofuran, DIBAL-H=diisobutylaluminium hydride, DMAP=dimethylaminopyridine, LHMDs= lithiumhexamethyldisilazane; Tlc refers to thin layer chromatography on silica plates, and dried refers to a solution dried over anhydrous sodium sulphate; r.t. (RT) refers to room temperature.

Intermediate 1

5-Allyl-4,6-dihydroxy-2-methyl-pyrimidine

- 10 Sodium (2 g) was added portionwise to anh. MeOH (100 mL), at 0°C, under N₂. After consumption of metallic sodium, acetamidine hydrochloride (8.4 g) was added. After 10 min. of stirring the precipitated NaCl was filtered off. Diethyl-allyl-malonate (6 mL) was added to the solution of free acetamidine and the mixture was stirred at r.t. for 2 days. The reaction mixture was concentrated and then neutralized with concentrated hydrochloric acid, filtered
- 15 to obtain the title compound (4.25 g) as a white solid.
NMR (¹H, DMSO-d₆): δ 11.61 (bs, 2H), 5.75 (m, 1H), 4.92 (m, 1H), 4.84 (m, 1H), 2.94 (d, 2H), 2.19 (s, 3H).
MS (m/z): 166 [M]⁺.

20 Intermediate 2

5-Allyl-4,6-dichloro-2-methylpyrimidine

- Intermediate 1 (6.0 g) was mixed with POCl₃ (70 mL) and heated at reflux for 3 hr. The resulting solution was cooled to r.t. and poured slowly into ice/water (600 mL) with vigorous stirring. The product was extracted with EtOAc (3x50 mL). The combined organic extracts
- 25 were washed with saturated NaHCO₃ (60 mL) and brine (40 mL), dried over anh. Na₂SO₄, filtered and concentrated *in vacuo*. The crude oil was purified by flash chromatography (silica gel, cHex 100%) to give the title compound (4.78 g) as a light yellow oil.
NMR (¹H, CDCl₃): δ 5.85 (m, 1H), 5.15 (dq, 1H), 5.11 (dq, 1H), 3.61 (dt, 2H), 2.67 (s, 3H).
MS (m/z): 202 [M]⁺.2Cl; 167 [MH-Cl]⁺.1Cl.

30

Intermediate 3

(5-Allyl-6-chloro-2-methylpyrimidin-4-yl)-(2,4-dichlorophenyl)amine

- A solution of 2,4-dichloroaniline (798 mg) in anh. THF (22 mL), under N₂, was treated with sodium hydride (95% in mineral oil, 393 mg) at 0°C for 15 min before intermediate 2 (1 g)
- 35 was added. The mixture was heated at reflux for 3 hr and quenched with water (20 mL). The product was extracted with ethyl acetate (2x20mL), dried over anh. Na₂SO₄ and concentrated *in vacuo*. The crude product was purified by flash chromatography (silica gel, EtOAc/cHex 4:96) to give the title compound (725 mg) as a white solid.
NMR (¹H, CDCl₃): δ 8.52 (d, 1H), 7.40 (d, 1H), 7.27 (dd, 1H), 7.21 (bs, 1H), 5.90 (m, 1H), 5.26 (m, 2H), 3.58 (m, 2H), 2.57 (s, 3H).
- 40 MS (m/z): 327 [M]⁺, 3Cl.

Intermediate 4

(5-Allyl-6-chloro-2-methylpyrimidin-4-yl)-(2,4-dichlorophenyl) carbamic acid tert-butyl ester

To a solution of intermediate 3 (146 mg) in anh. CH₂Cl₂ (11 mL), under N₂, was added (Boc)₂O (194 mg) and DMAP (cat). The reaction mixture was stirred at r.t. for 18 hr. The solution was diluted with water (10 mL) and extracted with EtOAc (3x15 mL). The combined organic extracts were dried over anh. Na₂SO₄, filtered and concentrated to dryness *in vacuo*. Flash chromatography of the crude product (silica gel, cHex/EtOAc 95:5) gave the title compound (164 mg) as a colorless oil.

¹H NMR (CDCl₃): δ 7.47 (d, 1H), 7.20 (dd, 1H), 7.17 (d, 1H), 5.75 (tq, 1H), 5.05 (dd, 1H), 4.97 (dd, 1H), 3.52 (d, 2H), 2.58 (s, 3H), 1.44 (s, 9H).

IR (nujol, cm⁻¹): 1729.

MS (*m/z*): 428 [MH]⁺, 3Cl; 372 [MH-tBu+H]⁺, 328 [MH-Boc+H]⁺

15 Intermediate 5

[6-Chloro-5-(2-hydroxyethyl)-2-methylpyrimidin-4-yl]-(2,4-dichlorophenyl)carbamic acid tert-butyl ester

A solution of intermediate 4 (160 mg) in CH₂Cl₂ (9 mL) and CH₃OH (1 mL) was ozonized (5g.h⁻¹) at -78°C for 10 min. When all the allyl pyrimidine had disappeared (according to TLC), the reaction mixture was first flushed with oxygen and then with nitrogen for 20 min. To the cooled reaction mixture was added NaBH₄ (56 mg) and the temperature was allowed to warm up to r.t.. The solution was stirred for 3 hr at r.t.. It was then diluted with water (10 mL) and extracted with CH₂Cl₂ (3x10 mL). The combined organic extracts were dried over anh. Na₂SO₄, filtered and concentrated to dryness *in vacuo*. The crude product was purified by flash chromatography (silica gel, cHex/EtOAc 85/15) to give the title compound (120 mg) as a white solid.

¹H NMR (CDCl₃): δ 7.49 (d, 1H), 7.37 (d, 1H), 7.23 (dd, 1H), 3.93 (q, 2H), 3.05 (t, 2H), 2.59 (s, 3H), 1.89 (bs, 1H), 1.45 (s, 9H).

IR (nujol, cm⁻¹): 3430, 1717.

30 MS (*m/z*): 432 [MH]⁺, 3Cl; 454 [MH+Na]⁺, 332 [MH-Boc+H]⁺

Intermediate 6

Methanesulfonic acid 2-{4-tert-butoxycarbonyl-(2,4-dichlorophenyl)amino]-6-chloro-2-methylpyrimidin-5-yl}ethyl ester

35 To a solution of intermediate 5 (337 mg) in anh. CH₂Cl₂ (15 mL), at r.t, under N₂, was added Et₃N (545 μl) and CH₃SO₂Cl (120 μl). The reaction mixture was stirred at r.t. for 18 hr. Water (15 mL) and EtOAc (15mL) were added, the phases were separated and the aqueous layer was extracted with additional EtOAc (2x15 mL). The combined organic extracts were washed with H₂O (20 mL), dried over anh. Na₂SO₄, filtered and concentrated *in vacuo*. The crude product was purified by flash chromatography (silica gel, cHex/EtOAc 75:25) to give the title compound (327 mg) as a white foam.

¹H NMR (CDCl₃): δ 7.49 (d, 1H), 7.34 (d, 1H), 7.26 (m, 1H), 4.52 (t, 2H), 3.24 (t, 2H), 2.98 (s, 3H), 2.58 (s, 3H), 1.45 (s, 9H).

40 MS (*m/z*): 510 [MH]⁺, 3Cl; 532 [MH+Na]⁺, 454 [MH-tBu+H]⁺, 410 [MH-Boc+H]⁺

Intermediate 7

Methanesulfonic acid 2-[4-chloro-6-(2,4-dichlorophenylamino)-2-methylpyrimidin-5-yl]-ethyl ester

- 5 A solution of intermediate 6 (327 mg) in 20% TFA in CH₂Cl₂ (10 mL) was stirred at r.t. for 2 hr. The solvent was removed *in vacuo* and the residue was partitioned between EtOAc (10 mL) and sat. aq. NaHCO₃ (10 mL), and the layers were separated. The aqueous layer was extracted with EtOAc (3x10 mL), and the combined organic extracts were dried over anh. Na₂SO₄, filtered and concentrated to dryness *in vacuo* to deliver the title compound (224 mg) as white solid.

10 NMR (¹H, CDCl₃): δ 8.39 (d, 1H), 7.49 (d, 1H), 7.44 (bs, 1H), 7.34 (dd, 1H), 4.56 (t, 2H), 3.28 (t, 2H), 3.03 (s, 3H), 2.61 (s, 3H).

MS (*m/z*): 410 [MH]⁺, 3Cl.

15 Intermediate 8

4-Chloro-7-(2,4-dichlorophenyl)-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-*d*] pyrimidine

- To a solution of intermediate 7 (224 mg) in anh. THF (10 mL) was added, at r.t., under N₂, NaH (95% mineral oil, 20 mg). The reaction was stirred for 2 hr at r.t.. The solution was diluted with water (10 mL) and extracted with ethyl acetate (2x15 mL). The combined organic extracts were dried over anh. Na₂SO₄, filtered and concentrated to dryness *in vacuo*. The crude product was purified by flash chromatography (silica gel, cHex/EtOAc 75:25) to give the title compound (158 mg) as a white solid.

20 NMR (¹H, CDCl₃): δ 7.51 (s, 1H), 7.33 (m, 2H), 4.04 (t, 2H), 3.21 (t, 2H), 2.44 (s, 3H).

MS (*m/z*): 313[MH]⁺, 3Cl

25

Intermediate 9

(5-Allyl-6-chloro-2-methylpyrimidin-4-yl)-(2-bromo-4-isopropylphenyl)amine

- A solution of 2-bromo-4-isopropyl-aniline (422 mg) in anh. THF (3 mL), under N₂, was treated with sodium hydride (80% in mineral oil, 90 mg) at 0°C for 15 min before intermediate 2 (400 mg) was added. The mixture was heated to reflux for 3 hr and quenched with water (10 mL). The product was extracted with ethyl acetate (2x15mL) and dried over anh. Na₂SO₄. The solids were filtered and the solvent evaporated *in vacuo*. The crude product was purified by flash chromatography (silica gel, EtOAc/cHex 1:99) to give the title compound (360 mg) as a clear oil.

- 30 NMR (¹H, CDCl₃): δ 8.37(d, 1H), 7.41 (d,1H), 7.19 (dd, 1H), 7.14 (bs, 1H), 5.92 (m, 1H), 5.27-5.23 (m, 2H), 3.57 (m, 2H), 2.87 (m, 1H), 2.56 (s, 3H), 1.24 (d, 6H).

MS (*m/z*): 380 [MH]⁺, 1Cl, 1Br.

Intermediate 10

- 40 (5-Allyl-6-chloro-2-methylpyrimidin-4-yl)-(2-bromo-4-isopropylphenyl) carbamic acid tert-butyl ester

To a solution of intermediate 9 (271 mg) in anh. CH₂Cl₂ (2 mL), under N₂, was added (Boc)₂O (218 mg) and DMAP (cat). The reaction was stirred at r.t. for 3 hr. The solution was diluted with water (10 mL) and extracted with CH₂Cl₂ (3x15 mL). The combined organic

extracts were dried over anh. Na₂SO₄, filtered and concentrated to dryness *in vacuo*. Flash chromatography of the crude product (silica gel, cHex/EtOAc 95:5) gave the title compound (295 mg) as a colorless oil.

NMR (¹H, CDCl₃): δ 7.49 (d, 1H), 7.09 (m, 2H), 5.63 (m, 1H), 4.96 (dd, 2H), 3.50 (d, 2H), 2.87 (m, 1H), 2.60 (s, 3H), 1.43 (s, 9H), 1.23 (d, 6H).

IR (nujol, cm⁻¹): 1729.

MS (*m/z*): 482 [MH]⁺, 1Cl, 1Br.

Intermediate 11

10 (2-Bromo-4-isopropylphenyl)-[6-chloro-5-(2-hydroxyethyl)-2-methylpyrimidin-4-yl]-carbamic acid tert-butyl ester

A solution of intermediate 10 (293 mg) in anh. CH₂Cl₂ (1.8 mL) and CH₃OH (0.2 mL) was ozonized (5g.h⁻¹) at -78°C for 30 min. When all the starting material had disappeared (according to TLC in cHex/EtOAc 7:3), the reaction mixture was first flushed with oxygen and then with nitrogen for 10 min. To the cooled reaction mixture was added NaBH₄ (90 mg) and the temperature was allowed to warm up to 22°C. The solution was stirred for 3 hr at r.t.. The solution was diluted with water (10 mL) and extracted with CH₂Cl₂ (3x10 mL). The combined organic extracts were dried over anh. Na₂SO₄, filtered and concentrated to dryness *in vacuo*. The crude product was purified by flash chromatography (silica gel, cHex/EtOAc

20 85:15) to give the title compound (260 mg) as a clear oil.

NMR (¹H, CDCl₃): δ 7.49 (d, 1H), 7.25 (d, 1H), 7.12 (dd, 1H), 3.84 (m, 2H), 3.02 (t, 2H), 2.88 (m, 1H), 2.61 (s, 3H), 1.8 (bt, 1H), 1.45 (s, 9H), 1.23 (d, 6H).

IR (nujol, cm⁻¹): 1725, 1708.

MS (*m/z*): 486 [MH]⁺, 1Cl, 1Br.

25

Intermediate 12

Methanesulfonic acid 2-[4-(2-bromo-4-isopropylphenylamino)-6-chloro-2-methylpyrimidin-5-yl]ethyl ester

To a solution of intermediate 11 (261 mg) in anh. CH₂Cl₂ (5 mL), at r.t., under N₂, was added Et₃N (380 μl) and CH₃SO₂Cl (84 μl). The reaction was stirred at r.t. for 18 hr. Water (15 mL) and CH₂Cl₂ (15 mL) were added, the phases were separated and the aqueous layer was extracted with additional CH₂Cl₂ (2x15 mL). The combined organic extracts were dried over anh. Na₂SO₄, filtered and concentrated *in vacuo*. The residue was dissolved in 20% TFA in CH₂Cl₂ (2 mL) and was stirred at r.t. for 2 hr. The solvent was removed *in vacuo* and the residue was taken up in EtOAc (10 mL) and saturated NaHCO₃ (10 mL), and the layers were separated. The aqueous layer was extracted with CH₂Cl₂ (3x10 mL), and the combined organic extracts were dried over anh. Na₂SO₄, filtered and concentrated to dryness *in vacuo* to deliver the title compound (231 mg) as yellow solid.

NMR (¹H, CDCl₃): δ 8.24 (d, 1H), 7.45 (d, 1H), 7.32 (bs, 1H), 7.22 (dd, 1H), 4.52 (t, 2H), 3.25 (t, 2H), 2.99 (s, 3H), 2.55 (s, 3H), 2.89 (m, 1H), 1.25 (d, 6H).

MS (*m/z*): 462 [MH]⁺, 1Cl, 1Br.

Intermediate 13

7-(2-Bromo-4-isopropylphenyl)-4-chloro-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine

To a solution of intermediate 12 (231mg) in anh. THF (4 mL) was added, at r.t., under N₂, NaH (80% mineral oil, 23 mg). The reaction mixture was stirred for 2 hr at 60°C. The solution was diluted with water (10 mL) and extracted with EtOAc (2x15 mL). The combined organic extracts were dried over anh. Na₂SO₄, filtered and concentrated to dryness *in vacuo*. The crude product was purified by flash chromatography (silica gel, cHex/EtOAc 90:10) to give the title compound (145 mg) as a white solid.

NMR (¹H, CDCl₃): δ 7.52(d, 1H), 7.24 (m, 2H), 4.02 (t, 2H), 3.19 (t, 2H), 2.91 (m, 1H), 2.43 (s, 3H), 1.26 (d, 6H).

MS (*m/z*): 366[MH]⁺, 1Cl, 1Br.

Intermediate 14

(5-Allyl-6-chloro-2-methylpyrimidin-4-yl)-(2,4-bis-trifluoromethylphenyl)amine

A solution of 2,4-bis-trifluoromethyl-aniline (563mg) in anh. THF (4 mL), at r.t., under N₂, was treated with sodium hydride (80% in mineral oil, 111 mg) at 0°C for 15 min.

Intermediate 2 (500 mg) was then added, the mixture was heated to reflux for 3 hr and quenched with water (10 mL). The aqueous layer was extracted with EtOAc (3x 15mL). The combined organic extracts were dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated *in vacuo*. The crude product was purified by flash chromatography (silica gel, EtOAc/cHex 4:96) to give the title compound (260 mg) as a brown oil.

NMR (¹H, CDCl₃): δ 8.55 (d, 1H), 7.88 (bs, 1H), 7.83 (bd, 1H), 7.19 (bs, 1H), 5.92 (m, 1H), 5.27 (m, 1H), 5.17 (m, 1H), 3.56 (m, 2H), 2.58 (s, 3H).

MS (*m/z*): 396 [MH]⁺.

Intermediate 15

(5-Allyl-6-chloro-2-methylpyrimidin-4-yl)-(2,4-bis-trifluoromethylphenyl)-carbamic acid tert-butyl ester

To a solution of intermediate 14 (435 mg) in anh. CH₂Cl₂ (3 mL), under N₂, at r.t., was added (Boc)₂O (336 mg) and DMAP (cat). The reaction was stirred at r.t. for 40 hr. The solution was diluted with water (10 mL) and extracted with EtOAc (3x15 mL). The combined organic extracts were dried over anh. Na₂SO₄, the solids were filtered and the solvent was evaporated to dryness *in vacuo*. Flash chromatography of the crude product (silica gel, cHex/EtOAc 96:4) gave the title compound as a yellow oil (460 mg).

NMR (¹H, CDCl₃): δ 7.96 (s, 1H), 7.83 (d, 1H), 7.55 (d, 1H), 5.90 (m, 1H), 5.18 (dd, 1H), 5.13 (d, 1H), 3.56 (m, 2H), 2.50 (s, 3H), 1.41 (s, 9H).

IR (nujol, cm⁻¹): 1726.

MS (*m/z*): 496 [MH]⁺; 440 [MH-tBu+H]⁺; 396 [MH-BOC+H]⁺.

Intermediate 16

(2,4-Bis-trifluoromethylphenyl)-[6-chloro-5-(2-hydroxyethyl)-2-methylpyrimidin-4-yl]-carbamic acid tert-butyl ester

A solution of intermediate 15 (460 mg) in anh. CH₂Cl₂ (9 mL) and CH₃OH (1 mL) was ozonized (5g.h⁻¹) at -78°C for 20 min. When all the starting material had disappeared (according to TLC in cHex/EtOAc 7:3), the reaction mixture was first flushed with oxygen and then with nitrogen for 5 min. To the cooled reaction mixture was added NaBH₄ (137 mg)

and the temperature was allowed to warm up to 22°C. The solution was stirred for 1.5 hr at r.t.. It was then diluted with water (10 mL) and extracted with CH₂Cl₂ (3x10 mL). The combined organic extracts were dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated to dryness *in vacuo*. The crude product was purified by flash chromatography (silica gel, cHex/EtOAc 9:1) to give the title compound as white solid (385 mg).

NMR (¹H, CDCl₃): δ 7.96 (bs, 1H), 7.86 (bd, 1H), 7.74 (d, 1H), 4.13-4.05 (m, 2H), 3.07 (td, 2H), 2.49 (s, 3H), 2.21 (bs, 1H), 1.41 (s, 9H).

IR (nujol, cm⁻¹): 1724, 1602.

MS (*m/z*): 500 [MH]⁺; 444 [MH-tBu+H]⁺; 400 [MH-Boc+H]⁺.

Intermediate 17

Methanesulfonic acid 2-[4-(2,4-bis-trifluoromethylphenylamino)-6-chloro-2-methyl-pyrimidin-5-yl]ethyl ester

15 To a solution of intermediate 16 (385 mg) in anh. CH₂Cl₂ (5 mL), at r.t., under N₂, were added Et₃N (540 μl) and CH₃SO₂Cl (120 μl). The reaction was stirred at r.t. for 18 hr. Water (15 mL) and CH₂Cl₂ (15mL) were added and the phases were separated. The aqueous layer was extracted with CH₂Cl₂ (2x15 mL). The combined extracts were dried over anh. Na₂SO₄, the solids filtered and the solvent evaporated *in vacuo*.

20 A solution of the crude product in 20% TFA/CH₂Cl₂ (4mL) was stirred at r.t. for 2 hr. The solvent was removed *in vacuo* and the residue was redissolved in EtOAc (10 mL) and saturated NaHCO₃ (10 mL). The phases were separated and the aqueous layer was extracted EtOAc (3x10 mL). The combined organic extracts were dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated to dryness *in vacuo* to deliver the title compound as a yellow solid (322 mg).

25 NMR (¹H, CDCl₃): δ 9.09 (bs, 1H), 8.12 (d, 1H), 8.09 (s, 1H), 7.74 (d, 1H), 4.36 (t, 2H), 3.23 (t, 2H), 3.15 (s, 3H), 2.19 (s, 3H).

IR (CDCl₃, cm⁻¹): 1346, 1177

MS (*m/z*): 478[MH]⁺.

30

Intermediate 18

7-(2,4-Bis-trifluoromethylphenyl)-4-chloro-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]-pyrimidine

35 To a solution of intermediate 17 (320mg) in anh. THF (8 mL) was added, at r.t., under N₂, NaH (80% mineral oil, 30 mg). The reaction mixture was stirred for 2 hr at 60°C. It was then diluted with water (10 mL) and extracted with EtOAc (2x15 mL). The combined organic extracts were dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated to dryness *in vacuo*. The crude product was purified by flash chromatography (silica gel, cHex/EtOAc 90:10) to give the title compound as a white solid (154 mg).

40 NMR (¹H, CDCl₃): δ 8.04 (s, 1H), 7.93 (s, 1H), 7.53 (d, 1H), 4.00 (t, 2H), 3.24 (t, 2H), 2.42 (s, 3H).

MS (*m/z*): 381[MH]⁺, 1Cl.

Intermediate 19(5-Allyl-6-chloro-2-methylpyrimidin-4-yl)-(2-chloro-4-trifluoromethylphenyl)amine

A solution of 2-chloro-4-trifluoromethylaniline (480mg) in anh. THF (4 mL), under N₂, was treated with sodium hydride (80% in mineral oil, 111 mg) at 0°C for 15 min before intermediate 2 (500 mg) was added. The mixture was heated to reflux for 3 hr and quenched with water (10 mL). The product was extracted with EtOAc (3x 15mL), dried over anh. Na₂SO₄ and concentrated *in vacuo*. The crude product was purified by flash chromatography (silica gel, EtOAc/cHex 5:95) to give the title compound (401 mg) as a white solid.

NMR (¹H, CDCl₃): δ 8.80 (d, 1H), 7.67 (d, 1H), 7.57 (dd, 1H), 7.45 (bs, 1H), 5.92 (m, 1H), 5.31-5.25 (m, 2H), 3.62 (m, 2H), 2.62 (s, 3H).

MS (*m/z*): 362 [MH]⁺, 2Cl.

Intermediate 20(5-Allyl-6-chloro-2-methylpyrimidin-4-yl)-(2-chloro-4-trifluoromethylphenyl)carbamic acid tert-butyl ester

To a solution of intermediate 19 (400 mg) in anh. CH₂Cl₂ (3 mL), under N₂, was added (Boc)₂O (1.4 eq, 336 mg) and DMAP (cat). The reaction was stirred at r.t. for 3 hr. The solution was diluted with water (10 mL) and extracted with EtOAc (3x15 mL). The combined organic extracts were dried over anh. Na₂SO₄, filtered and concentrated to dryness *in vacuo*. Flash chromatography of the crude product (silica gel, cHex/EtOAc 95/5) gave the title compound (462 mg) as a colorless oil.

NMR (¹H, CDCl₃): δ 7.74 (d, 1H), 7.49 (dd, 1H), 7.36 (d, 1H), 5.76 (m, 1H), 5.05-4.93 (m, 2H), 3.53 (d, 2H), 2.60 (s, 3H), 1.46 (s, 9H).

IR (nujol, cm⁻¹): 1723.

MS (*m/z*): 462 [MH]⁺ 2Cl; 406 [MH-tBu+H]⁺; 362 [MH-BOC+H]⁺.

Intermediate 21[6-Chloro-5-(2-hydroxyethyl)-2-methylpyrimidin-4-yl]-(2-chloro-4-trifluoromethylphenyl)-carbamic acid tert-butyl ester

A solution of intermediate 20 (462 mg) in CH₂Cl₂ (9 mL) and CH₃OH (1 mL) was ozonized (5g.h⁻¹) at -78°C for 20 min. When all the allyl pyrimidine had disappeared (according to TLC in cHex/EtOAc 7:3), the reaction mixture was first flushed with oxygen and then with nitrogen for 5 min. To the cooled reaction mixture was added NaBH₄ (148 mg) and the temperature was allowed to warm up to 22°C. The solution was stirred for 1.5 hr at r.t.. It was then diluted with water (10 mL) and extracted with CH₂Cl₂ (3x10 mL). The combined organic extracts were dried over anh. Na₂SO₄, filtered and concentrated to dryness *in vacuo*. The crude product was purified by flash chromatography (silica gel, cHex/EtOAc 90:10) to give the title compound (344 mg) as a white solid.

NMR (¹H, CDCl₃): δ 7.75 (d, 1H), 7.57 (d, 1H), 7.51 (dd, 1H), 3.95 (m, 2H), 3.05 (t, 2H), 2.59 (s, 3H), 1.85 (bs, 1H), 1.46 (s, 9H).

IR (nujol, cm⁻¹): 1718, 1672.

MS (*m/z*): 466 [MH]⁺; 410 [MH-tBu+H]⁺; 366 [MH-Boc+H]⁺

Intermediate 22Methanesulfonic acid 2-[4-chloro-6-(2-chloro-4-trifluoromethylphenylamino)-2-methyl-pyrimidin-5-yl]ethyl ester

5 To a solution of intermediate 21 (344 mg) in anh. CH₂Cl₂ (5 mL), at r.t., under N₂, was added Et₃N (515 µl) and CH₃SO₂Cl (110 µl). The reaction was stirred at r.t. for 18 hr. Water (15 mL) and CH₂Cl₂ (15 mL) were then added, the phases were separated and the aqueous layer was extracted with additional CH₂Cl₂ (2x15 mL). The combined organic extracts were dried over anh. Na₂SO₄, filtered and concentrated *in vacuo*.

10 A solution of the obtained oil in 20% TFA in CH₂Cl₂ (4 mL) was stirred at r.t. for 2 hr. The solvent was removed *in vacuo* and the residue was redissolved in EtOAc (10 mL) and saturated NaHCO₃ (10 mL), and the layers were separated. The aqueous layer was extracted with EtOAc (3x10 mL), and the combined organic extracts were dried over anh. Na₂SO₄, filtered and concentrated to dryness *in vacuo* to deliver the title compound (310 mg) as a yellow solid.

15 NMR (¹H, CDCl₃): δ 8.68 (d, 1H), 7.70 (s, 1H), 7.65 (bs, 1H), 7.58 (d, 1H), 4.55 (t, 2H), 3.27 (t, 2H), 2.99 (s, 3H), 2.61 (s, 3H).

IR (CDCl₃, cm⁻¹): 1323, 1177.

MS (*m/z*): 444 [MH]⁺.

20 Intermediate 23

4-Chloro-7-(2-chloro-4-trifluoromethylphenyl)-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine

25 To a solution of intermediate 22 (310 mg) in anh. THF (8 mL) was added, at r.t., under N₂, NaH (80% mineral oil, 32 mg). The reaction was stirred for 2 hr at 60°C. The solution was diluted with water (10 mL) and extracted with EtOAc (2x15 mL). The combined organic extracts were dried over anh. Na₂SO₄, filtered and concentrated to dryness *in vacuo*. The crude product was purified by flash chromatography (silica gel, cHex/EtOAc 90:10) to give the title compound (197 mg) as a white solid.

30 NMR (¹H, CDCl₃): δ 7.77 (m, 1H), 7.62-7.55 (m, 2H), 4.11 (t, 2H), 3.24 (t, 2H), 2.46 (s, 3H).
MS (*m/z*): 347 [MH]⁺, 312 [M-Cl]⁺.

Intermediate 24[6-Chloro-2-methyl-5-(2-oxoethyl)-pyrimidin-4-yl]-(2,4-dichlorophenyl)carbamic acid-tert-butyl ester

35 A solution of intermediate 4 (300 mg) in CH₂Cl₂ (10 mL) was ozonized (5g.h⁻¹) at -78°C for 10 min. When all the allyl pyrimidine had disappeared (TLC), the reaction mixture was first flushed with oxygen and then with nitrogen for 20 min. To the cooled reaction mixture was added (CH₃)₂S (256 µl) and the temperature was allowed to warm up to 22°C. The solution
40 was stirred for 18 hr at r.t.. The solvent was removed *in vacuo* and the crude product was purified by flash chromatography (silica gel, cHex/EtOAc 18.5:1.5) to give the title compound (250 mg) as a white solid.

NMR (¹H, CDCl₃): δ 9.59 (s, 1H), 7.77+7.57 (d+d, 1H), 7.47+7.37 (dd+dd, 1H), 7.47+7.41 (d+d, 1H), 3.83 (s, 2H), 2.46 (s, 3H), 1.33 (bs, 9H).

IR (nujol, cm^{-1}): 1729.

MS (m/z): 430 $[\text{MH}]^+$, 3Cl; 452 $[\text{MH}+\text{Na}]^+$, 330 $[\text{MH}-\text{Boc}+\text{H}]^+$

Intermediate 25

5 [6-Chloro-5-(3-methoxyallyl)-2-methylpyrimidin-4-yl]-(2,4-dichlorophenyl)carbamic acid *tert*-butyl ester

To a stirred suspension of (methoxy-methyl) triphenylphosphonium chloride (198 mg) in 3 mL of dry THF was added, at 0°C , under N_2 , $n\text{-BuLi}$ 1.6M in hexane (2.8 eq) dropwise. The mixture was allowed to stir for 10 min before a solution of intermediate 24 (83 mg) in dry THF (1mL) was added. The reaction mixture was allowed to warm slowly to r.t. and left stirring for 3 hr. The mixture was quenched with water (5 mL) and extracted with EtOAc (3x 8 mL). The combined organic extracts were dried over anhydrous Na_2SO_4 , filtered and concentrated to dryness *in vacuo*. The crude product was purified by flash chromatography (silica gel, cHex/EtOAc 9:1) to give the title compound (39 mg) as a white solid.

10 NMR (^1H , CDCl_3): δ 7.50-7.47 (s, 1H), 7.28-7.15 (dd/d, 1+1H), 6.37-5.98 (d, 1H, $J_{\text{trans}}=13\text{Hz}$, $J_{\text{cis}}=6\text{Hz}$), 4.58-4.34 (m, 1H, $J_{\text{trans}}=13\text{Hz}$, $J_{\text{cis}}=6\text{Hz}$), 3.55-3.37 (d, 2H), 3.60-3.44 (s, 3H), 2.58-2.53 (s, 3H), 1.55 (s, 9H).

MS (m/z): 458 $[\text{MH}]^+$, 3Cl; 480 $[\text{MH}+\text{Na}]^+$, 402 $[\text{MH}-t\text{Bu}+\text{H}]^+$, 358 $[\text{MH}-\text{Boc}+\text{H}]^+$

20 Intermediate 26

[6-Chloro-2-methyl-5-(3-oxopropyl)pyrimidin-4-yl]-(2,4-dichlorophenyl)carbamic acid *tert*-butyl ester

Intermediate 25 (39 mg) was stirred at r.t. with 4 mL of 4:1 THF-2N HCl for 78 hr. The mixture was then diluted with H_2O (4 mL) and extracted with EtOAc (4x5 mL). The combined organic extracts were dried over anhydrous Na_2SO_4 , filtered and concentrated to dryness *in vacuo*. The crude product was purified by flash chromatography (silica gel, cHex/EtOAc 19:1) to give the title compound (26 mg) as a white solid.

25 NMR (^1H , CDCl_3): δ 9.83 (s, 1H), 7.45 (d, 1H), 7.3-7.2 (d/dd, 2H), 3.00 (m, 2H), 2.92 (m, 2H), 2.55 (s, 3H), 1.41 (s, 9H).

30 MS (m/z): 444 $[\text{MH}]^+$, 3Cl; 466 $[\text{MH}+\text{Na}]^+$, 344 $[\text{MH}-\text{Boc}+\text{H}]^+$

Intermediate 27

[6-Chloro-5-(3-hydroxypropyl)-2-methylpyrimidin-4-yl]-(2,4-dichlorophenyl)carbamic acid *tert*-butyl ester

35 To a solution of intermediate 26 (21mg) in anhydrous CH_3OH (1 mL), at r.t., under N_2 was added NaBH_4 (4 eq). The reaction mixture was stirred for 1 hr. The solvent was removed *in vacuo* and the residue was redissolved in EtOAc (10 mL)/ H_2O (10 mL), and the layers were separated. The aqueous layer was extracted with EtOAc (3x10 mL), and the combined organic extracts were dried over anhydrous Na_2SO_4 , filtered, and concentrated *in vacuo* to afford the title compound (15 mg) as a white solid.

40 NMR (^1H , CDCl_3): δ 7.49 (m, 1H), 7.23 (m, 2H), 3.71 (m, 2H), 2.78 (m, 2H), 2.60 (s, 3H), 1.82 (m, 2H), 1.45 (s, 9H).

MS (m/z): 446 $[\text{MH}]^+$, 3Cl; 468 $[\text{MH}+\text{Na}]^+$, 346 $[\text{MH}-\text{Boc}+\text{H}]^+$, 390 $[\text{MH}-t\text{Bu}+\text{H}]^+$

Intermediate 28

Methanesulfonic acid 3-{4-[*tert*-butoxycarbonyl(2,4-dichlorophenyl)amino]-6-chloro-2-methylpyrimidin-5-yl}propyl ester

To a solution of intermediate 27 (13 mg) in anh. CH₂Cl₂ (1 mL), at r.t., under N₂, was added Et₃N (20 µl) and CH₃SO₂Cl (4 µl). The reaction was stirred at r.t. for 18 hr. The reaction mixture was diluted with water (5 mL) and extracted with EtOAc (3x5 mL). The combined organic extracts were dried over anh. Na₂SO₄, filtered and concentrated *in vacuo*. The crude product was purified by flash chromatography (silica gel, cHex/EtOAc 75/25) to give the title compound (25 mg) as a white solid.

10 NMR (¹H, CDCl₃): δ 7.48 (t, 1H), 7.24 (m, 2H), 4.28 (t, 2H), 3.02 (s, 3H), 2.80 (m, 2H), 2.58 (s, 3H), 2.03 (m, 2H), 1.42 (s, 9H).

MS (*m/z*): 524 [MH]⁺, 3Cl; 546 [MH+Na]⁺, 468 [MH-*t*Bu+H]⁺, 424 [MH-Boc+H]⁺.

Intermediate 29

15 Methanesulfonic acid 3-[4-chloro-6-(2,4-dichlorophenylamino)-2-methylpyrimidin-5-yl]-propyl ester

A solution of intermediate 28 (50 mg) in TFA 20% CH₂Cl₂ (4 mL) was stirred at r.t. for 2 hr. The solvent was removed *in vacuo* and the residue was dissolved in EtOAc (10 mL) and saturated NaHCO₃ (10 mL), and the layers were separated. The aqueous layer was extracted with EtOAc (3x10 mL), and the combined organic extracts were dried over anh. Na₂SO₄, filtered and concentrated to dryness *in vacuo* to deliver the title compound (40 mg) as a white solid.

20 NMR (¹H, CDCl₃): δ 8.49 (d, 1H), 7.44 (d, 2H), 7.31 (dd, 2H), 7.22 (d, 1H), 4.39 (t, 2H), 3.05 (s, 3H), 2.93 (m, 2H), 2.56 (s, 3H), 2.13 (m, 2H).

25 MS (*m/z*): 424[MH]⁺, 3Cl

Intermediate 30

4-Chloro-8-(2,4-dichlorophenyl)-2-methyl-5,6,7,8-tetrahydropyrido[2,3-*d*] pyrimidine

To a solution of intermediate 29 (40 mg) in anh. THF (2mL) was added, at r.t., under N₂, NaH (95%/mineral oil, 5 mg). The reaction mixture was stirred for 2 hr at r.t.. The solution was diluted with water (8 mL) and extracted with EtOAc (2x8 mL). The combined organic extracts were dried over anh. Na₂SO₄, filtered and concentrated to dryness *in vacuo*. The crude product was purified by flash chromatography (silica gel, cHex/EtOAc 9:1) to give the title compound (25 mg) as a white solid.

35 NMR (¹H, CDCl₃): δ 7.51 (d, 1H), 7.32 (dd, 2H), 7.20 (d, 2H), 3.60 (m, 2H), 2.87 (m, 3H), 2.29 (s, 3H), 2.13 (m, 2H).

Intermediate 31

2-(2,4-dichlorophenyl)hexanedioic acid 6-ethyl ester 1-methyl ester

40 To a solution of *i*-Pr₂NH (0.921 mL, 1.2 eq) in anh. THF (22 mL), at 0°C, under N₂, was added a 1.6 M solution of BuLi in hexane (3.42 mL, 1 eq) and the mixture was stirred at 0°C for 10 min. It was then cooled to -78°C and a solution of methyl 2,4-dichlorophenylacetate (1.2 g, 5.478 mmol) in anh. THF (3.3 mL) was added dropwise. The mixture was stirred at -78°C for 45 min before the addition of a solution of ethyl 4-iodobutyrate (1.72 g, 1.3 eq) in

anh. THF (2 mL). The cooling bath was then removed and the mixture was stirred at r.t. for 4 hr. The solvents were evaporated under reduced pressure. The residue was dissolved in CH₂Cl₂, washed with water (2x25 mL) and brine (1x 25 mL) and dried over anh. Na₂SO₄. The solids were filtered and the solvent evaporated. The crude product was purified by flash chromatography (silica gel, cHex/EtOAc 9:1). Mixed fractions were repurified with the same eluent. The title compound was obtained as a pale yellow oil (1.36 g, 4.088 mmol, 75%).

NMR (¹H, CDCl₃): δ 7.63 (d, 1H), 7.44 (dd, 1H), 7.40 (d, 1H), 4.05 (dd, 1H), 4.01 (q, 2H), 3.59 (s, 3H), 2.28 (dt, 2H), 2.01 (m, 1H), 1.74 (m, 1H), 1.47 (m, 1H), 1.35 (m, 1H), 1.14 (t, 3H).

10 IR (film, cm⁻¹): 1736.

MS (*m/z*): 332 [M]⁺, 300 [M-CH₃OH]⁺.

Intermediate 32

3-(2,4-Dichlorophenyl)-2-oxo-cyclopentanecarboxylic acid methyl ester

15 Sodium (376 mg, 4 eq) was added portionwise, under N₂, to anh. MeOH (5 mL). After consumption of metallic sodium, MeOH was evaporated under a nitrogen flux. Anh. toluene (30 mL) was then added to the residue, followed by a solution of intermediate 31 (1.36 g, 4.088 mmol) in anh. toluene (30 mL). The mixture was heated at 90°C for 45 min. The reaction mixture was acidified with glacial AcOH, diluted with EtOAc and washed with
20 water (2x20 mL) and with diluted aqueous NaHCO₃ (2x20 mL) and dried over anh. Na₂SO₄. The solids were filtered and the solvent evaporated. The title compound was obtained as a pale yellow oil (1 g, 3.48 mmol, 85%), as a mixture of two diastereoisomers in a 7:3 ratio and was used in the following step without further purification.

NMR (¹H, CDCl₃): δ 7.38 (m, 1H), 7.19 (m, 1H), 7.06, 7.01, (2d, 1H), 3.93-3.85, 3.78 (m + dd, 1H), 3.79, 3.76 (2s, 3H), 3.49-3.44, 3.40 (m + dd, 1H), 2.60-1.90 (m, 4H).

25 IR (film, cm⁻¹): 1755, 1732.

MS (*m/z*): 286 [M]⁺, 226, 219, 172.

Intermediate 33

4-Hydroxyl-7-(2,4-dichlorophenyl)-2-methyl-6,7-dihydro-5H-cyclopentapyrimidine

30 Sodium (240 mg, 3 eq) was added portionwise to anh. MeOH (6 mL) under N₂. After consumption of metallic sodium acetamidine hydrochloride (1.04 g, 3 eq) was added. After 10 min of stirring the precipitated NaCl was filtered off and washed with anh. MeOH (2 mL). The solution of free acetamidine was added to neat intermediate 32 (1 g, 3.483 mmol) and
35 the mixture was stirred at r.t. for 2 days and then at 70°C for 7 hr. The solvent was evaporated and the crude product was purified by flash chromatography (silica gel, gradient: CH₂Cl₂/MeOH 98:2 to 95:5). The pure title compound was obtained as a white solid (455 mg, 1.54 mmol, 44%).

40 NMR (¹H, DMSO-d₆): δ 12.31 (s, 1H), 7.60 (d, 1H), 7.34 (dd, 1H), 7.04 (d, 1H), 4.54 (t, 1H), 2.75-2.60 (2m, 2H), 2.58-2.50 (m, 1H), 2.20 (s, 3H), 1.80-1.72 (m, 1H).

MS (*m/z*): 295 [MH]⁺.

Intermediate 34

4-Chloro-7-(2,4-dichlorophenyl)-2-methyl-6,7-dihydro-5H-cyclopentapyrimidine

Intermediate 33 (453 mg, 1.535 mmol) was suspended in POCl₃ (16 mL) and the mixture was refluxed for 2.5 hr. The excess POCl₃ was then evaporated and the residue was dissolved in CH₂Cl₂. A few drops of conc. NH₄OH were added and the mixture was diluted with water and CH₂Cl₂. The phases were separated and the aqueous layer was extracted with CH₂Cl₂ (3x20 mL). The combined organic layers were washed with water and brine (2x20 mL) and dried over anh. Na₂SO₄. The solids were filtered and the solvent evaporated. The crude title compound was obtained as a brown oil (378 mg, 1.2 mmol, 79%) and was used in the next step without further purification.

NMR (¹H, CDCl₃): δ 7.44 (d, 1H), 7.19 (dd, 1H), 6.82 (d, 1H), 4.83 (t, 1H), 3.05 (m, 2H), 2.79 (m, 1H), 2.68 (s, 3H), 2.00 (m, 1H).

MS (m/z): 313 [MH]⁺.

Intermediate 35

2,4-Dichloro-1-cyclohex-1-enyl benzene

To a solution of *n*-butyl lithium 1.6M in hexanes (13.8 mL, 1.4 eq) in anh. THF (40 mL) at -78°C, under N₂, was added dropwise HN(iPr)₂ (3.32 mL, 1.5 eq). After stirring for 15 min, a solution of cyclohexanone (1.6 mL, 15.45 mmol) in anh. THF (4 mL) was added. After stirring for 15 min the enolate solution was warmed to room temperature and stirred for 2h. It was then cooled to -78°C and a solution of N-phenyl triflimide (6.1g, 17 mmol, 1.1 eq) in anh. THF (20 mL) was added to the enolate at -78°C. The reaction mixture was warmed to 0°C and stirred for 4h. The resulting solution was poured into water, the volume was reduced under vacuum and the residue was taken up in EtOAc and washed with H₂O (3x25 mL). The organic phase was dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated. The triflate was used as such in the following step.

A mixture of the crude triflate obtained above (3g), 2,4-dichloro-benzeneboronic acid (3.2g, 1.1 eq), 1,1'-bis(diphenylphosphino-ferrocene)PdCl₂ (315mg, 0.025 eq) and K₂CO₃ (4.2 g, 2 eq), in toluene/acetone/water (26/26/6,5 mL) was heated at 80°C for 3h. The mixture was then treated with 1N NaOH (15 mL) and H₂O₂ 30% (10 mL) for 20 min at r.t. to reduce the residual borane. The product was extracted with toluene, washed with brine and dried over anh. Na₂SO₄. The solids were filtered, the solvent was evaporated and the residue was purified by flash chromatography (silica gel, 100% cHex). The title compound was obtained as a clear oil (2.18 g, 9.58 mmol, 62%)

NMR (¹H, DMSO): δ 7.6 (d, 1H), 7.4 (dd, 1H), 7.27 (d, 1H), 5.69 (sett, 1H), 2.24 (m, 2H), 2.16 (m, 2H), 1.72 (m, 2H), 1.69 (m, 2H).

MS (m/z): 226 [M]⁺ 2Cl.

Intermediate 36

1-(2,4-Dichlorophenyl)-7-oxa-bicyclo[4.1.0]heptane

A solution of m-CPBA (2.25g, 3eq) in EtOAc (6 mL) was added dropwise to a stirred solution of intermediate 35 (1g, 4.4 mmol) in EtOAc (6 mL) at 0°C, under N₂. The reaction mixture was stirred at 0°C for 1h and at r.t. for 12h. When the reaction was complete (by t.l.c.) the reaction mixture was washed with 1N NaOH (3x10 mL) and H₂O (2x10 mL). It was then dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated. The title compound was obtained as a clear oil (940 mg, 3.87 mmols, 89%).

NMR (^1H , DMSO): δ 7.60 (m, 1H), 7.39 (m, 2H), 3.09 (t, 1H), 1.93 (m, 4H), 1.39 (m, 4H).
MS (m/z): 242 $[\text{M}]^+ 2\text{Cl}$.

Intermediate 37

5 2-(2,4-Dichlorophenyl)-cyclohexanone

A solution of intermediate 36 (940 mg, 3.8 mmols) in EtOH (5 mL) was treated with conc. H_2SO_4 (1 mL) dissolved in H_2O (1 mL) and EtOH (5 mL). The solution was refluxed for 24 h and the EtOH was evaporated. The residue was dissolved in EtOAc, washed with sat. aq. NaHCO_3 and H_2O . It was then dried over anh. Na_2SO_4 , the solids were filtered and the solvent evaporated. The crude oil was purified by flash chromatography (silica gel, cHex/EtOAc 95:5). The title compound was obtained as a clear solid (345 mg, 1.42 mmol, 37%)

10 NMR (^1H , CDCl_3): δ 7.40 (d, 1H), 7.25 (dd, 1H), 7.15 (d, 1H), 4.06 (dd, 1H), 2.55 (m, 2H), 2.20 (m, 2H), 2.0-1.7 (m, 2H).

15 IR (CDCl_3 , cm^{-1}): 2926, 2854, 1713.

MS (m/z): 242 $[\text{M}]^+ 2\text{Cl}$.

Intermediate 38

3-(2,4-Dichlorophenyl)-2-oxo-cyclohexanecarboxylic acid ethyl ester

20 To a suspension of NaH 80%/oil (48mg, 1.1 eq) in anh. THF (2mL), at 0°C , under N_2 , was added intermediate 37 (350mg, 1.44mmol) dissolved in anh. THF (2.5 mL). After stirring for 15 min, to this solution was added dropwise a solution of LDA 0.5M/THF (3.2mL, 1.1 eq). After 15 min the solution was cooled to -78°C and ethyl cyanoformate (0.16mL, 1.1 eq) was added dropwise. The reaction mixture was stirred at -78°C for 20' and was then poured into

25 water and ice and extracted with CH_2Cl_2 (3x10 mL). The combined organic extracts were dried over anh. Na_2SO_4 , the solids were filtered and the solvent evaporated. The crude oil was purified by flash chromatography (silica gel, cHex/EtOAc 95:5). The title compound was obtained as a clear oil (150mg, 0.48 mmol, 33%) as a mixture of β -keto-ester and its enolic form in a 65:35 ratio.

30 NMR (^1H , DMSO): δ 12.18 (s, 1H), 7.55 (d, 1H), 7.53 (d, 2H), 7.4-7.36 (dd, 2H), 7.32 (d+t, 2H), 7.23 (d, 1H), 4.23 (m, 2H), 4.11 (m, 2H), 4.03 (ta, 1H), 3.84 (ta, 1H), 2.4-1.8 (m, 12H), 1.27 (t+t, 6H).

IR (film, cm^{-1}): 3417, 1653, 1614.

MS (m/z): 314 $[\text{MH}]^+ 2\text{Cl}$.

35

Intermediate 39

8-(2,4-Dichlorophenyl)-2-methyl-5,6,7,8-tetrahydro-quinazolin-4-ol

Sodium (20 mg, 1.84 eq) was added portionwise, under N_2 , to anh. MeOH (2 mL). After consumption of metallic sodium, acetamidine hydrochloride (88 mg, 1.84 eq) was added to

40 the solution. After 10 min the solid NaCl was filtered off and to the clear solution was added intermediate 38 (150 mg, 0.48 mmol) dissolved in anh. MeOH (2 mL). The reaction mixture was stirred at r.t. for 96 h and the solvent was then evaporated. The residue was purified by flash chromatography (silica gel, $\text{CH}_2\text{Cl}_2/\text{MeOH}$ 95:5). The title compound was obtained as a white solid (92mg, 0.30 mmol, 62%).

NMR (^1H , CDCl_3): δ 11.2 (broad, 1H), 7.42 (d, 1H), 7.13 (dd, 1H), 6.72 (d, 1H), 4.34 (t, 1H), 2.65 (m, 1H), 2.56 (m, 1H), 2.34 (s, 3H), 2.07 (m, 1H), 1.92 (m, 1H), 1.72 (m, 1H), 1.65 (m, 1H).

MS (m/z): 309 $[\text{MH}]^+ 2\text{Cl}$

5

Intermediate 40

4-Chloro-8-(2,4-dichlorophenyl)-2-methyl-5,6,7,8-tetrahydroquinazoline

10 Intermediate 39 (95 mg, 0.29 mmol) was dissolved in POCl_3 (3 mL) and the solution was refluxed for 3h. The POCl_3 was evaporated, the residue was dissolved in CH_2Cl_2 and poured into ice and conc. NH_4OH . The organic phase was separated and dried over anh. Na_2SO_4 . The solids were filtered and the solvent evaporated. The crude product was purified by flash chromatography (silica gel, cHex/EtOAc 8:2) to obtain the title compound as a white solid (88mg, 0.27 mmol, 93%).

15 NMR (^1H , CDCl_3): δ 7.42 (d, 1H), 7.13 (dd, 1H), 6.58 (d, 1H), 4.54 (t, 1H), 2.83 (m, 2H), 2.56 (s, 3H), 2.14 (m, 1H), 2.00 (m, 1H), 1.84 (m, 2H).

MS (m/z): 327 $[\text{MH}]^+ 3\text{Cl}$

Intermediate 41

2-(2,4-Dimethoxyphenyl)cyclopentanone

20 A solution of 1-bromo-2,4-dimethoxybenzene (345 μL , 1.2 eq.) in dry THF (0.5 mL) was added dropwise, under N_2 , to a suspension of Mg turnings (64 mg, 1.3 eq.) in dry THF (0.7 mL) and in presence of a catalytic amount of I_2 . The reaction mixture was stirred at reflux for 1 hr and then cooled down to 0°C . To this mixture was added dropwise a solution of 2-chlorocyclopentanone (0.2 mL, 2 mmol) in anh. THF (0.5 mL) and the reaction mixture was
25 heated to reflux for 2 hr. The mixture was allowed to cool at r.t., it was diluted with Et_2O and slowly mixed with ice and 1M HCl. The organic layer was then separated, washed twice with brine and dried over anh. Na_2SO_4 . The solids were filtered and the solvent evaporated. The crude red oil was purified by flash chromatography (silica gel, cHex/EtOAc 8:2) to give the title compound (297 mg, 67%) as a yellow oil.

30 NMR (^1H , CDCl_3): δ 6.97 (d, 1H), 6.44 (m, 2H), 3.78 (s, 3H), 3.74 (s, 3H), 3.30 (dd, 1H), 2.4-2.3 (m, 3H), 2.13-2.04 (m, 2H), 1.86 (m, 1H).

IR (film, cm^{-1}): 1738.

MS (m/z): 220 $[\text{M}]^+$.

35 Intermediate 42

3-(2,4-Dimethoxyphenyl)-2-oxocyclopentanecarboxylic acid methyl ester

To a solution of freshly distilled diisopropylamine (148 μL , 1.2 eq.) in anh. THF (3.5 mL), at 0°C , under N_2 , was added 1.6M $n\text{-BuLi}$ in hexane (660 μL , 1.12 eq) and the resulting mixture was stirred for 10 min and then cooled down at -78°C . A solution of intermediate 41 (195
40 mg, 0.88 mmol) in anh. THF (1 mL) was added dropwise and the reaction was stirred for 15 min. Methyl chloroformate (75 μL , 1.eq.) was then added to the enolate solution and the reaction flask was stirred for 15 min. The cold reaction mixture was poured into 0.5N HCl (10 mL) and diethyl ether (10 mL). The phases were separated and the organic layer was washed with saturated NaHCO_3 , saturated NaCl and it was then dried over anh. Na_2SO_4 . The

solids were filtered and the solvent evaporated. The crude oil was purified by flash chromatography (silica gel, cHex/Et₂O 7:3) and the title compound was obtained as a yellow oil (66 mg, 27%)

NMR (¹H, CDCl₃): δ 6.97 (d, 1H), 6.44-6.42 (m, 2H), 3.8-3.69 (m, 9H), 3.41 (m, 2H), 2.31 (m, 1H), 2.08 (m, 1H).

IR (film, cm⁻¹): 1755, 1728.

MS (*m/z*): 278 [M]⁺.

Intermediate 43

10 7-(2,4-Dimethoxyphenyl)-2-methyl-6,7-dihydro-5H-cyclopentapyrimidin-4-ol

Acetamidine hydrochloride (50 mg, 2.3 eq.) was added to a solution of freshly prepared MeONa (37 mg, 2.3 eq.) in anh. MeOH (1 mL). The resulting suspension was filtered and added to a flask containing intermediate 42 (65 mg, 0.23 mmol) in anh. MeOH (1 mL). The reaction mixture was stirred for 1 day and then a second portion of the free acetamidine was prepared as described above and added to the reaction flask. After stirring for 2 days, the solution was concentrated *in vacuo* and the crude oil was purified by flash chromatography (silica gel, 100% EtOAc). The title compound was obtained as a white solid (35 mg, 53%)

NMR (¹H, CDCl₃): δ 10.44 (bs, 1H), 6.79 (d, 1H), 6.46 (d, 1H), 6.41 (dd, 1H), 4.53 (t, 1H), 3.78 (s, 6H), 2.88 (m, 1H), 2.78 (m, 1H), 2.55 (m, 1H), 2.41 (s, 3H), 1.90 (m, 1H).

20 MS (*m/z*): 287 [MH]⁺.

Intermediate 44

4-Chloro-7-(2,4-dimethoxyphenyl)-2-methyl-6,7-dihydro-5H-cyclopentapyrimidine

A solution of intermediate 43 (21 mg, 0.07 mmol) in POCl₃ (1 mL) was heated at 100° C for 3 hr and then concentrated *in vacuo*. The crude oil was diluted with EtOAc and washed with conc. NH₄OH. It was then dried over anh. Na₂SO₄, the solids were filtered and the solvent was evaporated to give the title compound (20.6 mg, 90%) as an orange oil, which was used as such in the next step.

NMR (¹H, CDCl₃): δ 6.82 (d, 1H), 6.40 (m, 2H), 4.6 (dd, 1H), 3.8 (s, 3H), 3.7 (s, 3H), 3.1-2.85 (m, 2H), 2.65 (s, 3H), 2.60 (m, 1H), 2.05 (m, 1H).

Intermediate 45

(4,6-Dichloro-2-methyl-pyrimidin-5-yl)acetic acid methyl ester

Sodium (1.74 g, 3 eq) was added portionwise to anh. MeOH (60 mL), at 0°C, under N₂. After consumption of metallic sodium, acetamidine hydrochloride (7.06 g, 3 eq) was added. After 20 min. of stirring the precipitated NaCl was filtered off. A solution of 2-ethoxycarbonyl-succinic acid diethyl ester (6.04g, 24.5mmol) in anhydrous CH₃OH (20 mL) was added to the solution of free acetamidine and the mixture was stirred at r.t. for 2 days. The reaction mixture was concentrated to dryness *in vacuo* and the yellow foam (8.69 g) obtained was then mixed with POCl₃ (6 eq) and CH₃CN (10 Vol.) and heated at reflux for 18 hours. The resulting solution was cooled to r.t. and poured slowly into ice/water and conc. NH₄OH with vigorous stirring. The product was extracted with EtOAc (3x). The combined organic extracts were washed with brine, dried over anh. Na₂SO₄, filtered and concentrated *in vacuo*.

The crude oil was purified by flash chromatography (silica gel, cHex/EtOAc 8:2). The title compound was obtained as a yellow solid (98% in two steps)

NMR (^1H , CDCl_3): δ 5.85 (m, 1H), 5.15 (dq, 1H), 5.11 (dq, 1H), 3.61 (dt, 2H), 2.67 (s, 3H).

MS (m/z): 202 $[\text{M}]^+$ (2Cl).

5

Intermediate 46

(4,6-Dichloro-2-methylpyrimidin-5-yl)acetaldehyde

To a solution of intermediate 45 (300 mg, 1.276 mmol) in anh. CH_2Cl_2 (6 mL), at -78°C , under N_2 , was added DIBAL-H (1M solution in hexane, 1.8 eq, 2.3 mL). After the addition was complete the reaction mixture was stirred at -78°C for 1 hr and at -55°C for 2 hr. The reaction mixture was poured into a solution of HCl 0.5N in ice and extracted with CH_2Cl_2 (3x). The combined organic extracts were dried over anh. Na_2SO_4 , the solids were filtered and the solvent evaporated. The crude product was purified by flash chromatography (silica gel, cHex/EtOAc 8:2) to give the title compound as a colourless oil (160 mg, 62%).

10

NMR (^1H , CDCl_3): δ 9.78 (s, 1H), 4.09 (s, 2H), 2.70 (s, 3H).

15

MS (m/z): 204 $[\text{M}]^+$ (2Cl).

Intermediate 47

4,6-Dichloro-5-(3-methoxyallyl)-2-methylpyrimidine

To a stirred suspension of (methoxy-methyl) triphenylphosphonium chloride (675 mg, 2eq.) in anh. THF (6 mL) was added, at 0°C , under N_2 , $n\text{-BuLi}$ 1.6M in hexane (2 eq., 1.22 mL) dropwise. The mixture was allowed to stir for 30 min before a solution of intermediate 46 (200 mg, 0.985 mmol) in anh. THF (1mL) was added at -78°C . The reaction mixture was allowed to warm slowly to r.t. and left stirring for 3 hr. The mixture was quenched with water and extracted with EtOAc (3x). The combined organic extracts were dried over anh. Na_2SO_4 , the solids were filtered and the solvent evaporated. The crude product was purified by flash chromatography (silica gel, cHex/EtOAc 9:1) to give the title compound as a white solid (85 mg, 40%).

20

25

NMR (^1H , CDCl_3): δ 6.55 (bd, 1H), 4.75 (m, 1H), 3.51 e 3.47(s e dd, 5H), 2.66 (s, 3H).

30

MS (m/z): 233 $[\text{MH}]^+$ (2Cl).

Intermediate 48

3-(4,6-dichloro-2-methyl-pyrimidin-5-yl)propionaldehyde

Intermediate 47 (125 mg, 0.345 mmol) was stirred at r.t. with 12 mL of a 1:3 mixture of THF-2N HCl for 15 hr. The mixture was then diluted with H_2O and extracted with EtOAc (3x). The combined organic extracts were dried over anh. Na_2SO_4 , the solids were filtered and the solvent evaporated. The crude product was purified by flash chromatography (silica gel, cHex/EtOAc 8:2) to give the title compound as a white solid (75 mg, 99%).

35

NMR (^1H , CDCl_3): δ 9.87 (s, 1H), 3.18 (m, 2H), 2.78-2.67 (m-s, 5H).

40

MS (m/z): 218 $[\text{M}]^+$ (2Cl).

Intermediate 49

3-(4,6-Dichloro-2-methylpyrimidin-5-yl)propan-1-ol

To a solution of intermediate 48 (75 mg, 0.345 mmol) in anh. CH₃OH (6 mL) was added NaBH₄ (52 mg, 4 eq) at 0 °C. The reaction was stirred for 1 hr. The solvent was removed *in vacuo* and the residue was taken up in EtOAc/H₂O, and the layers were separated. The aqueous layer was extracted with EtOAc (3x), and the combined organic extracts were dried over anh. Na₂SO₄. The solids were filtered and the solvent evaporated to afford the title compound as a white solid. (75 mg, 99%)
NMR (¹H, CDCl₃): δ 4.59 (t, 1H), 3.46 (q, 2H), 2.80 (dd, 2H), 2.54 (s, 3H), 1.82 (m, 2H).
MS (*m/z*): 202 [M-18]⁺ (2Cl).

10 Intermediate 50

Methanesulfonic acid 3-(4,6-dichloro-2-methylpyrimidin-5-yl)propyl ester

To a solution of intermediate 49 (104 mg, 0.473 mmol) in anh. CH₂Cl₂ (10 mL), at r.t., under N₂, was added Et₃N (4 eq., 262 µl) and CH₃SO₂Cl (2.5 eq., 91 µl). The reaction was stirred at r.t. for 3 hr. The reaction mixture was diluted with water and extracted with CH₂Cl₂ (3x). The combined organic extracts were dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated. The crude product was purified by flash chromatography (silica gel, cHex/EtOAc 8:2) to give the title compound as a white solid (134 mg, 95%).
NMR (¹H, CDCl₃): δ 4.31 (t, 2H), 3.02 (s, 3H), 2.95 (m, 2H), 2.62 (s, 3H), 2.03 (m, 2H).
MS (*m/z*): 299 [MH]⁺ (2Cl).

20 Intermediate 51

4-Chloro-8-(2,4-bis-trifluoromethylphenyl)-2-methyl-5,6,7,8-tetrahydropyrido[2,3d]pyrimidine

To a solution of 2,4-bis-trifluoromethyl-aniline (134 mg, 0.448 mmol) in anh. DMF (18 mL) was added, at 0°C, under N₂, NaH (80% mineral oil, 2 eq, 1.6 mg). The reaction was stirred for 30 min at r.t. and then, at 0 °C, was added a solution of intermediate 50 in anh. DMF. It was stirred at room temperature for 1 hr. The solution was diluted with water and extracted with EtOAc (3x). The combined organic extracts were dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated. The crude product was purified by flash chromatography (silica gel, Toluene/EtOAc 9:1) to give the title compound as a white solid (95 mg, 54 %)
NMR (¹H, CDCl₃): δ 8.03 (s, 1H), 7.91 (dd, 1H), 7.42 (d, 1H), 3.62 (t, 2H), 2.92 (m, 1H), 2.83 (m, 1H), 2.26 (s, 3H), 2.14 (m, 2H).
MS (*m/z*): 396 [MH]⁺ (1Cl)

35 Intermediate 52

2-(4,6-Dichloro-2-methyl-pyrimidin-5-yl)-ethanol

To a solution of intermediate 45 (4.0 g, 0.017 mol) in anh. THF (60 mL), at -78°C, under N₂, was added DIBAL-H 1M/THF (52.5 mL, 3 eq) dropwise. After the addition was complete, the reaction mixture was stirred at -30°C for 3 hr. A Rochelle salt solution was then added at 0°C and the phases were separated. The aqueous layer was extracted with EtOAc (2x50 mL) and the combined organic extracts were dried over anh. Na₂SO₄. The solids were filtered and the solvent evaporated. The title compound was obtained as a clear oil (3.1 gr, 89%) and was used in the next step without further purification.

NMR (¹H, CDCl₃): δ 4.90 (t, 2H), 3.15 (t, 2H), 2.64 (s, 3H), 1.70 (bs, 1H).

MS (*m/z*): 207 [MH]⁺

Intermediate 53

5 5-[2-*tert*-Butyl-dimethyl-silanoxy)-ethyl]-4,6-dichloro-2-methyl-pyrimidine

To a solution of intermediate 52 (3.1 g, 0.015 mol) in anh. DMF (100 mL), at 0°C, under N₂, were added imidazole (17 g, 17 eq), *t*-butyldimethylsilyl chloride (6.35 gr, 2.8 eq) and DMAP (catalytic amount). The solution was stirred at r.t. for 18 hr. EtOAc (100 mL) and sat.aq. NH₄Cl (50 mL) were added and the phases were separated. The organic layer was
10 washed with sat.aq. NaCl (2 x 100 mL) and dried over anh. Na₂SO₄. The solids were filtered and the solvent evaporated. The crude compound was purified by flash chromatography (silica gel, cHex/EtOAc 9:1) to give the title compound as a clear oil (4.6 g, 95%).

NMR (¹H, CDCl₃): δ 3.86 (t, 2H), 3.12 (t, 2H), 2.66 (s, 3H), 0.85 (s, 9H), 0.01 (s, 6H).

MS (*m/z*): 321 [MH]⁺

15

Intermediate 54

(2,4-Bis-trifluoromethyl-phenyl)-{5-[2-(*tert*-butyl-dimethyl-silanoxy)-ethyl]-6-chloro-2-methyl-pyrimidin-4-yl}-amine

To a solution of 2,4-bis-trifluoromethyl-aniline (984 μL, 1 eq) in anh. DMF (15 mL), at 0°C, under N₂, was added NaH 80%/oil (400 mg, 2.2 eq). The reaction mixture was stirred at 0°C
20 for 30 min and was then added to a solution of intermediate 53 (2 g, 6 mmol) in anh. DMF (15 mL) at r.t., under N₂. The reaction mixture was stirred at r.t. for 30 min. The excess NaH was carefully destroyed with sat.aq. NaCl and the reaction mixture was diluted with EtOAc. The phases were separated, the organic layer was washed with sat.aq. NaCl (2x30 mL) and
25 dried over anh. Na₂SO₄. The solids were filtered and the solvent evaporated. The crude compound was purified by flash chromatography (silica gel, cHex/EtOAc 95:5 → 90:10). The title compound was obtained as a clear oil (1.84 g, 56%).

NMR (¹H, CDCl₃): δ 8.61 (d, 1H), 8.04 (bs, 1H), 7.86 (s, 1H), 7.79 (d, 1H), 4.95 (t, 2H), 3.95 (t, 2H), 2.53 (s, 3H), 0.73 (s, 9H), -0.90 (s, 6H).

30 MS (*m/z*): 514 [MH]⁺

Intermediate 55


2-[4-(2,4-Bis-trifluoromethyl-phenylamino)-6-chloro-2-methyl-pyrimidin-5-yl]-ethanol

To a solution of intermediate 54 (1.84 g, 3.58 mmols) in anh. DMF (30 mL), at r.t., under N₂,
35 was added Et₃N·3HF (2.4 mL, 3 eq). The reaction mixture was stirred at r.t. for 18 hr. It was then diluted with cold sat.aq. NaCl (50 mL) and extracted with EtOAc (3x50 mL). The combined organic extracts were dried over anh. Na₂SO₄. The solids were filtered and the solvent evaporated. The title compound was obtained as a clear oil (1.4 gr, 98%) and was used in the next step without further purification.


40 NMR (¹H, CDCl₃): δ 8.59 (bs, 1H), 8.22 (d, 1H), 7.84 (s, 1H), 7.75 (d, 1H), 4.06 (t, 2H), 3.01 (t, 2H), 2.50 (s, 3H)

MS (*m/z*): 400 [MH]⁺

Synthesis of representative compounds of structure (1a-1)



Synthesis of representative compounds of structure (1-1)



5

[7-(2,4-Dichlorophenyl)-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl]-(1-ethyl-propyl)amine (1-1-1)

10 A mixture of intermediate 8 (15 mg) and 1-ethylaminopropane (0.3 mL) was heated at 140°C (screw cap vial) for 18 hr. It was then cooled down to r.t. and the amine was evaporated. The residue was partitioned between CH₂Cl₂/2.5 M NaOH and the phases were separated. The aqueous layer was extracted with CH₂Cl₂ (2x) and the combined organic extracts were dried over anh. Na₂SO₄. The solids were filtered and the solvent evaporated. The residue was purified by flash chromatography (silica gel, 15% EtOAc/toluene) to give the title compound (9 mg) as a yellow oil.

15

The compounds 1-1-4, 1-1-5, 1-1-7, 1-1-8, 1-1-9, 1-1-10, 1-1-11 and 1-1-12, whose analytical data are reported in the following Table 1, were prepared analogously starting from the appropriate amine.

20 [7-(2-Bromo-4-isopropylphenyl)-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl]-(1-ethylpropyl)amine (1-1-2)

25 A mixture of intermediate 13 (21 mg) and 1-ethylaminopropane (300 µl) was heated at 160°C (screw cap vial) for 48 hr. The reaction mixture was cooled down to r.t. and diluted with water and CH₂Cl₂. The phases were separated and the organic layer was dried and concentrated. The crude oil was purified by flash chromatography (silica gel, cHex/EtOAc 95:5) to give the title compound as a white solid (8 mg).

[7-(2,4-Bis-trifluoromethylphenyl)-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl]-(1-propylbutyl)amine (1-1-3)










30 A mixture of intermediate 18 (20 mg) and 4-heptylamine (150 µL) was heated at 130°C (screw cap vial) for 8 hr. The reaction mixture was directly purified by flash chromatography (silica gel, cHex/EtOAc 8:2) to give the title compound as a yellow waxy solid (10 mg)




All the analytical data are set forth in the following Table 1.

35


Table 1

Cpd.	R	R ₁	R ₂	R ₃	Analytical Data
------	---	----------------	----------------	----------------	-----------------

N°.					
1-1-1	2,4-dichloro-phenyl	CH ₃		H	NMR (¹ H, CDCl ₃): δ 7.43 (d, 1H), 7.38 (d, 1H), 7.25 (dd, 1H), 4.02 (s, 1H), 3.93 (m, 1H), 3.93 (t, 2H), 2.97 (t, 2H), 2.33 (s, 3H), 1.65 (m, 2H), 1.5 (m, 2H), 0.94 (t, 6H). IR (CDCl ₃ , cm ⁻¹): 3429. MS (m/z): 365 [MH] ⁺ .
1-1-2	2-bromo-4-iso-propylphenyl	CH ₃		H	NMR (¹ H, CDCl ₃): δ 7.43 (d, 1H), 7.24 (d, 1H), 7.15 (dd, 1H), 4.00 (bs, 1H), 3.90 (m, 1H), 3.89 (t, 2H), 2.94 (t, 2H), 2.84 (m, 1H), 2.29 (s, 3H), 1.65-1.4 (m, 4H), 1.21 (d, 6H), 0.91 (t, 6H). MS (m/z): 417 [MH] ⁺ , 1Br.
1-1-3	2,4-trifluoro-methylphenyl	CH ₃		H	NMR (¹ H, CDCl ₃): δ 7.97 (bd, 1H), 7.82 (bdd, 1H), 7.58 (d, 1H), 4.13 (bs, 1H), 4.00 (bs, 1H), 3.89 (t, 2H), 2.98 (m, 2H), 2.32 (s, 3H), 1.6-1.3 (m, 8H), 0.95 (t, 6H). MS (m/z): 461 [MH] ⁺ .
1-1-4	2,4-dichloro-phenyl	CH ₃		H	NMR (¹ H, CDCl ₃): δ 7.43 (d, 1H), 7.37 (d, 1H), 7.25 (dd, 1H), 4.43-4.32 (m, 2H), 3.94 (t, 2H), 3.44 (d, 2H), 3.39 (s, 3H), 2.94 (t, 2H), 2.35 (s, 3H), 1.26 (d, 3H). MS (m/z): 367 [MH] ⁺ (2Cl).
1-1-5	2,4-dichloro-phenyl	CH ₃		H	NMR (¹ H, CDCl ₃): δ 7.44 (d, 1H), 7.37 (d, 1H), 7.35-7.20 (m, 6H), 4.53 (bm, 1H), 4.45 (bm, 1H), 3.94 (t, 2H), 3.40 (m, 5H), 3.01 (dd, 1H), 2.91 (m, 3H), 2.39 (s, 3H). MS (m/z): 443 [MH] ⁺ (2Cl).
1-1-6	2,4-dichloro-phenyl	CH ₃		H	NMR (¹ H, CDCl ₃): δ (DMSO) 9.60-8.40 (broad, 2H), 7.74 (s, 1H), 7.50 (m, 2H), 3.92 (t, 2H), 3.04 (t, 2H), 2.28 (s, 3H). MS (m/z): 390 [MH] ⁺ .
1-1-7	2,4-dichloro-phenyl	CH ₃		H	NMR (¹ H, CDCl ₃): δ 7.40 (bd, 1H), 7.33 (d, 1H), 7.22 (dd, 1H), 4.23 (bd, 1H), 3.89 (t, 2H), 3.75 (m, 1H), 3.02 (t, 2H), 2.30 (s, 3H), 2.28 (d, 1H), 2.23 (d, 1H), 1.80 (m, 1H), 1.20 (m, 1H), 1.60-0.80 (m, 6H). MS (m/z): 389 [MH] ⁺ (2Cl).
1-1-8	2,4-dichloro-phenyl	CH ₃		H	NMR (¹ H, CDCl ₃): δ 7.43 (d, 1H), 7.36 (d, 1H), 7.25 (dd, 1H), 4.38 (bs, 1H), 3.94 (t, 2H), 3.34 (t, 2H), 3.01 (t, 2H), 2.36 (s, 3H), 1.07 (m, 1H), 0.56 (q, 2H), 0.27 (q, 2H). MS (m/z): 349 [MH] ⁺ (2Cl).
1-1-9	2,4-dichloro-phenyl	CH ₃		H	NMR (¹ H, CDCl ₃): δ 7.43 (d, 1H), 7.38 (d, 1H), 7.24 (dd, 1H), 3.92 (t, 2H), 4.1-3.6 (m, 1H), 2.99 (m, 2H), 2.34 (s, 3H), 2.1-1.95 (m, 1H), 1.85-1.1 (m, 10H), 1.00-0.94 (2d, 3H). MS (m/z): 391 [MH] ⁺ (2Cl).

1-1-10	2,4-dichloro-phenyl	CH ₃		H	NMR (¹ H, CDCl ₃): δ 7.44 (d, 1H), 7.39 (d, 1H), 7.26 (dd, 1H), 4.10 (m, 1H), 4.00 (m, 1H), 3.94 (t, 2H), 2.97 (t, 2H), 2.34 (s, 3H), 1.80-1.00 (m, 11H), 1.17 (d, 3H). MS (m/z): 405 [MH] ⁺ (2Cl).
1-1-11	2,4-dichloro-phenyl	CH ₃		H	NMR (¹ H, CDCl ₃): δ 7.44 (d, 1H), 7.37 (d, 1H), 7.25 (dd, 1H), 4.49 (m, 2H), 3.94 (t, 2H), 3.01 (t, 2H), 2.35 (s, 3H), 2.40 (m, 2H), 1.91 (m, 2H), 1.75 (m, 2H). MS (m/z): 349 [MH] ⁺ (2Cl).
1-1-12	2,4-dichloro-phenyl	CH ₃		H	NMR (¹ H, CDCl ₃): δ 7.44 (d, 1H), 7.38 (d, 1H), 7.26 (dd, 1H), 4.34 (m, 2H), 3.94 (t, 2H), 3.03 (t, 2H), 2.35 (s, 3H), 2.05 (m, 2H), 1.8-1.4 (m, 6H). MS (m/z): 363 [MH] ⁺ (2Cl).

Synthesis of representative compounds of structure (1-2)



5

Butyl-[7-(2,4-dichlorophenyl)-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl]ethylamine (1-2-1)

10 A mixture of intermediate 8 (11.8 mg) and n-butyl-ethylamine (300 μl) was heated in a sealed vial at 160°C for 18 hr. The crude oil was directly purified by flash chromatography (silica gel, cHex/EtOAc 19:1) to give the title compound (10 mg) as a light yellow oil.

The compounds 1-2-6, 1-3-1, 1-3-2 and 1-3-3, whose analytical data are reported in the following Table 1-2, were prepared analogously starting from the appropriate amine.

15

[7-(2-Bromo-4-isopropylphenyl)-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl]-butylethylamine (1-2-2)

20 A mixture of intermediate 13 (20 mg) and n-butyl-ethylamine (300 μl) was heated in a sealed vial at 160°C for 18 hr. The reaction mixture was cooled down to r.t. and diluted with water and CH₂Cl₂. The phases were separated and the organic layer was dried and concentrated. The crude oil was purified by flash chromatography (silica gel, cHex/EtOAc 95:5) to give the title compound as a yellow oil.

Butyl-[7-(2-chloro-4-trifluoromethylphenyl)-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl]ethylamine (1-2-3)

25

5 A mixture of intermediate 23 (21 mg) and of n-butyl-ethylamine (300 µl) were heated in a sealed vial at 160°C for 18 hr. The reaction mixture was cooled down to r.t. and diluted with water and CH₂Cl₂. The phases were separated and the organic layer was dried and concentrated. The crude oil was purified by flash chromatography (silica gel, cHex/EtOAc 95:5) to give the title compound as a white solid (20 mg).

[7-(2,4-Bis-trifluoromethylphenyl)-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl]-butylethylamine (1-2-4)

10 A mixture of intermediate 18 (21 mg) and n-butyl-ethylamine (300µl) was heated in a sealed vial at 160°C for 18 hr. The reaction mixture was cooled down to r.t. and diluted with water and CH₂Cl₂. The phases were separated and the organic layer was dried and concentrated. The crude oil was purified by flash chromatography (silica gel, cHex/EtOAc 95:5) to give the title compound as a yellow oil (14 mg).







15 Butyl-[7-(2,4-dichlorophenyl)-2-trifluoromethyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl]ethylamine (1-2-5)

The sequence for the preparation of example 1-2-5 is similar to the preparation of example 1-2-1 (intermediate 1 to intermediate 8) except that 2,2,2-trifluoroacetamidine hydrochloride was used instead of acetamidine hydrochloride in the first step (intermediate 1).


20

All the analytical data are set forth in the following Table 1-2.

Table 1-2

Cpd. No.	R	R ₁	R ₂ -	R ₃ -	Analytical Data
1-2-1	2,4-dichloro-phenyl	CH ₃		Et	NMR (¹ H, CDCl ₃): δ 7.43 (d, 1H), 7.37 (d, 1H), 7.25 (dd, 1H), 3.84 (t, 2H), 3.56 (q, 2H), 3.48 (dd, 2H), 3.25 (t, 2H), 2.32 (s, 3H), 1.59(m, 2H), 1.36 (m, 2H), 1.19 (t, 3H), 0.97 (t, 3H). MS (m/z): 379[MH] ⁺ , 2Cl
1-2-2	2-bromo-4-iso-propylphenyl	CH ₃		Et	NMR (¹ H, CDCl ₃): δ 7.47 (d, 1H), 7.28 (d, 1H), 7.19 (dd, 1H), 3.83 (t, 2H), 3.55 (q, 2H), 3.48 (m, 2H), 3.24 (t, 2H), 2.89 (m, 1H), 2.31 (s, 3H), 1.58 (m, 2H), 1.36 (m, 2H), 1.25 (d, 6H), 1.18 (t, 3H), 0.97 (t, 3H). MS (m/z): 431[MH] ⁺ , 1Cl, 1Br.
1-2-3	2-chloro-4-trifluoromethyl-phenyl	CH ₃		Et	NMR (¹ H, CDCl ₃): δ 7.68 (d, 1H), 7.61 (d, 1H), 7.51 (dd, 1H), 3.92 (t, 2H), 3.57 (q, 2H), 3.49 (t, 2H), 3.27 (t, 2H), 2.33 (s, 3H), 1.61 (m, 2H), 1.37 (m, 2H), 1.19 (t, 3H), 0.98 (t, 3H). MS (m/z): 413 [MH] ⁺ .
1-2-4	2,4-bis-trifluoro-methylphenyl	CH ₃		Et	NMR (¹ H, CDCl ₃): δ 7.95 (bs, 1H), 7.81 (dd, 1H), 7.53 (d, 1H), 3.78 (t, 2H), 3.56 (q, 2H), 3.48 (m, 2H), 3.25 (t, 2H), 2.29 (s, 3H), 1.60 (m, 2H), 1.36 (m, 2H), 1.19 (t, 3H), 0.97 (t, 3H). MS (m/z): 447 [MH] ⁺ .
1-2-5	2,4-dichloro-phenyl	CF ₃		Et	NMR (¹ H, CDCl ₃): δ 7.45 (d, 1H), 7.35 (d, 1H), 7.28 (dd, 1H), 3.94 (t, 2H), 3.57 (q, 2H), 3.50 (t, 2H), 3.33 (t, 2H), 1.62 (m, 2H), 1.37 (m, 2H), 1.22 (t, 3H), 0.98 (t, 3H). MS (m/z): 433 [MH] ⁺ (2Cl; 100 %).
1-2-6	2,4-dichloro-phenyl	CH ₃		Et	MS (m/z): 414 [MH] ⁺ (2Cl)




Synthesis of representative compounds of structure (1-3)




- 5 Representative compounds of this invention were prepared by the procedure set forth above for compounds of general formula (1-2).

All the analytical data are set forth in the following Table 1-3.

Table 1-3

Cpd. No.	R	R ₁	R ₂ -	R ₃ -	Analytical Data
1-3-1	2,4-dichloro-phenyl	CH ₃		Me	NMR (¹ H,): δ . 7.43 (d, 1 H), 7.37 (d, 1 H), 7.25 (dd, 1 H), 4.91 (s, 1 H), 4.85 (s, 1 H), 4.07 (s, 2 H), 3.81 (t, 2 H), 3.55 (q, 2 H), 3.24 (t, 2 H), 2.33 (s, 3 H); 1.74 (s, 3 H), 1.17 (t, 3 H). MS (m/z): 377 [MNH ₄] ⁺ . 2 Cl
1-3-2	2,4-dichloro-phenyl	CH ₃		Me	MS (m/z): 397 [MH] ⁺ (2Cl)
1-3-3	2,4-dichloro-phenyl	CH ₃		Me	MS (m/z): 351 [MH] ⁺ (2Cl)

Synthesis of representative compounds of structure (1-4)



5 [7-(2-Chloro-4-trifluoromethyl-phenyl)-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl]cyclopropylmethylpropylamine (1-4-1)

A mixture of intermediate 23 (20.6 mg) and of N-propyl cyclopropane methyl amine (300 μl) were heated in a sealed vial at 160°C for 18 hr. The reaction mixture was cooled down to r.t. and diluted with water and CH₂Cl₂. The phases were separated and the organic layer was dried and concentrated. The crude oil was purified by flash chromatography (silica gel, cHex/EtOAc 95:5) to give the title compound as a white solid (21 mg)

10 [7-(2,4-Bis-trifluoromethylphenyl)-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl]-cyclopropylmethylpropylamine (1-4-2)

15 A mixture of intermediate 18 (20.4 mg) and of N-propyl cyclopropane methyl amine (300 μl) was heated in a sealed vial at 160°C for 18 hr. The reaction mixture was cooled down to r.t. and diluted with water and CH₂Cl₂. The phases were separated and the organic layer was dried and concentrated. The crude oil was purified by flash chromatography (silica gel, cHex/EtOAc 95:5) to give the title compound as a yellow oil (11 mg).

20 [7-(2-Bromo-4-isopropylphenyl)-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl]-cyclopropylmethylpropylamine (1-4-3)

25 A mixture of intermediate 13 (22 mg) and N-propyl cyclopropane-methylamine (300 μl) was heated in a sealed vial at 160°C for 18 hr. The reaction mixture was cooled down to r.t. and diluted with water and CH₂Cl₂. The phases were separated and the organic layer was dried and concentrated. The crude oil was purified by flash chromatography (silica gel, cHex/EtOAc 95:5) to give the title compound as a yellow oil (17 mg).











Cyclopropylmethyl-[7-(2,4-dichlorophenyl)-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl]propylamine (1-4-4)

- 5 A mixture of intermediate 8 (12 mg) and N-propyl cyclopropane methyl amine (300 μ l) was heated in a sealed vial at 160°C for 18 hours. The crude oil was directly purified by flash chromatography (silica gel, cHex/EtOAc 8:2) to give the title compound as a light yellow oil (11 mg).


All the analytical data are set forth in the following Table 1-4.

10

Table 1-4

Cpd. N°.	R	R ₁	R ₂ -	R ₃ -	Analytical Data
1-4-1	2-chloro-4-tri-fluoromethyl-phenyl	CH ₃			NMR (¹ H, CDCl ₃): δ 7.68 (d, 1H), 7.61 (d, 1H), 7.52 (dd, 1H), 3.93 (t, 2H), 3.52 (t, 2H), 3.47 (d, 2H), 3.30 (t, 2H), 2.33 (s, 3H), 1.66 (m, 2H), 1.07 (m, 1H), 0.93 (t, 3H), 0.55-0.29 (m, 4H). MS (<i>m/z</i>): 425 [MH] ⁺ .
1-4-2	2,4-bistrifluoro-methylphenyl	CH ₃			NMR (¹ H, CDCl ₃): δ 7.95 (d, 1H), 7.81 (dd, 1H), 7.54 (d, 1H), 3.78 (t, 2H), 3.50 (m, 2H), 3.46 (d, 2H), 3.29 (t, 2H), 2.28 (s, 3H), 1.63 (m, 2H), 1.05 (m, 1H), 0.93 (t, 3H), 0.53 (m, 2H), 0.29 (q, 2H). MS (<i>m/z</i>): 459[MH] ⁺ .
1-4-3	2-bromo-4-iso-propylphenyl	CH ₃			NMR (¹ H, CDCl ₃): δ 7.46 (d, 1H), 7.28 (d, 1H), 7.18 (dd, 1H), 3.84 (t, 2H), 3.51 (m, 2H), 3.46 (m, 2H), 3.27 (t, 2H), 2.89 (m, 1H), 2.31 (s, 3H), 1.66 (m, 2H), 1.25 (d, 6H), 1.09 (m, 1H), 0.93 (t, 3H), 0.53 (m, 2H), 0.28 (q, 2H). MS (<i>m/z</i>): 431[MH] ⁺ , 1Cl, 1Br.
1-4-4	2,4-dichloro-phenyl	CH ₃			NMR (¹ H, CDCl ₃): δ 7.43 (d, 1H), 7.37 (d, 1H), 7.25 (dd, 1H), 3.84 (t, 2H), 3.50 (dd, 2H), 3.46 (d, 2H), 3.28 (t, 2H), 2.31 (s, 3H), 1.65 (m, 2H), 1.07 (m, 1H), 0.93 (t, 3H), 0.53 (m, 2H), 0.29 (m, 2H). MS (<i>m/z</i>): 391 [MH] ⁺ (2Cl)
1-4-5	3,4-dimethoxy-phenyl	CH ₃			NMR (¹ H, CDCl ₃): δ 6.80 (d, 1H), 6.70 (s, 1H), 6.60 (d, 1H), 4.10 (dd, 1H), 3.85 (s, 6H), 3.45 (m, 2H), 3.15 (m, 1H), 3.05 (m, 1H), 2.25 (m, 1H), 2.45 (s, 3H), 1.95 (m, 1H), 1.65 (m, 2H), 1.05 (m, 1H), 0.80-0.95 (m, 5H), 0.55 (m, 2H), 0.30 (m, 2H). MS (<i>m/z</i>): 382 [MH] ⁺ .

Synthesis of representative compounds of structure (1-5)



Representative compounds of this invention were prepared by the procedure set forth above for compounds of general formula (1-2).


All the analytical data are set forth in the following Table 1-5.

5

Table 1-5

Cpd. No.	R	R ₁	R ₂ -	R ₃ -	Analytical Data
1-5-1	2,4-dichloro-phenyl	CH ₃			NMR (¹ H, CDCl ₃): δ 7.41 (d, 1H), 7.37 (d, 1H), 7.23 (dd, 1H), 3.80 (t, 2H), 3.63 (m, 1H), 3.45 (t, 2H), 3.15 (t, 2H), 2.24 (s, 3H), 1.75 (m, 2H), 1.06 (m, 2H), 0.93 (t, 3H), 0.70-0.30 (m, 8H). MS (m/z): 431[MH] ⁺ (2Cl)

Synthesis of representative compounds of structure (1-6)



10

7-(2,4-Dichlorophenyl)-4-(2-ethylpiperidin-1-yl)-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine (1-6-3)

A mixture of intermediate 8 (10 mg) and 2-ethylpiperidine (120 μL) was heated in a sealed vial at 160°C for 7 hr. The crude oil was directly purified by flash chromatography (silica gel, cHex/EtOAc 4:1) to give the title compound (8.7 mg) as a yellow oil.

15






The compounds 1-6-1, 1-6-2, 1-6-4 and 1-6-5, whose analytical data are reported in the following Table 1-6, were prepared analogously starting from the appropriate amine.

20


All the analytical data are set forth in the following Table 1-6.

Table 1-6

Cpd. No.	R	R ₁	R ₂ -R ₃ -	Analytical Data
----------	---	----------------	----------------------------------	-----------------

1-6-1	2,4-dichloro-phenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 7.43 (d, 1H), 7.35 (d, 1H), 7.24 (dd, 1H), 4.41 (m, 2H), 3.84 (t, 2H), 3.24 (t, 2H), 2.32 (s, 3H), 2.30 (m, 2H), 1.85 (m, 1H), 1.66 (m, 2H), 0.91 (d, 6H), 0.80 (m, 1H). MS (<i>m/z</i>): 391 [MH] ⁺ .
1-6-2	2,4-dichloro-phenyl	CH ₃		NMR (¹ H,): δ 7.42 (d, 1H), 7.35 (d, 1H), 7.23 (dd, 1H), 4.71 (m, 1H), 4.33 (bd, 1H), 3.83 (t, 2H), 3.24 (m, 2H), 3.02 (dt, 1H), 2.32 (s, 3H), 1.78-1.49 (m, 6H), 1.21 (d, 3H). MS (<i>m/z</i>): 377 [MH] ⁺ .
1-6-3	2,4-dichloro-phenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 7.42 (d, 1H), 7.36 (d, 1H), 7.24 (dd, 1H), 4.44 (m, 1H), 4.38 (m, 1H), 3.83 (m, 2H), 3.22 (t, 2H), 2.97 (m, 1H), 2.31 (s, 3H), 1.73 (m, 2H), 1.80-1.10 (m, 6H), 0.88 (t, 3H). MS (<i>m/z</i>): 391 [MH] ⁺ .
1-6-4	2,4-dichloro-phenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 7.44 (d, 1H), 7.35 (d, 1H), 7.25 (dd, 1H), 4.25 (d, 2H), 3.87 (t, 2H), 3.69 (m, 2H), 3.25 (t, 2H), 2.64 (d, 2H), 2.33 (s, 3H), 1.24 (d, 6H). MS (<i>m/z</i>): 393 [MH] ⁺ .
1-6-5	2,4-dichloro-phenyl	CH ₃		MS (<i>m/z</i>): 381 [MH] ⁺ (2Cl)

Synthesis of representative compounds of structure (1-7)








7-(2,4-Dichlorophenyl)-4-[(2R,5R)-2,5-dimethylpyrrolidin-1-yl]-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine (1-7-3)

A mixture of intermediate 8 (11.8 mg) and (2R, 5R)-(-)-trans-2,5-dimethyl-pyrrolidine (150 μl) was heated in a sealed vial at 160°C for 18 hr. The crude oil was directly purified by flash chromatography (silica gel, cHex/EtOAc 19:1) to give the title compound (7 mg) as a white solid.


The compounds 1-7-1, 1-7-2, 1-7-4 and 1-7-5, whose analytical data are reported in the following Table 1-7, were prepared analogously starting from the appropriate amine.

All the analytical data are set forth in the following Table 1-7.

Table 1-7

Cpd. No.	R	R ₁	R ₂ -R ₃ -	Analytical Data
1-7-1	2,4-dichloro-phenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 7.42 (d, 1H), 7.36 (d, 1H), 7.24 (dd, 1H), 3.83 (t, 2H), 3.66 (t, 4H), 3.35 (t, 2H), 2.33 (s, 3H), 1.92 (m, 4H). MS (<i>m/z</i>): 349 [MH] ⁺ (2Cl)
1-7-2	2,4-dichloro-phenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 7.42 (d, 1H), 7.37 (d, 1H), 7.24 (dd, 1H), 4.39 (m, 1H), 3.88 (m, 2H), 3.76 (m, 1H), 3.60 (m, 1H), 3.30 (m, 2H), 2.32 (s, 3H), 2.06 (m, 2H), 1.90 (m, 1H), 1.65 (m, 1H), 1.21 (d, 3H). MS (<i>m/z</i>): 363 [MH] ⁺ (2Cl).
1-7-3	2,4-dichloro-phenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 7.41 (d, 1H), 7.39 (d, 1H), 7.24 (dd, 1H), 4.4 (m, 2H), 3.9-3.8 (m, 2H), 3.16 (m, 2H), 2.32 (s, 3H), 2.18 (m, 2H), 1.6 (m, 2H), 1.13 (d, 6H). MS (<i>m/z</i>): 377[MH] ⁺ , 2Cl
1-7-4	2,4-dichloro-phenyl	CH ₃		MS (<i>m/z</i>): 437 [MH] ⁺ (2Cl).
1-7-5	2,4-dichloro-phenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 7.44 (d, 1H), 7.34 (d, 1H), 7.26 (dd, 1H), 7.12 (bs, 1H), 5.29 (bs, 1H), 4.62 (bm, 1H), 3.86 (t, 2H), 3.81 (m, 1H), 3.60 (m, 1H), 3.36 (m, 2H), 2.81 (dd, 1H), 2.32 (s, 3H), 2.24 (dd, 1H), 2.01 (m, 4H). MS (<i>m/z</i>): 406 [MH] ⁺ (2Cl).


Synthesis of representative compounds of structure (1-8)




Representative compounds of this invention were prepared by the procedure set forth above for compounds of general formula (1-7).

All the analytical data are set forth in the following Table 1-8.

Table 1-8

Cpd. No.	R	R ₁	R ₂ -R ₃ -	Analytical Data
1-8-1	2,4-dichloro-phenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 7.43 (d, 1H), 7.38 (d, 1H), 7.25 (dd, 1H), 5.80 (s, 2H), 4.94 (q, 2H), 3.84 (t, 2H), 3.32 (t, 2H), 2.33 (s, 3H), 1.42 (d, 6H). MS (<i>m/z</i>): 375 [MH] ⁺ (2Cl).

Synthesis of representative compounds of structure (1-9)




- 5 Representative compounds of this invention were prepared by the procedure set forth in the examples below (example 1-10-1) using the appropriate pyrrole or indole derivative. All the analytical data are set forth in the following Table 1-9.

Table 1-9

Cpd. No.	R	R ₁	R ₂ -R ₃ -	Analytical Data
1-9-1	2,4-dichloro-phenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 7.54 (t, 2H), 7.50 (d, 1H), 7.38 (d, 1H), 7.32 (d, 1H), 6.37 (t, 2H), 4.04 (t, 2H), 3.44 (t, 2H), 2.46 (s, 3H). MS (m/z): 345 [MH] ⁺ (2Cl).
1-9-2	2,4-dichloro-phenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 8.24 (d, 1H), 7.61 (d, 1H), 7.53 (d, 1H), 7.52 (d, 1H), 7.41 (d, 1H), 7.35 (dd, 1H), 7.26 (dd, 1H), 6.67 (d, 1H), 4.06 (t, 2H), 3.37 (t, 2H), 2.55 (s, 3H). MS (m/z): 429 [MH] ⁺ (3Cl).
1-9-3	2,4-dichloro-phenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 7.49 (d, 1H), 7.39 (d, 1H), 7.32 (dd, 1H), 6.62 (s, 1H), 5.87 (s, 1H), 3.99 (t, 2H), 3.27 (t, 2H), 2.44 (s, 3H), 2.40 (s, 3H), 2.07 (s, 3H). MS (m/z): 373 [MH] ⁺ (2Cl).

Synthesis of representative compounds of structure (1-10)



5 7-(2,4-dichlorophenyl)-2-methyl-4-(3-thiazol-2-yl-pyrazol-1-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine (1-10-1)

2-(1*H*-pyrazol-3-yl)-thiazole (22 mg) was added to a suspension of NaH 80%/oil (4 mg) in anh. DMF (300 μ L). After stirring for 30 min, intermediate 8 (15 mg) was added at r.t. and the resulting mixture was heated at 110° C for 3 hr. The reaction was then concentrated *in vacuo* and the residue was diluted with H₂O and extracted with CH₂Cl₂ (3x5 mL). The combined organic extracts were dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated. The title compound was obtained after chromatographic purification (silica gel, cHex/EtOAc 4:1) as a white solid (16.5 mg).

15 The compounds 1-1-6, 1-9-1, 1-9-2, 1-9-3, 1-10-4, 1-10-5, 1-10-12, 1-10-13, 1-10-20, 1-10-21, 1-10-24, 1-10-25, 1-10-26 and 3-2-1, whose analytical data are reported in the following Table 1-10 or in the corresponding tables, were prepared analogously starting from the appropriate amine, pyrrole or pyrazole derivative.

20 7-(2,4-bis-trifluoromethyl-phenyl)-2-methyl-4-(3-Thiazol-2-yl-pyrazol-1-yl)-6,7-dihydro-5H-pyrrolo[2,3-d] pyrimidine (1-10-2)

To a suspension of NaH 80 %/oil (3.54mmol, 3.0 eq) in dry DMF (13 mL) at r.t., under N₂, was added 2-(1*H*-pyrazol-3-yl)-thiazole (538 mg, 3.54 mmol, 3 eq). The reaction mixture was stirred at r.t. for 30 min. Intermediate 18 (450 mg, 1.18 mmol) was added and the reaction mixture was heated at 100 °C (screw cap vial) for 4h. It was cooled down and poured into EtOAc. The organic layer was washed with sat. aq. NaCl (3x) and dried over anh. Na₂SO₄. The solids were filtered and the solvent evaporated. The crude product was purified by flash chromatography (silica gel, Toluene/EtOAc 9:1) to give the title compound as white solid (535 mg, 99%).

30 The compounds 1-10-31, 1-10-32, 1-10-33, 1-10-37 and 1-10-40, whose analytical data are reported in the following Table 1-10, were prepared analogously using respectively 4-(1*H*-pyrazol-3-yl)-morpholine (*J.Org.Chem.*, **1984**, 269-276), 3-(1*H*-pyrazol-3-yl)-pyridine (*Bioorg.Med.Chem.Lett.*, **2000**, 1211-1214), 2-(1*H*-pyrazol-3-yl)-pyrazine (*Tet.Lett.*, **1999**, 4779-4782), 3-(1*H*-imidazol-2-yl)-1*H*-pyrazole (*J.Het.Chem.*, **1989**, 893) and 5-(1*H*-pyrazol-3-yl)-oxazole (*Tet.Lett.*, **1972**, 2369-2372) instead of 2-(1*H*-pyrazol-3-yl)-thiazole.

35 The compounds 1-10-35 and 1-10-38, whose analytical data are reported in the following Table 1-10, were prepared analogously using 1*H*-pyrazole-3-carboxylic acid ethyl ester instead of 2-(1*H*-pyrazol-3-yl)-thiazole. The ester group was then transformed into the

corresponding N-methyltriazole and oxadiazole following procedures known in the literature (*J.Het.Chem.*, **1986**, 1391).

Compound 1-10-36, whose analytical data are reported in the following Table 1-10, was prepared by methylation of compound 1-10-37 using NaH as a base and methyl iodide as a methylating agent.

The compounds 1-10-29, 1-10-34 and 1-10-39, whose analytical data are reported in the following Table 1-10, were prepared analogously using respectively 2-amino-3,5-dichloropyridine, 2-amino-3-chloro-5-trifluoromethylpyridine and 3-amino-2-trifluoromethylpyridine instead of 2,4-bis-trifluoromethyl-aniline in the preparation of intermediate 54.

Compound 1-10-30, whose analytical data are reported in the following Table 1-10, was prepared analogously using 2,6-dimethoxy-3-aminopyridine in THF with EtONa as a base instead of 2,4-bis-trifluoromethyl-aniline in DMF with NaH as a base in the preparation of intermediate 54.

7-(2,4-Dichlorophenyl)-2-methyl-4-(3-trifluoromethylpyrazol-1-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine (1-10-5)

To a suspension of NaH 80%/oil (6 mg) in anh. DMF, at r.t., under N₂, was added 3-(trifluoromethyl)pyrazole (20 mg). The reaction mixture was stirred at r.t. until gas evolution ceased (20 min). Intermediate 8 (15 mg) was then added and the reaction mixture was heated at 100°C (screw cap vial) for 4 hr. It was then cooled down to r.t. and poured into EtOAc. The organic layer was washed with sat.aq. NaCl (3x5mL) and dried over anh. Na₂SO₄. The solids were filtered and the solvent evaporated. The crude product was purified by flash chromatography (silica gel, cHex/EtOAc 95:5) to give the title compound as a yellow solid (0.011 g).

7-(2-Bromo-4-isopropylphenyl)-2-methyl-4-(3-trifluoromethylpyrazol-1-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine (1-10-6)

3-(Trifluoromethyl)pyrazole (22.7 mg) was added to a suspension of NaH (80% in mineral oil, 5mg) in anh. DMF (0.5 mL) at 0°C. After 10 min, 20 mg of intermediate 13 (20 mg) were added and the solution was heated in a sealed vial at 100°C for 4 hr. The reaction mixture was poured into water and extracted with EtOAc (3x5mL). The combined organic extracts were dried over anh. Na₂SO₄. The solids were filtered, the solvent was evaporated and the crude oil was purified by flash chromatography (silica gel, cHex/EtOAc 95:5) to give the title compound as a clear oil (12 mg).

7-(2,4-Dichlorophenyl)-4-(5-isopropyl-3-trifluoromethylpyrazol-1-yl)-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine and 7-(2,4-Dichlorophenyl)-4-(3-isopropyl-5-trifluoromethylpyrazol-1-yl)-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine (1-10-7)

To a solution of intermediate 8 (22 mg) in anh. MeOH (0.7 mL), at r.t., under N₂, was added hydrazine monohydrate (34 µL). The reaction mixture was heated at 130°C in a sealed vial for 18 hr. It was then cooled down to r.t. and the solvent was evaporated to dryness *in vacuo*. The oil obtained was dissolved into anh. EtOH (0.7 mL) and 1,1,1-trifluoromethyl-5-methylhexanedione (26 mg) was added. The reaction mixture was heated at 110°C in a sealed

vial for 18 hr. The solvent was evaporated and the crude product was purified by flash chromatography (silica gel, cHex/EtOAc 95:5) to give the title compound (14 mg) as a mixture of regioisomers: 5-isopropyl-3-trifluoromethyl-pyrazole (60%) and 3-isopropyl-5-trifluoromethyl-pyrazole (40%).

5

4-(4-Bromo-5-methyl-3-trifluoromethylpyrazol-1-yl)-7-(2,4-dichlorophenyl)-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine (1-10-8)

4-Bromo-5-methyl-3-trifluoromethyl-1H-pyrazole (48 mg) was added to a suspension of NaH 80%/oil (4 mg) in anh. DMF (300 μ L). After stirring for 30 min, intermediate 8 (15 mg) was added at r.t. and the resulting mixture was heated at 110°C for 3 hr. The reaction was then concentrated *in vacuo* and the residue was diluted with H₂O and extracted CH₂Cl₂ (3x5mL). The combined organic extracts were dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated. The title compound was obtained after chromatographic purification (silica gel, cHex/EtOAc 95:5) as a white solid (12 mg).

15

7-(2,4-dichlorophenyl)-4-(3-ethyl-5-trifluoromethylpyrazol-1-yl)-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine (1-10-9)

A solution of intermediate 8 (21 mg) and hydrazine monohydrate (65 μ L) in anh. MeOH (300 μ L) was heated at 130° C for 6 hr. The mixture was then concentrated *in vacuo* and the residue was dissolved in EtOH (300 μ L). 1,1,1-trifluoro-2,4-hexanedione (32 mg) was added and the solution was stirred at 120°C for 18 hr. The solvent was evaporated and the residue was purified by flash chromatography (silica gel, cHex/EtOAc 96:4). The title compound was obtained as a colorless oil (5 mg).

20

7-(2,4-Dichlorophenyl)-2-methyl-4-(3-methylpyrazol-1-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine (1-10-10)

To a suspension of NaH 80%/oil (5.5 mg, 3 eq) in anh. DMF (0.3 mL), at r.t., under N₂, was added 3-methyl-pyrazole (16 mg, 3 eq) and the reaction mixture was stirred at r.t. for 30 min. Intermediate 8 (20 mg, 0.064 mmol) was added and the reaction mixture was stirred at 100°C (screw cap vial) for 6 hr. The solvent was evaporated and the residue taken up in H₂O and extracted with CH₂Cl₂ (3x). The combined organic extracts were dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated. The crude product was purified by flash chromatography (silica gel, cHex/EtOAc 9:1) to give the title compound as a white solid (17.5 mg, 76%) along with a small quantity of its 5-methyl-pyrazole isomer (example 1-10-12, 1 mg, 6%).

30

35

7-(2,4-Dichlorophenyl)-4-(3,5-dimethylpyrazol-1-yl)-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine (1-10-11)

To a suspension of NaH 80%/oil (5 mg, 3 eq) in anh DMF (0.5 mL), at r.t., under N₂, was added 3,5-dimethylpyrazole (14 mg, 3 eq) and the reaction mixture was stirred for 20 min at r.t. Intermediate 8 (15 mg, 0.048 mmol) was then added and the reaction mixture was heated at 100°C (screw cap vial) for 18 hr. It was then cooled down to r.t. and poured into EtOAc/sat.aq. NaCl. The phases were separated and the organic layer was washed with sat.aq. NaCl (2x) and dried over anh. Na₂SO₄. The solids were filtered and the solvent

40

evaporated. The residue was purified by flash chromatography (silica gel, cHex/EtOAc 9:1) to give the title compound as a white solid (9 mg).

7-(2,4-Dichlorophenyl)-4-(3-ethoxy-5-methylpyrazol-1-yl)-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-*d*]pyrimidine (1-10-14)

To a suspension of NaH 80%/oil (5 mg, 3 eq) in anh. DMF (0.5 mL), at r.t., under N₂, was added 3-ethoxy-5-methyl-pyrazole (18 mg, 3 eq) and the reaction mixture was stirred at r.t. until gas evolution ceased (20 min). Intermediate 8 (15 mg, 0.048 mol) was then added and the reaction mixture was stirred at 100°C (screw cap vial) for 4 hr. It was then cooled down to r.t. and partitioned between EtOAc/sat.aq. NaCl. The phases were separated and the organic layer was washed with sat.aq. NaCl (2x). It was dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated. The crude product was purified by flash chromatography (silica gel, cHex/EtOAc 8:2) to give the title compound as a yellow solid (6 mg)

7-(2,4-Dichlorophenyl)-4-(3-dimethoxymethylpyrazol-1-yl)-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-*d*]pyrimidine (1-10-15)

To a suspension of NaH 80%/oil (4 mg, 3 eq) in anh. DMF (0.3 mL), at r.t., under N₂, was added pyrazol-3-carboxaldehyde dimethyl acetal (20.5 mg, 3 eq) and the reaction mixture was stirred at r.t. for 30 min. Intermediate 8 (15 mg, 0.048 mmol) was added and the reaction mixture was stirred at 100°C (screw cap vial) for 3 hr. The solvent was evaporated and the residue taken up in H₂O and extracted with CH₂Cl₂ (3x). The combined organic extracts were dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated. The crude product was purified by flash chromatography (silica gel, cHex/EtOAc 8:2) to give the title compound as a white solid (16 mg, 80%).

7-(2,4-dichlorophenyl)-4-(3-ethyl-5-trifluoromethylpyrazol-1-yl)-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-*d*]pyrimidine (1-10-16)

A solution of intermediate 8 (21 mg, 0.067 mmol) and hydrazine monohydrate (65 µL, 1.34 mmol) in anh MeOH (300 µL) was heated at 130°C (screw cap vial) for 6 hr. The mixture was then concentrated *in vacuo* and 1,1,1-trifluoro-2,4-hexanedione (32 mg, 0.113 mmol) was added to the crude product dissolved in 300 µL of EtOH. The solution was stirred overnight at 120°C and, after evaporation of the solvent, was purified by flash chromatography (silica gel, cHex/EtOAc 96:4). The title compound was obtained as a clear oil (5 mg)

7-(2,4-Dichlorophenyl)-2-methyl-4-(5-methyl-3-trifluoromethylpyrazol-1-yl)-6,7-dihydro-5H-pyrrolo[2,3-*d*]pyrimidine (1-10-17)

To a suspension of NaH 80%/oil (6 mg) in anh. DMF, at r.t., under N₂, was added 3-methyl-5-(trifluoromethyl)pyrazole (22 mg). The reaction mixture was stirred at r.t. until gas evolution ceased (20 min). Intermediate 8 (15 mg) was then added and the reaction mixture was heated at 100°C (screw cap vial) for 18 hr. It was then cooled down to r.t. and poured into EtOAc. The organic layer was washed with sat.aq. NaCl (3x5 mL) and dried over anh. Na₂SO₄. The solids were filtered and the solvent evaporated. The crude product was purified

by flash chromatography (silica gel, cHex/EtOAc 95:5) to give the title compound (0.013 g) as a yellow solid.

5 4-(4-Bromo-3-methylpyrazol-1-yl)-7-(2,4-dichlorophenyl)-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-*d*]pyrimidine (1-10-18)

To a suspension of NaH 80%/oil (6 mg) in anh. DMF, at r.t., under N₂, was added 3-methyl-4-bromopyrazole (23 mg). The reaction mixture was stirred at r.t. until gas evolution ceased (20 min). Intermediate 8 (15 mg) was then added and the reaction mixture was heated at 100°C (screw cap vial) for 4 hr. It was then cooled down to r.t. and poured into EtOAc. The organic layer was washed with sat. aq. NaCl (3x5 mL) and dried over anh. Na₂SO₄. The solids were filtered and the solvent evaporated. The crude product was purified by flash chromatography (silica gel, cHex/EtOAc 95:5) to give the title compound as a yellow solid (0.018 g).

15 4-(4-Bromo-pyrazol-1-yl)-7-(2,4-Dichlorophenyl)-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-*d*]pyrimidine (1-10-19)

3-Bromopyrazole (21 mg) was added to a suspension of NaH 80%/oil (4 mg) in anh. DMF (300 µL). After stirring for 30 min at r.t., intermediate 8 (15 mg) was added and the resulting mixture was heated at 110°C for 3 hr. The reaction was then concentrated *in vacuo* and the residue was diluted with H₂O and extracted with CH₂Cl₂ (3x5 mL). The combined organic extracts were dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated. The title compound was obtained as a white solid (3.5 mg) after two chromatographic purifications (silica gel, EtOAc/cHex 95:5).

25 7-(2,4-Dichlorophenyl)-4-[3-(4-fluorophenyl)pyrazol-1-yl]-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-*d*]pyrimidine (1-10-22)

3-(3-fluoro phenyl) pyrazole (3 eq, 0.19 mmol) was added to a suspension of NaH 80%/oil (6 mg, 3eq) in anh. DMF (0.5 mL) at 0°C. After 10 min intermediate 8 (20 mg, 0.064 mmol) was added and the solution was heated in a sealed vial at 100°C for 3 hr. The reaction mixture was diluted with water and extracted with EtOAc (3x). The combined organic extracts were dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated. The crude oil was purified by flash chromatography (silica gel, cHex/EtOAc 90:10). The title compound was obtained as a white solid (79%)

35 7-(2,4-Dichlorophenyl)-4-[3-(4-chlorophenyl)pyrazol-1-yl]-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-*d*]pyrimidine (1-10-23)

3-(3-chloro phenyl) pyrazole (3 eq, 0.19 mmol) was added to a solution of NaH 80%/oil (6 mg, 3eq) in anh. DMF (0.5 mL) at 0°C. After 10 min, intermediate 8 (20 mg, 0.064 mmol) was added and the solution was heated in a sealed vial at 100°C for 3 hr. The reaction mixture was diluted with water and extracted with EtOAc (3x). The combined organic extracts were dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated. The crude oil was purified by flash chromatography (silica gel, cHex/EtOAc 90:10). The title compound was obtained as a white solid (60%).

1-[7-(2,4-Dichlorophenyl)-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl]-1H-pyrazole-3-carbonitrile (1-10-27)

To a suspension of NaH 80%/oil (4 mg, 3 eq) in anh. DMF (0.3 mL), at r.t., under N₂, was added 3-cyano-pyrazole (14 mg, 3 eq) and the reaction mixture was stirred at r.t. for 30 min.




- 5 Intermediate 8 (15 mg, 0.048 mmol) was added and the reaction mixture was stirred at 100°C (screw cap vial) for 4 hr. The solvent was evaporated and the residue taken up in H₂O and extracted with CH₂Cl₂ (3x). The combined organic extracts were dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated. The crude product was purified by flash chromatography (silica gel, cHex/EtOAc 8:2) to give the title compound as a white solid (11 mg, 62%).










N-{5-Cyclopropyl-2-[7-(2,4-dichlorophenyl)-2-methyl-7H-pyrrolo[2,3d]pyrimidin-4-yl]-2H-pyrazol-3-yl}acetamide (1-10-28)










To a suspension of NaH 95% (3.7 mg) in anh. DMF (0.5 mL) was added *N*-(5-cyclopropyl-2H-pyrazol-3-yl)-acetamide (24 mg) and the mixture was stirred for 20 min at r.t. Intermediate 8 (15 mg) was then added and the solution was heated in a sealed vial from 70°C to 140°C for 23 hr. It was then partitioned between H₂O and EtOAc. The organic layer was washed with brine, dried with anh. Na₂SO₄ and the solvent was removed under reduced pressure. The crude compound was purified by flash chromatography (silica gel, cHex/EtOAc 2:8) to give the title compound as a white solid (14 mg).







All the analytical data are set forth in the following Table 1-10.

Table 1-10







Cpd. No.	R	R ₁	R ₂ -R ₃ -	Analytical Data
1-10-1	2,4-dichlorophenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 8.74 (d, 1H), 7.91 (d, 1H), 7.53 (d, 1H), 7.40 (d, 1H), 7.37 (d, 1H), 7.34 (dd, 1H), 7.07 (d, 1H), 4.11 (t, 2H), 3.77 (t, 2H), 2.53 (s, 3H). MS (<i>m/z</i>): 429 [MH] ⁺ .
1-10-2	2,4-bis-trifluoro-methylphenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 8.69 (d, 1H), 8.06 (bs, 1H), 7.93 (bd, 1H), 7.91 (d, 1H), 7.59 (d, 1H), 7.37 (d, 1H), 7.05 (d, 1H), 4.06 (t, 2H), 3.79 (t, 2H). MS (<i>m/z</i>): 497 [MH] ⁺ .
1-10-3	2,4-dichlorophenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 8.63 (d, 1H), 7.50 (d, 1H), 7.38 (d, 1H), 7.32 (dd, 1H), 6.59 (d, 1H), 4.05 (t, 2H), 3.69 (t, 2H), 2.69 (s, 3H), 2.67 (s, 3H), 2.46 (s, 3H). MS (<i>m/z</i>): 457 [MH] ⁺ (2Cl).

1-10-4	2,4-dichlorophenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 9.62 (d, 1H), 7.52 (d, 1H), 7.43 (dd, 1H), 7.40 (d, 1H), 7.33 (dd, 1H), 7.31 (dd, 1H), 7.10 (dd, 1H), 6.68 (d, 1H), 4.07 (t, 2H), 3.75 (t, 2H), 2.48 (s, 3H). MS (<i>m/z</i>): 428 [MH] ⁺ (2Cl).
1-10-5	2,4-dichlorophenyl	CH ₃		NMR (¹ H,): δ 8.65 (m, 1H), 7.51 (d, 1H), 7.38 (d, 1H), 7.33 (dd, 1H), 6.68 (m, 1H), 4.04 (t, 2H), 3.65 (t, 2H), 2.46 (s, 3H). IR (cm ⁻¹): 1570, 1626. MS (<i>m/z</i>): 414 [MH] ⁺ .
1-10-6	2-bromo-4-isopropylphenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 8.67 (d, 1H), 7.54 (d, 1H), 7.30 (d, 1H), 7.25 (dd, 1H), 6.69 (d, 1H), 4.05 (t, 2H), 3.65 (t, 2H), 2.93 (m, 1H), 2.47 (s, 3H), 1.28 (d, 6H). MS (<i>m/z</i>): 466 [MH] ⁺ , 1Br.
1-10-7	2,4-dichlorophenyl	CH ₃		<u>Isomer 1</u> (5-isopropyl-3-trifluoromethyl): δ 7.52 (d, 1H), 7.37 (d, 1H), 7.34 (dd, 1H), 6.47 (s, 1H), 4.03 (t, 2H), 4.00 (m, 1H), 3.53 (t, 2H), 2.45 (s, 3H), 1.33 (d, 3H), 1.31 (d, 3H). <u>Isomer 2</u> (3-isopropyl-5-trifluoromethyl): δ 7.51 (d, 1H), 7.39 (d, 1H), 7.31 (dd, 1H), 6.69 (s, 1H), 4.02 (t, 2H), 3.51 (t, 2H), 3.03 (m, 1H), 2.45 (s, 3H), 1.33 (d, 3H), 1.31 (d, 3H). MS (<i>m/z</i>): 456 [MH] ⁺ .
1-10-8	2,4-dichlorophenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 7.52 (d, 1H), 7.36 (d, 1H), 7.33 (dd, 1H), 4.03 (t, 2H), 3.52 (t, 2H), 2.72 (s, 3H), 2.45 (s, 3H). MS (<i>m/z</i>): 506 [MH] ⁺ .
1-10-9	2,4-dichlorophenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 7.51 (d, 1H), 7.39 (d, 1H), 7.32 (dd, 1H), 6.68 (s, 1H), 4.03 (t, 2H), 3.53 (t, 2H), 2.73 (q, 2H), 2.45 (s, 3H), 1.31 (t, 3H). MS (<i>m/z</i>): 442 [MH] ⁺ .
1-10-10	2,4-dichlorophenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 8.49 (d, 1H), 7.50 (d, 1H), 7.39 (d, 1H), 7.31 (dd, 1H), 6.23 (d, 1H), 4.02 (t, 2H), 3.64 (t, 2H), 2.46 (s, 3H), 2.37 (s, 3H). MS (<i>m/z</i>): 360 [MH] ⁺ (2Cl).
1-10-11	2,4-dichlorophenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 7.59 (d, 1H), 7.51 (d, 1H), 7.38 (d, 1H), 7.32 (dd, 1H), 6.17 (bd, 1H), 4.01 (t, 2H), 3.55 (t, 2H), 2.70 (s, 3H), 2.46 (s, 3H). MS (<i>m/z</i>): 360 [MH] ⁺ (2Cl).
1-10-12	2,4-dichlorophenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 7.49 (d, 1H), 7.37 (d, 1H), 7.30 (dd, 1H), 5.96 (s, 1H), 3.99 (t, 2H), 3.54 (t, 2H), 2.64 (s, 3H), 2.44 (s, 3H), 2.27 (s, 3H). MS (<i>m/z</i>): 374 [MH] ⁺ 2 Cl.


1-10-13	2,4-dichlorophenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 8.38 (m, 1H), 7.58 (bs, 1H), 7.50 (d, 1H), 7.39 (d, 1H), 7.32 (dd, 1H), 4.02 (t, 2H), 3.62 (t, 2H), 2.46 (s, 2H), 2.17 (s, 3H). MS (<i>m/z</i>): 360 [MH] ⁺ (2Cl).
1-10-14	2,4-dichlorophenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 7.48 (d, 1H), 7.37 (d, 1H), 7.29 (dd, 1H), 5.63 (s, 1H), 4.26 (q, 2H), 3.96 (t, 2H), 3.57 (t, 2H), 2.66 (s, 3H), 2.41 (s, 3H), 1.40 (t, 3H). MS (<i>m/z</i>): 404 [MH] ⁺ (2Cl).
1-10-15	2,4-dichlorophenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 8.56 (d, 1H), 7.50 (d, 1H), 7.37 (d, 1H), 7.31 (dd, 1H), 6.51 (d, 1H), 5.50 (s, 1H), 4.02 (t, 2H), 3.65 (t, 2H), 3.43 (s, 6H), 2.46 (s, 3H). MS (<i>m/z</i>): 420 [MH] ⁺ (2Cl).
1-10-16	2,4-dichlorophenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 7.51 (d, 1H), 7.39 (d, 1H), 7.32 (dd, 1H), 6.68 (s, 1H), 4.03 (t, 2H), 3.53 (t, 2H), 2.73 (q, 2H), 2.45 (s, 3H), 1.31 (t, 3H). MS (<i>m/z</i>): 442 [MH] ⁺ .
1-10-17	2,4-dichlorophenyl	CH ₃		NMR (¹ H,): δ 7.52 (d, 1H), 7.37 (d, 1H), 7.33 (dd, 1H), 6.43 (s, 1H), 4.03 (t, 2H), 3.55 (t, 2H), 2.72 (s, 3H), 2.46 (s, 3H). MS (<i>m/z</i>): 428 [MH] ⁺ .
1-10-18	2,4-dichlorophenyl	CH ₃		NMR (¹ H,): δ 8.55 (s, 1H), 7.50 (d, 1H), 7.37 (d, 1H), 7.31 (dd, 1H), 4.01 (t, 2H), 3.59 (t, 2H), 2.43 (s, 3H), 2.31 (s, 3H). MS (<i>m/z</i>): 440 [MH] ⁺ .
1-10-19	2,4-dichlorophenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 8.63 (s, 1H), 7.68 (s, 1H), 7.50 (d, 1H), 7.37 (d, 1H), 7.32 (dd, 1H), 4.03 (t, 2H), 3.59 (t, 2H), 2.44 (s, 3H). MS (<i>m/z</i>): 424 [MH] ⁺ .
1-10-20	2,4-dichlorophenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 8.70 (s, 1H), 7.5 (d, 1H), 7.3-7.2 (m, 2H), 4.00 (t, 2H), 3.60 (t, 2H), 2.40 (s, 3H). MS (<i>m/z</i>): 425 [MH] ⁺ (3Cl).
1-10-21	2,4-dichlorophenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 8.8, (s, 1H), 7.5 (d, 1H), 7.3-7.2 (m, 2H), 4.05 (t, 2H), 3.10 (t, 2H), 2.5 (s, 3H). MS (<i>m/z</i>): 468 [MH] ⁺ (1Cl, 1Br).

1-10-22	2,4-dichlorophenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 8.64 (d, 1H), 7.88 (dd, 2H), 7.51 (d, 1H), 7.39 (d, 1H), 7.32 (dd, 1H), 7.13 (t, 2H), 6.72 (d, 1H), 4.07 (t, 2H), 3.77 (t, 2H), 2.48 (s, 3H). MS (<i>m/z</i>): 440 [MH] ⁺ (2Cl).
1-10-23	2,4-dichlorophenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 8.64 (d, 1H), 7.84 (d, 2H), 7.51 (d, 1H), 7.40 (m, 3H), 7.32 (dd, 1H), 6.75 (d, 1H), 4.07 (t, 2H), 3.76 (t, 2H), 2.48 (s, 3H). MS (<i>m/z</i>): 456 [MH] ⁺ (3Cl).
1-10-24	2,4-dichlorophenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 8.67 (d, 1H), 7.77 (dd, 1H), 7.68 (dd, 1H), 7.62 (dt, 1H), 7.50 (d, 1H), 7.37 (d, 1H), 7.31 (dd, 1H), 6.69 (d, 1H), 4.05 (t, 2H), 3.57 (t, 2H), 2.46 (s, 3H). MS (<i>m/z</i>): 467 [MH] ⁺ (1Cl).
1-10-25	2,4-dichlorophenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 9.00 (d, 1H), 8.67 (d, 1H), 8.24 (dd, 1H), 7.51 (d, 1H), 7.40 (d, 1H), 7.33 (dd, 1H), 7.07 (d, 1H), 7.05 (d, 1H), 4.10 (t, 2H), 4.07 (s, 3H), 3.80 (t, 1H), 2.48 (s, 3H). MS (<i>m/z</i>): 497 [MH] ⁺ (2Cl).
1-10-26	2,4-dichlorophenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 8.87 (d, 1H), 8.77 (d, 2H), 8.31 (d, 2H), 7.55 (d, 1H), 7.40 (d, 1H), 7.36 (dd, 1H), 7.06 (d, 1H), 4.14 (t, 2H), 3.78 (t, 2H), 2.52 (s, 3H). MS (<i>m/z</i>): 423 [MH] ⁺ (2Cl).
1-10-27	2,4-dichlorophenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 8.74 (d, 1H), 7.53 (dd, 1H), 7.4-7.3 (m, 2H), 6.83 (d, 1H), 4.09 (t, 2H), 3.66 (t, 2H), 2.49 (s, 3H). MS (<i>m/z</i>): 371 [MH] ⁺ (2Cl).

1-10-28	2,4-dichlorophenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 7.62 (bs, 1H), 7.50 (d, 1H), 7.39 (d, 1H), 7.32 (dd, 1H), 6.46 (s, 1H), 3.99 (t, 2H), 3.47 (t, 2H), 2.83 (m, 1H), 2.45 (s, 3H), 2.17 (s, 3H), 1.03 – 0.8 (m, 4H). IR (CDCl ₃ , cm ⁻¹): 3432, 1691. MS (<i>m/z</i>): 443 [MH] ⁺ .
1-10-29	2-(3,5-dichloro-pyridine)	CH ₃		NMR (¹ H, CDCl ₃): δ 8.69 (d, 1H), 8.36 (d, 1H), 7.91 (d, 1H), 7.85 (d, 1H), 7.38 (d, 1H), 7.05 (d, 1H), 4.27 (t, 2H), 3.75 (t, 2H), 2.56 (s, 3H). MS (<i>m/z</i>): 430 [M] ⁺ .
1-10-30	3-(2,6-bismethoxy-pyridine)	CH ₃		NMR (¹ H, CDCl ₃): δ 8.70 (ba, 1H), 7.88 (d, 1H), 7.63 (d, 1H), 7.36 (d, 1H), 7.04 (d, 1H), 6.39 (d, 1H), 4.04 (t, 2H), 3.96 (t, 3H), 3.94 (t, 3H), 3.69 (t, 2H), 2.51 (s, 3H). MS (<i>m/z</i>): 422 [MH] ⁺ .
1-10-31	2,4-bis-trifluoro-methylphenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 8.46 (d, 1H), 8.02 (bs, 1H), 7.9 (bd, 1H), 7.56 (d, 1H), 5.96 (d, 1H), 3.98 (t, 2H), 3.87 (t, 4H), 3.67 (t, 2H), 3.30 (t, 4H), 2.41 (s, 3H). MS (<i>m/z</i>): 500 [MH] ⁺ .
1-10-32	2,4-bis-trifluoro-methylphenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 9.17 (bs, 1H), 8.70 (d, 1H), 8.62 (d, 1H), 8.20 (d, 1H), 8.06 (bs, 1H), 7.93 (d, 1H), 7.59 (d, 1H), 7.41 (dd, 1H), 6.84 (d, 1H), 4.06 (t, 2H), 3.82 (t, 2H), 2.47 (s, 3H). MS (<i>m/z</i>): 491 [MH] ⁺ .
1-10-33	2,4-bis-trifluoro-methylphenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 9.36 (d, 1H), 8.73 (d, 1H), 8.61 (dd, 1H), 8.54 (d, 1H), 8.06 (sa, 1H), 7.94 (d, 1H), 7.59 (d, 1H), 7.16 (d, 1H), 4.07 (t, 2H), 3.82 (t, 2H), 2.47 (s, 3H). MS (<i>m/z</i>): 492 [MH] ⁺ .
1-10-34	2-(3-chloro-5-trifluoromethyl-pyridine)	CH ₃		NMR (¹ H, DMSO-d ₆): δ 8.70 (d, 1H), 8.63 (d, 1H), 8.04 (d, 1H), 7.91 (d, 1H), 7.38 (d, 1H), 7.06 (d, 1H), 4.35 (t, 2H), 3.76 (t, 2H), 2.55 (s, 3H). MS (<i>m/z</i>): 464 [MH] ⁺ .

1-10-35	2,4-bis-trifluoro-methylphenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 8.76 (d, 1H) 8.43 (s, 1H), 8.06 (s, 1H), 7.94 (d, 1H), 7.58 (d, 1H), 7.26 (d, 1H), 4.16 (s, 3H), 4.05 (t, 2H), 3.69 (t, 2H), 2.47 (s, 3H). MS (m/z): 495 [MH] ⁺ .
1-10-36	2,4-bis-trifluoro-methylphenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 8.72 (d, 1H), 8.06 (d, 1H), 7.94 (dd, 1H), 7.58 (d, 1H), 7.5 (broad, 1H), 7.30 (bs, 1H), 7.05 (bs, 1H), 4.19 (s, 3H), 4.04 (t, 2H), 3.70 (t, 2H), 2.46 (s, 3H). MS (m/z): 494 [MH] ⁺ , 238, 414.
1-10-37	2,4-bis-trifluoro-methylphenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 8.63 (d, 1H), 8.05 (d, 1H), 7.92 (dd, 1H), 7.57 (d, 1H), 7.22 (s, 2H), 7.21 (bs, 1H), 4.03 (t, 2H), 3.74 (t, 2H), 2.44 (s, 3H). MS (m/z): 480 [MH] ⁺ , 414
1-10-38	2,4-bis-trifluoro-methylphenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 8.76 (d, 1H) 8.50 (s, 1H), 8.04 (s, 1H), 7.93 (d, 1H), 7.57 (d, 1H), 7.12 (d, 1H), 4.05 (t, 2H), 3.77 (t, 2H), 2.45 (s, 3H). MS (m/z): 482 [MH] ⁺ .
1-10-39	3-(2-trifluoro-methylpyridine)	CH ₃		NMR (¹ H, CDCl ₃): 8.97 (s, 1H), 8.79 (d, 1H), 8.70 (d, 1H), 7.91 (d, 1H), 7.62 (s, 1H), 7.31 (d, 1H), 7.00 (d, 1H), 4.16 (t, 2H), 3.78 (t, 2H), 2.52 (s, 3H). MS (m/z): 430 [MH] ⁺
1-10-40	2,4-bis-trifluoro-methylphenyl	CH ₃		NMR (¹ H, Acetone-d ₆): δ 8.76 (d, 1H) 8.28 (s, 1H), 8.20 (m, 2H), 7.95 (d, 1H), 7.61 (s, 1H), 6.91 (d, 1H), 4.17 (t, 2H), 3.67 (t, 2H), 3.75 (t, 2H), 2.35 (s, 3H). MS (m/z): 481 [MH] ⁺ .

Synthesis of representative compounds of structure (1-11)



7-(2,4-Dichlorophenyl-2-methyl-4-(3-trifluoromethyl(1,2,4)triazol-1-yl)-6,7-dihydro-5H-pyrrolo(2,3-d)pyrimidine (1-11-2)

- 5 A solution of intermediate 8 (30 mg, 0.095 mmol) and hydrazine hydrate (0.095 mmol) in methanol (950 μ l) was heated at 130°C (screw cap vial) for 18hr. The mixture was then evaporated to dryness and the crude product obtained together with formyltrifluoroacetylrimide (43 mg, 0.3 mmol) in N-methylpyrrolidone (200 μ l) were heated at 100°C (screw cap vial) for 5hr. The mixture was then diluted with cold brine and extracted with EtOAc (3x). The combined organic extracts were dried over anh. Na₂SO₄, then filtered and the solvent evaporated *in vacuo*. The crude compound was purified by flash chromatography (silica gel, EtOAc/cHex 9:1) to give the title compound as a white solid (99%).
- 10
- 15 The compound 1-11-1, whose analytical data are reported in the following Table 1-11, was prepared analogously using diacetamide instead of formyltrifluoroacetylrimide.


All the analytical data are set forth in the following Table 1-11.

20

Table 1-11

Cpd. No.	R	R ₁	R ₂ -R ₃ -	Analytical Data
1-11-1	2,4-dichloro-phenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 7.51 (d, 1H), 7.37 (d, 1H), 7.33 (dd, 1H), 4.02 (t, 2H), 3.54 (t, 2H), 2.84 (s, 3H), 2.46 (s, 3H), 2.40 (s, 3H). MS (<i>m/z</i>): 375 [MH] ⁺ .
1-11-2	2,4-dichloro-phenyl	CH ₃		NMR (¹ H, CDCl ₃): 8.13 δ (s,1H), 7.54 δ (d,1H), 7.38 δ (d,1H), 7.35 δ (dd,1H), 4.08 δ (t,2H), 3.48 δ (t,2H), 2.47 δ (s,3H) . MS (<i>m/z</i>):415 [MH] ⁺ (2Cl).

Synthesis of representative compounds of structure (1-12)



7-(2,4-Dichlorophenyl)-2-methyl-4-(2-methyl-imidazol-1-yl)-6,7-dihydro-5H-pyrrolo[2,3-*d*]pyrimidine (1-12-3)

5 To a suspension of NaH 80%/oil (3 mg, 2 eq) in anhyd DMF (0.5 mL), at r.t., under N₂, was added 2-methyl-imidazole (8 mg, 2 eq) and the reaction mixture was stirred for 20 min at r.t. Intermediate 8 (15 mg, 0.048 mmol) was then added and the reaction mixture was heated at 80°C (screw cap vial) for 90 min. It was then cooled down to r.t. and poured into EtOAc/sat.aq. NaCl. The phases were separated and the organic layer was washed with sat.aq. NaCl (2x) and dried over anhyd. Na₂SO₄. The solids were filtered and the solvent

10 evaporated. The residue was purified by flash chromatography (silica gel, 8% MeOH/EtOAc) to give 6 mg of the title compound as a white solid (0.017 mmol, 35%)

The compounds 1-12-1, 1-12-2, 1-12-4, 1-12-5, 1-12-6 and 1-12-7, whose analytical data are reported in the following Table 1-12, were prepared analogously starting from the

15 appropriate imidazole.









1-[7-(2,4-Dichlorophenyl)-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-*d*]pyrimidin-4-yl]-1H-imidazole-4-carboxylic acid phenylamide (1-12-8)

20 To a suspension of NaH 95% (3.7 mg) in anhyd. DMF (0.5 mL) was added 1H-imidazole-4-carboxylic acid phenylamide (27 mg) and the mixture was stirred for 20 min at r.t.. Intermediate 8 (15 mg) was then added and the solution was heated in a sealed vial from 70 to 120°C for 6 hr. It was then partitioned between H₂O and EtOAc. The organic layer was washed with brine, dried with anhyd. Na₂SO₄ and the solvent was removed under reduced pressure. The crude compound was purified by flash chromatography (silica gel, cHex/EtOAc 1:9) to give the title compound (9.8 mg) as a yellow solid.

25


All the analytical data are set forth in the following Table 1-12.

Table 1-12


Cpd. No.	R	R ₁	R ₂ -R ₃ -	Analytical Data
1-12-1	2,4-dichloro-phenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 7.51 (dd, 1H), 7.37 (dd, 1H), 7.32 (dd, 1H), 7.07 (d, 1H), 7.04 (d, 1H), 4.01 (t, 2H), 3.16 (t, 2H), 2.90 (q, 2H), 2.45 (s, 3H), 1.32 (t, 3H). MS (<i>m/z</i>): 374 [MH] ⁺ (2Cl).
1-12-2	2,4-dichloro-phenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 7.50 (d, 1H), 7.36 (d, 1H), 7.31 (dd, 1H), 7.07 (d, 1H), 7.04 (d, 1H), 4.02 (t, 2H), 3.16 (t, 2H), 2.88 (dd, 2H), 2.46 (s, 3H), 1.75 (m, 2H), 0.93 (t, 3H). MS (<i>m/z</i>): 388 [MH] ⁺ (2Cl).
1-12-3	2,4-dichloro-phenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 7.52 (d, 1H), 7.38 (d, 1H), 7.34 (dd, 1H), 7.11 (d, 1H), 7.03 (d, 1H), 4.04 (t, 2H), 3.21 (t, 2H), 2.58 (s, 3H), 2.47 (s, 3H). MS (<i>m/z</i>): 360 [MH] ⁺ 2 Cl.
1-12-4	2,4-dichloro-phenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 8.31 (s, 1H), 7.52 (d, 1H), 7.50 (s, 1H), 7.37 (d, 1H), 7.33 (dd, 1H), 4.09 (t, 2H), 3.73 (t, 2H), 3.42 (t, 2H), 3.40 (s, 3H), 2.94 (t, 2H), 2.46 (s, 3H). MS (<i>m/z</i>): 404 [MH] ⁺ (2Cl).
1-12-5	2,4-dichloro-phenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 7.53 (d, 1H), 7.38 (d, 1H), 7.34 (dd, 1H), 6.83 (s, 1H), 4.04 (t, 2H), 3.22 (t, 2H), 2.56 (s, 3H), 2.47 (s, 3H), 2.23 (s, 3H). MS (<i>m/z</i>): 374 [MH] ⁺ .
1-12-6	2,4-dichloro-phenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 8.34 (s, 1H), 8.05 (s, 1H), 7.54 (s, 1H), 7.36 (m, 2H), 4.13 (t, 2H), 3.45 (t, 2H), 2.47 (s, 3H). MS (<i>m/z</i>): 415 [MH] ⁺ (2Cl)
1-12-7	2,4-dichloro-phenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 7.52 (d, 1H), 7.38 (d, 1H), 7.33 (dd, 1H), 6.79 (s, 1H), 4.03 (t, 2H), 3.19 (t, 2H), 2.90 (q, 2H), 2.46 (s, 3H), 2.24 (s, 3H), 1.31 (t, 3H). MS (<i>m/z</i>): 388 [MH] ⁺ .
1-12-8	2,4-dichloro-phenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 9.02 (bs, 1H), 8.48 (d, 1H), 8.26 (d, 1H), 7.74 (d, 2H), 7.54 (d, 1H), 7.38 (t, 2H), 7.36 (d, 1H), 7.25 (d, 1H), 7.14 (t, 1H), 4.13 (t, 2H), 3.48 (t, 2H), 2.48 (s, 3H). IR (CDCl ₃ , cm ⁻¹): 3389, 1674. MS (<i>m/z</i>): 465 [MH] ⁺ .

EXAMPLE 2

Synthesis of representative compounds of structure (Ia-2)



Synthesis of representative compounds of structure (2-1)



- 5 Representative compounds of this invention were prepared by the procedure set forth above for the compounds of general formula (2-2).


All the analytical data are set forth in the following Table 2-1.

Table 2-1

Cpd. No.	R	R ₁	R ₂ -	R ₃ -	Analytical Data
2-1-1	2,4-dichloro-phenyl	CH ₃		H	NMR (¹ H, CDCl ₃): δ 7.38 (d, 1H), 7.12 (dd, 1H), 6.76 (d, 1H), 4.64 (m, 1H), 4.51 (br t, 1H), 3.40 (m, 2H), 2.80 (m, 2H), 2.66 (m, 1H), 2.50 (s, 3H), 1.84 (m, 1H), 1.10 (m, 1H), 0.58 (m, 2H), 0.30 (m, 2H). MS (<i>m/z</i>): 348 [MH] ⁺ .

10

Synthesis of representative compounds of structure (2-2)



15

Butyl-[7-(2,4-dichlorophenyl)-2-methyl-6,7-dihydro-5H-cyclopentapyrimidin-4-yl]-ethyl-amine (2-2-5)

20

Intermediate 34 (12 mg, 0.04mmol) was dissolved in 300 μl of butylethylamine and heated at 160°C (screw cap vial) for 18 hr. The reaction mixture was diluted with water and extracted with CH₂Cl₂ (3x). The combined organic extracts were dried over anhydrous Na₂SO₄, the solids were filtered and the solvent evaporated. The crude oil was purified by flash chromatography (silica gel, cHex/EtOAc 85:15) to give the title compound (6mg, 40%) as a yellow oil.

The compounds 2-1-1, 2-2-1, 2-2-2, 2-2-3, 2-2-4, 2-2-6 and 2-2-7, whose analytical data are reported in the following Table 2-2, were prepared analogously starting from the appropriate amine.







In particular a differently substituted Grignard reagent, (intermediate 41), phenyl acetic ester (intermediate 31) or phenyl boronic acid (intermediate 35) was used:


- 5 compound 2-2-1: methyl 2,4-difluorophenylacetate (commercially available);
 compound 2-2-2: 2-bromo-5-fluorotoluene (commercially available);
 compound 2-2-3: 2-bromo-5-methyltoluene (commercially available);
 compound 2-2-4: 1-bromo-2,4-dimethoxybenzene (commercially available);
 compound 2-2-7: 1-bromo-3,4-dimethoxybenzene (commercially available).

All the analytical data are set forth in the following Table 2-2.


10

Table 2-2

Cpd. No.	R	R ₁	R ₂ -	R ₃ -	Analytical Data
2-2-1	2,4-bistrifluoro-methylphenyl	CH ₃		Et	NMR (¹ H, CDCl ₃): δ 6.88 (m, 1H), 6.77 (m, 2H), 4.40 (t, 1H), 3.6 (m, 2H), 3.5 (m, 2H), 3.03 (m, 2H), 2.52 (m, 1H), 2.42 (s, 3H), 1.86 (m, 1H), 1.60 (m, 2H), 1.35 (m, 2H), 1.19 (t, 3H), 0.95 (t, 3H). MS (m/z): 346 [MH] ⁺ .
2-2-2	2-methyl-4-fluorophenyl	CH ₃		Et	NMR (¹ H, CDCl ₃): δ 6.88 (dd, 1H), 6.75 (td, 1H), 6.64 (dd, 1H), 4.32 (m, 1H), 3.64 (m, 2H), 3.54 (m, 2H), 3.02 (m, 2H), 2.52 (m, 1H), 2.45 (s, 3H), 2.39 (s, 3H), 1.78 (m, 1H), 1.65 (m, 2H), 1.36 (m, 2H), 1.20 (t, 3H), 0.96 (t, 3H). MS (m/z): 342 [MH] ⁺ .
2-2-3	2,4-isopropyl-phenyl	CH ₃		Et	NMR (¹ H, CDCl ₃): δ 6.98 (d, 1H), 6.86 (dd, 1H), 6.56 (d, 1H), 4.32 (m, 1H), 3.70-3.44 (m, 2H+2H), 3.02 (m, 2H), 2.50 (m, 1H), 2.42 (s, 3H), 2.35 (s, 3H), 2.25 (s, 3H), 1.8 (m, 1H), 1.6 (m, 2H), 1.35 (m, 2H), 1.19 (t, 3H), 0.96 (t, 3H). MS (m/z): 338 [MH] ⁺ (100%).
2-2-4	2,4-dimethoxy-phenyl	CH ₃		Et	NMR (¹ H, CDCl ₃): δ 6.67 (d, 1H), 6.46 (d, 1H), 6.38 (dd, 1H), 4.44 (dd, 1H), 3.79 (s, 3H), 3.78 (s, 3H), 3.67-3.44 (m, 4H), 3.00 (m, 2H), 2.45 (m, 1H), 2.44 (s, 3H), 1.83 (m, 1H), 1.6 (m, 2H), 1.36 (m, 2H), 1.20 (t, 3H), 0.97 (t, 3H). MS (m/z): 370 [MH] ⁺ .
2-2-5	2,4-dichloro-phenyl	CH ₃		Et	NMR (¹ H, CDCl ₃): δ 7.39 (d, 1H), 7.12 (dd, 1H), 6.76 (d, 1H), 4.56 (m, 1H), 3.58 (m, 4H), 3.02 (m, 2H), 2.60 (m, 1H), 2.45 (s, 3H), 1.79 (m, 1H), 1.62 (m, 2H), 1.37 (m, 2H), 1.21 (t, 3H), 0.98 (t, 3H). MS (m/z): 378 [MH] ⁺ (2Cl)
2-2-6	2,4-dichloro-phenyl	CH ₃		Et	NMR (¹ H, CDCl ₃): δ 7.37 (d, 1H), 7.15 (dd, 1H), 6.84 (d, 1H), 4.98 (s,

					1H), 4.97 (bm, 2H), 4.74 (s, 1H), 4.15 (bm, 2H), 3.72 (bm, 2H), 3.09 (m, 2H), 2.68 (bs, 3H), 2.56 (bm, 1H), 2.04 (bm, 1H), 1.75 (s, 3H), 1.26 (t, 3H). MS (<i>m/z</i>): 376 [MH] ⁺ (2Cl).
2-2-7	3,4-dimethoxy-phenyl	CH ₃		Et	MS (<i>m/z</i>): 370 [MH] ⁺

Synthesis of representative compounds of structure (2-3)



5 Cyclopropylmethyl-[7-(2,4-dimethoxy-phenyl)-2-methyl-6,7-dihydro-5H-cyclopentapyrimidin-4-yl]-propyl-amine (2-3-5)

Intermediate 44 (16 mg, 0.053 mmol) and cyclopropylmethyl-propylamine (75 μ L, 10 eq) in DMSO (1 mL) were heated at 100°C (screw cap vial) for 18 hr. The reaction mixture was taken up in EtOAc and washed with sat.aq. NaCl (2x). The organic layer was dried over anh.

10 Na₂SO₄, the solids were filtered and the solvent evaporated. The crude product was purified by flash chromatography (silica gel, cHex/EtOAc 8:2) to give the title compound as a clear oil (10 mg, 50%).

15 Cyclopropylmethyl-[7-(2,4-dichlorophenyl)-2-methyl-6,7-dihydro-5H-cyclopentapyrimidin-4-yl]-propyl-amine (2-3-6)

Intermediate 34 (12 mg, 0.038 mmol) was dissolved in cyclopropylmethyl-propylamine (0.3 mL, 55 eq) and the mixture was stirred in a screw cap vial at 160°C for 22 hr. The excess amine was evaporated and the residue was purified by flash chromatography (silica gel, gradient: cHex/EtOAc 95:5 to 9:1). The title compound was obtained as a colourless oil (7

20 mg, 0.018 mmol, 47%).







The compounds 2-3-1, 2-3-2, 2-3-3, 2-3-4 and 2-3-7, whose analytical data are reported in the following Table 2-3, were prepared analogously starting from the appropriate amine.







In particular a differently substituted Grignard reagent, (intermediate 41), phenyl acetic ester (intermediate 31) or phenyl boronic acid (intermediate 35) was used:

- 25 compound 2-3-1: 2-bromo-5-methyltoluene (commercially available);
 compound 2-3-2: methyl 2,4-difluorophenylacetate (commercially available);
 compound 2-3-3: 2-bromo-5-methyltoluene (commercially available);
 compound 2-3-4: 2-bromo-5-methyltoluene (commercially available);
 30 compound 2-2-7: 1-bromo-3,4-dimethoxybenzene (commercially available).


All the analytical data are set forth in the following Table 2-3.

Table 2-3

Cpd. No.	R	R ₁	R ₂ -	R ₃ -	Analytical Data
2-3-1	3-methyl-5-methylphenyl	CH ₃			NMR (¹ H, CDCl ₃): δ 6.85 (d, 1H), 6.73 (m, 2H), 4.05 (dd, 1H), 3.45-3.7 (m, 3H), 3.13 (m, 1H), 3.05 (m, 1H), 2.40 (s, 3H), 2.25 (s, 6H), 2.00 (m, 1H), 1.67 (m, 2H), 1.10 (m, 1H), 1.95 (m, 5H), 0.55 (m, 2H), 0.30 (m, 2H). MS (<i>m/z</i>): 350 [MH] ⁺ .
2-3-2	2,4-difluorophenyl	CH ₃			NMR (¹ H, CDCl ₃): δ 6.87 (m, 1H), 6.77 (m, 2H), 4.40 (t, 1H), 3.58 (m, 2H), 3.45 (m, 2H), 3.04 (m, 2H), 2.55 (m, 1H), 2.43 (s, 3H), 1.86 (m, 1H), 1.65 (m, 2H), 1.07 (m, 1H), 0.92 (t, 3H), 0.58 (m, 2H), 0.27 (m, 2H). MS (<i>m/z</i>): 358 [MH] ⁺ (100 %).
2-3-3	2,4-dimethylphenyl	CH ₃			NMR (¹ H, CDCl ₃): δ 6.98 (d, 1H), 6.87 (dd, 1H), 6.58 (d, 1H), 4.33 (m, 1H), 3.66-3.44 (m, 2H+2H), 3.05 (m, 2H), 2.50 (m, 1H), 2.42 (s, 3H), 2.35 (s, 3H), 2.26 (s, 3H), 1.85 (m, 1H), 1.60 (m, 2H), 1.08 (m, 1H), 0.91 (t, 3H), 0.53 (m, 2H), 0.29 (m, 2H). MS (<i>m/z</i>): 350 [MH] ⁺ (100%)

2-3-4	2-methyl-4-fluorophenyl	CH ₃			NMR (¹ H, CDCl ₃): δ 6.87 (dd, 1H), 6.74 (td, 1H), 6.63 (dd, 1H), 4.31 (dd, 1H), 3.56 (m, 2H), 3.51 (dd, 2H), 3.04 (m, 2H), 2.50 (m, 1H), 2.44 (s, 3H), 2.38 (s, 3H), 1.80 (m, 1H), 1.66 (q, 2H), 0.92 (t, 3H), 1.08-0.85 (m, 1H), 0.54 (m, 2H), 0.29 (m, 2H). MS (<i>m/z</i>): 353 [M] ⁺ .
2-3-5	2,4-dimethoxyphenyl	CH ₃			NMR (¹ H, CDCl ₃): δ 6.64 (d, 1H), 6.45 (d, 1H), 6.36 (dd, 1H), 4.45 (dd, 1H), 3.78 (s, 3H), 3.76 (s, 3H), 3.6-3.4 (m, 2H), 3.55-3.49 (m, 2H), 3.1-2.9 (m, 2H), 2.45 (m, 1H), 2.44 (s, 3H), 1.81 (m, 1H), 1.66 (m, 2H), 1.08 (m, 1H), 0.91 (t, 3H), 0.6-0.2 (m, 4H). MS (<i>m/z</i>): 382 [MH] ⁺ .
2-3-6	2,4-dichlorophenyl	CH ₃			NMR (¹ H, CDCl ₃): δ 7.35 (d, 1H), 7.10 (dd, 1H), 6.75 (d, 1H), 4.55 (dd, 1H), 3.65-3.40 (m, 4H), 3.00 (t, 2H), 2.60 (m, 1H), 2.40 (s, 3H), 1.75 (m, 1H), 1.60 (m, 2H), 1.05 (m, 1H), 0.90 (t, 3H), 0.55 (m, 2H), 0.25 (m, 2H). MS (<i>m/z</i>): 390 [MH] ⁺ .

Synthesis of representative compounds of structure (2-4)




5

Representative compounds of this invention were prepared by the procedure set forth above for the compounds of general formula (2-1) (intermediate 41: phenyl magnesium bromide was used as the Grignard reagent).


All the analytical data are set forth in the following Table 2-4.

10

Table 2-4

Cpd. No.	R	R ₁	R ₂ -R ₃ -	Analytical Data
2-4-1	phenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 7.27 (m, 2H), 7.20 (m, 1H), 7.13 (d, 2H), 4.22 (dd, 1H), 3.78 (m, 4H), 3.75 (m, 4H), 3.07 (m, 1H), 2.96 (m, 1H), 2.54 (m, 1H), 2.46 (s, 3H), 2.05 (m, 1H). MS (<i>m/z</i>): 295 [MH] ⁺ .

Synthesis of representative compounds of structure (2-5)



7-(2,4-Dichlorophenyl)-4-[(2R,5R)-2,5-dimethyl-pyrrolidin-1-yl]-2-methyl-6,7-dihydro-5H-cyclopentapyrimidine (2-5-1) and 7-(2,4-dichlorophenyl)-4-[(2R,5R)-2,5-dimethyl-pyrrolidin-1-yl]-2-methyl-6,7-dihydro-5H-cyclopentapyrimidine (2-5-2)

- 5 Intermediate 34 (27 mg, 0.086 mmol) was dissolved in anh. DMSO (0.3 mL). Enantiomerically pure (2R,5R)-(-)-2,5-dimethylpyrrolidine (0.1 mL, 10 eq) was added and the mixture was stirred in a screw cap vial at 160°C for 4 hr. The mixture was cooled to r.t., diluted with EtOAc, washed with water (3x10 mL) and dried over anh. Na₂SO₄. The solids were filtered and the solvent evaporated. The two diastereoisomers were separated by flash
- 10 chromatography (silica gel, cHex/EtOAc 9:1). The two title compounds were obtained as colourless oils (isomer 1: 11 mg, 0.029 mmol, 34%) (isomer 2: 13 mg, 0.035 mmol, 40%)

All the analytical data are set forth in the following Table 2-5.


15

Table 2-5

Cpd. No.	R	R ₁	R ₂ -R ₃ -	Analytical Data
2-5-1	α-2,4-dichloro-phenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 7.39 (d, 1H), 7.13 (dd, 1H), 6.75 (d, 1H), 4.64 (dd, 1H), 4.50 (br s, 1H), 2.99 (m, 2H), 2.65 (m, 1H), 2.47 (s, 3H), 2.22 (m, 2H), 1.78 (m, 1H), 1.65 (m, 2H), 1.15 (br d, 6H). MS (m/z): 376 [MH] ⁺ .
2-5-2	β-2,4-dichloro-phenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 7.39 (d, 1H), 7.12 (dd, 1H), 6.77 (d, 1H), 4.54 (dd, 1H), 4.50 (br s, 1H), 2.95 (m, 2H), 2.63 (m, 1H), 2.48 (s, 3H), 2.23 (m, 2H), 1.81 (m, 1H), 1.66 (m, 2H), 1.14 (br d, 6H). MS (m/z): 376 [MH] ⁺ .

EXAMPLE 3

Synthesis of representative compounds of structure (Ib-1)



5 [8-(2,4-Bis-trifluoromethylphenyl)-2-methyl-5,6,7,8-tetrahydro-pyrido[2,3-*d*]pyrimidin-4-yl]-(1-propyl-butyl)amine (3-1-1)

A mixture of intermediate 51 (22 mg, 0.0505 mmol) and 4-heptylamine (150 μ l) was heated at 130°C (screw cap vial) for 18 hr. The crude oil was directly purified by flash chromatography (silica gel, cHex/EtOAc 95:5) to give the title compound as light yellow oil (7 mg, 30%).

Butyl[8-(2,4-dichlorophenyl)-2-methyl-5,6,7,8-tetrahydropyrido[2,3-*d*]pyrimidin-4-yl]ethyl-amine (3-1-2)

A mixture of intermediate 30 (8 mg) and *n*-butyl-ethylamine (300 μ l) was heated in a sealed vial at 160°C for 18 hr. The crude oil was directly purified by flash chromatography (silica gel, cHex/EtOAc 9:1) to give the title compound (4 mg) as a light yellow oil.

Cyclopropylmethyl[8-(2,4-dichlorophenyl)-2-methyl-5,6,7,8-tetrahydropyrido[2,3-*d*]pyrimidin-4-yl]-propyl-amine (3-1-3)

Intermediate 30 (8 mg, 0.024 mmol) and cyclopropylmethyl-propyl-amine (300 μ l) were heated at 160°C (screw cap vial) for 18 hr. The crude oil was directly purified by flash chromatography (silica gel, cHex/EtOAc 9:1) to give the title compound as light yellow oil (4 mg, 41%).


All the analytical data are set forth in the following Table 3.

Table 3

Cpd. No.	R	R ₁	R ₂ -	R ₃ -	Analytical Data
3-1-1	2,4-bistrifluoro-methylphenyl	CH ₃		H	NMR (¹ H, CDCl ₃): δ 7.96 (d, 1H), 7.79(dd, 1H), 7.39 (d, 1H), 4.31 (m, 1H), 3.86 (da, 1H), 3.51 (m, 2H), 2.39 (m, 2H), 2.15 (m, 2H), 2.13 (s, 3H), 1.5-1.2 (m, 8H), 0.88 (t, 6H). MS (<i>m/z</i>): 475 [MH] ⁺ .
3-1-2	2,4-dichloro-phenyl	CH ₃		Et	NMR (¹ H, CDCl ₃): δ 7.4-7.2 (m, 3H), 3.63 (bm, 1H), 3.50 (bm, 1H), 3.32-3.26 (m, 4H), 2.63 (m, 2H), 2.21 (s, 3H), 2.00 (m, 2H), 1.5 (m, 2H), 1.30 (m, 2H), 1.14 (t, 3H), 0.92 (t, 3H). MS (<i>m/z</i>): 405[MH] ⁺ , 2Cl.
3-1-3	2,4-dichloro-phenyl	CH ₃			NMR (¹ H, CDCl ₃): δ 7.46 (d, 1H), 7.26-7.21(dd/d, 2H), 3.64 (bm, 1H),

				3.50 (bm, 1H), 3.35 (dd, 2H), 3.17 (dd, 2H), 2.67 (t, 2H), 2.21 (s, 3H), 2.01 (m, 2H), 1.57 (m, 2H), 1.03 (m, 1H), 0.88 (t, 3H), 0.49 (m, 2H), 0.17 (m, 2H). MS (<i>m/z</i>): 405[MH] ⁺ , 2Cl.
--	--	--	--	--

Synthesis of representative compounds of structure (3-2)



- 5 Representative compounds of this invention were prepared by the procedure set forth above for the compounds of general formula 1-10.

All the analytical data are set forth in the following Table 3-2.


Table 3-2

Cpd. No.	R	R ₁	R ₂ -R ₃ -	Analytical Data
3-2-1	2,4-bis-trifluoro-methylphenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 8.45 (d, 1H), 8.04/7.93 (bs/bd, 2H), 7.43 (d, 1H), 6.69 (d, 1H), 3.67 (m, 2H), 3.21 (m, 2H), 2.28/2.11 (s/m, 5H). MS (<i>m/z</i>): 496 [MH] ⁺ .

10


EXAMPLE 4

Synthesis of representative compounds of structure (Ib-2)



15

Synthesis of representative compounds of structure (4-1)







Representative compounds of this invention were prepared by the procedure set forth below for the compounds of general formula (4-2).


All the analytical data are set forth in the following Table 4-1.

20

Table 4-1

Cpd. No.	R	R ₁	R ₂ -	R ₃ -	Analytical Data
4-1-1	2,4-dimethoxy-phenyl	CH ₃			NMR (¹ H, CDCl ₃): δ 6.47 (d, 1H), 6.44 (d, 1H), 6.33(dd, 1H), 4.35 (t, 1H), 3.77 (s, 6H), 3.46 (m, 1H), 3.40 (m, 1H), 3.27 (m, 2H), 2.58 (m, 2H), 2.40 (s, 3H), 2.11 (m, 1H), 1.78 (m, 2H), 1.60 (m, 3H), 1.08 (m, 1H), 0.89 (t, 3H), 0.51 (m, 2H), 0.20 (m, 2H). MS (<i>m/z</i>): 396 [MH] ⁺ .
4-1-2	2-methyl-4-fluorophenyl	CH ₃			NMR (¹ H, CDCl ₃): δ 6.87 (dd, 1H), 6.72 (td, 1H), 6.51 (dd, 1H), 4.26 (bt, 1H), 3.50 (m, 1H), 3.40 (m, 1H), 3.29 (d, 2H), 2.63 (m, 2H), 2.41 (s, 3H), 2.39 (s, 3H), 2.18 (m, 1H), 1.80 (m, 1H), 1.72 (m, 1H), 1.60 (m, 3H) 1.09 (m, 1H), 0.91 (t, 3H), 0.53 (dm, 2H), 0.21 (m, 2H). MS (<i>m/z</i>): 368 [MH] ⁺ .

Synthesis of representative compounds of structure (4-2)



5

Butyl[8-(2,4-dichlorophenyl)-2-methyl-5,6,7,8-tetrahydroquinazolin-4-yl]ethylamine

Intermediate 40 (89 mg, 0.27 mmol) and butyl ethyl amine (0.4 mL, 10 eq) dissolved in anh. DMSO (4 mL) were heated at 100°C (screw cap vial) for 4 h. The reaction mixture was then cooled down to r.t. and poured in EtOAc/H₂O. The phases were separated and the organic layer was dried over anh. Na₂SO₄. The solids were filtered, the solvent was evaporated and the crude oil was purified by flash chromatography (silica gel, toluene/acetone 97:3). The title compound was obtained as a yellow oil (25 mg, 0.06 mmol, 24%).

10

Compounds 4-1-1, 4-1-2, 4-2-1, 4-2-2 and 4-2-3 were prepared analogously using the appropriate amine. The chloro-pyrimidine intermediates of examples 4-1-1, 4-1-2, 4-2-1, 4-2-2 and 4-2-3 were prepared using the procedure set forth for intermediate 41, except that:

15

- a) 2-chloro-cyclohexanone was used instead of 2-chloro-pentanone, and
b) different Grignard reagents were used:





4-1-1 and 4-2-1 (1-bromo-2,4-dimethoxybenzene),

20

4-1-2 and 4-2-2 (2-bromo-5-fluoro-toluene) and 4-2-3 (2-bromo-5-methyl-toluene).

Table 4-2

Cpd. No.	R	R ₁	R ₂ -	R ₃ -	Analytical Data
----------	---	----------------	------------------	------------------	-----------------

4-2-1	2,4-dimethoxy-phenyl	CH ₃		Et	NMR (¹ H, CDCl ₃): δ 6.47 (d, 1H), 6.44 (d, 1H), 6.33 (dd, 1H), 4.36 (t, 1H), 3.76 (s, 6H), 3.45-3.30 (m, 4H), 2.60 (m, 2H), 2.40 (s, 3H), 2.10 (m, 1H), 1.70-1.60 (m, 5H), 1.32 (q, 2H), 1.17 (t, 3H), 0.94 (t, 3H). MS (m/z): 383 [MH] ⁺ .
4-2-2	2-methyl-4-fluorophenyl	CH ₃		Et	NMR (¹ H, CDCl ₃): δ 6.87 (dd, 1H), 6.72 (m, 1H), 6.51 (dd, 1H), 4.25 (m, 1H), 3.5-3.3 (m, 4H), 2.60 (m, 2H), 2.41 (s, 3H), 2.39 (s, 3H), 2.17 (m, 1H), 1.78 (m, 1H), 1.75-1.60 (m, 2H), 1.60 (m, 2H), 1.34 (m, 2H), 1.21 (t, 3H), 0.95 (t, 3H). MS (m/z): 356 [MH] ⁺ .
4-2-3	2,4-dimethyl-phenyl	CH ₃		Et	NMR (¹ H, CDCl ₃): δ 6.98 (bs, 1H), 6.84 (bd, 1H), 6.46 (d, 1H), 4.25 (t, 1H), 3.50 (m, 1H), 3.38 (m, 1H), 3.28 (m, 2H), 2.60 (m, 2H), 2.38 (s, 3H), 2.37 (s, 3H), 2.26 (s, 3H), 2.17 (m, 1H), 1.82 (m, 1H), 1.72 (m, 1H), 1.63 (m, 3H), 1.08 (m, 1H), 0.89 (t, 3H), 0.51 (m, 2H), 0.20 (m, 2H). MS (m/z): 364 [MH] ⁺ .
4-2-4	2,4-dichloro-phenyl	CH ₃		Et	NMR (¹ H, CDCl ₃): δ 7.37 (d, 1H), 7.07 (dd, 1H), 6.57 (d, 1H), 4.45 (t, 1H), 3.43 (m, 4H), 2.59 (m, 2H), 2.38 (s, 3H), 2.24 (m, 2H), 1.73 (m, 2H), 1.6-1.5 (m, 2H), 1.32 (m, 2H), 1.38 (t, 3H), 0.94 (t, 3H). MS (m/z): 392 [MH] ⁺ (2Cl)

EXAMPLE 5

CRF Binding Activity

5

CRF binding affinity has been determined in vitro by the compounds' ability to displace ¹²⁵I-oCRF and ¹²⁵I-Sauvagine for CRF1 and CRF2 SPA, respectively, from recombinant human CRF receptors expressed in Chinese Hamster Ovary (CHO) cell membranes. For membrane preparation, CHO cells from confluent T-flasks were collected in SPA buffer (HEPES/KOH 50mM, EDTA 2mM; MgCl₂ 10mM, pH 7.4.) in 50mL centrifuge tubes, homogenized with a Polytron and centrifuged (50'000g for 5min at 4°C: Beckman centrifuge with JA20 rotor). The pellet was resuspended, homogenized and centrifuged as before.

10

The SPA experiment has been carried out in Optiplate by the addition of 100 μL the reagent mixture to 1μL of compound dilution (100% DMSO solution) per well. The assay mixture was prepared by mixing SPA buffer, WGA SPA beads (2.5 mg/mL), BSA (1 mg/mL) and membranes (50 and 5 μg of protein/mL for CRF1 and CRF2 respectively) and 50 pM of radioligand.

15

The plate was incubated overnight (>18 hrs) at room temperature and read with the Packard Topcount with a WGA-SPA ¹²⁵I counting protocol.

20

EXAMPLE 6
CRF functional assay

5 Compounds of the invention were characterised in a functional assay for the determination of their inhibitory effect. Human CRF-CHO cells were stimulated with CRF and the receptor activation was evaluated by measuring the accumulation of cAMP.

10 CHO cells from a confluent T-flask were resuspended with culture medium without G418 and dispensed in a 96-well plate, 25'000c/well, 100 μ L/well and incubated overnight. After the incubation the medium was replaced with 100 μ L of cAMP IBMX buffer warmed at 37°C (5mM KCl, 5mM NaHCO₃, 154mM NaCl, 5mM HEPES, 2.3mM CaCl₂, 1mM MgCl₂; 1g/L glucose, pH 7.4 additioned by 1mg/mL BSA and 1mM IBMX) and 1 μ L of antagonist dilution in neat DMSO. After 10 additional minutes of incubation at 37°C in a plate incubator without CO₂, 1 μ L of agonist dilution in neat DMSO was added. As before, the plate was incubated for 10 minutes and then cAMP cellular content was measured by using the Amersham RPA 538 kit.


20 All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

It is to be understood that the present invention covers all combinations of particular and preferred groups described herein above.

25 The application of which this description and claims forms part may be used as a basis for priority in respect of any subsequent application. The claims of such subsequent application may be directed to any feature or combination of features described herein. They may take the form of product, composition, process, or use claims and may include, by way of example and without limitation, the following claims:

Claims

1. Compounds of formula (I) including stereoisomers, prodrugs and pharmaceutically acceptable salts or solvates thereof



wherein

10 R is aryl or heteroaryl, each of which may be substituted by 1 to 4 groups selected from: halogen, C1-C6 alkyl, C1-C6 alkoxy, halo C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halo C1-C6 alkoxy, -COR₄, nitro, -NR₉R₁₀ cyano, and a group R₅;

15 R₁ is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halo C1-C6 alkyl, halo C1-C6 alkoxy, halogen, NR₉R₁₀ or cyano;

R₂ is hydrogen, C3-C7 cycloalkyl, or a group R₆;

R₃ has the same meanings as R₂, but R₂ and R₃ may not be simultaneously hydrogen; or

20 R₂ and R₃ together with N form a saturated or unsaturated heterocycle, which may be substituted by 1 to 3 R₇ groups; or

R₂ and R₃ together with N form a 5-10 membered heteroaryl group, in which the 5-membered heteroaryl group contains at least one heteroatom selected from oxygen, sulphur or nitrogen and the 6-10 membered heteroaryl group contains from 1 to 3 nitrogen atoms and wherein said 5-10 membered heteroaryl may be substituted by 1 to 3 R₇ groups;

25 R₄ is a C1-C4 alkyl, -OR₉ or -NR₉R₁₀;

R₅ is a 5-6 membered heterocycle, which may be saturated or may contain one to three double bonds, and which may be substituted by 1 or more R₈ groups;

30 R₆ is a C1-C6 alkyl that may be substituted by one or more groups selected from: C3-C7 cycloalkyl, C1-C6 alkoxy, haloC1-C6 alkoxy, hydroxy, haloC1-C6 alkyl;

35 R₇ is a group R₅, a group R₆, C3-C7 cycloalkyl, C1-C6 alkoxy, hydroxy, halogen, nitro, cyano, C(O)NR₉R₁₀, phenyl which may be substituted by 1 to 4 R₈ groups;

R₈ is C1-C6 alkyl, halo C1-C2 alkyl, halogen, nitro, C1-C6 alkoxy or cyano;

R₉ is hydrogen or C1-C6 alkyl;

40 R₁₀ independently from R₉, has the same meanings;


X is carbon or nitrogen;
n is 1 or 2.

2. Compounds, according to claim 1, in which

5 R₂ and R₃ together with N form a saturated or unsaturated heterocycle, which may be substituted by 1 to 3 R₇ groups; or


10 R₂ and R₃ together with N form a 5-10 membered heteroaryl group, in which the 5-membered heteroaryl group contains at least one heteroatom selected from oxygen, sulphur or nitrogen and the 6-10 membered heteroaryl group contains from 1 to 3 nitrogen atoms and wherein said 5-10 membered heteroaryl may be substituted by 1 to 3 R₇ groups;

3. Compounds, according to claim 1, of general formula (Ia)




15 in which R, R₁, R₂, R₃ and X are defined as in claim 1.

4. Compounds, according to claim 3, of general formula (Ia-1)



20 in which R, R₁, R₂, and R₃ are defined as in claim 1.

5. Compounds, according to claim 3, of general formula (Ia-2)




25 in which R, R₁, R₂, and R₃ are defined as in claim 1.

6. Compounds, according to claim 4, in which the group NR₂R₃ represents a 5-6 membered heterocycle.

7. Compounds, according to claim 6, of general formula


77



in which R, R₁, and R₇ are defined as in claim 1.

8. Compounds, according to claim 6, of general formula


5



in which R, R₁, and R₇ are defined as in claim 1.

9. Compounds, according to claim 1, of general formula (Ib)


10



in which R, R₁, R₂, R₃ and X are defined as in claim 1.

10. Compounds, according to claim 9, of general formula (Ib-1)


15



in which R, R₁, R₂, and R₃ are defined as in claim 1.

11. Compounds, according to claim 9, of general formula (Ib-2)

20



in which R, R₁, R₂, and R₃ are defined as in claim 1.

12. Compounds, according to any of claims from 1 to 11, wherein

25

R₁ is C1-C3 alkyl group or halo C1-C3 alkyl group.

13. Compounds, according to any of claims from 1 to 12, wherein

R is an aryl group selected from: 2,4-dichlorophenyl, 2-chloro-4-methylphenyl, 2-chloro-4-trifluoromethyl, 2-chloro-4-methoxyphenyl, 2,4,5-trimethylphenyl, 2,4-dimethylphenyl, 2-methyl-4-methoxyphenyl, 2-methyl-4-chlorophenyl, 2-methyl-4-trifluoromethyl, 2,4-dimethoxyphenyl, 2-methoxy-4-trifluoromethylphenyl, 2-methoxy-4-chlorophenyl, 3-methoxy-4-chlorophenyl, 2,5-dimethoxy-4-chlorophenyl, 2-methoxy-4-isopropylphenyl, 2-methoxy-4-trifluoromethylphenyl, 2-methoxy-4-isopropylphenyl, 2-methoxy-4-methylphenyl, 2-trifluoromethyl-4-chlorophenyl, 2,4-trifluoromethylphenyl, 2-trifluoromethyl-4-methylphenyl, 2-trifluoromethyl-4-methoxyphenyl, 2-bromo-4-isopropylphenyl, 4-methyl-6-dimethylaminopyridin-3-yl, 3,5-dichloro-pyridin-2-yl, 2,6-bismethoxy-pyridin-3-yl and 3-chloro-5-trichloromethyl-pyridin-2-yl.

14. A compound, according to any of claims from 1 to 13, selected in a group consisting from:

[7-(2,4-dichlorophenyl)-2-methyl-6,7-dihydro-5*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]-(1-ethyl-propyl)amine;

[7-(2-bromo-4-isopropylphenyl)-2-methyl-6,7-dihydro-5*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]-(1-ethylpropyl)amine;

[7-(2,4-bis-trifluoromethylphenyl)-2-methyl-6,7-dihydro-5*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]-(1-propylbutyl)amine;

butyl-[7-(2,4-dichlorophenyl)-2-methyl-6,7-dihydro-5*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]ethylamine;

[7-(2-bromo-4-isopropylphenyl)-2-methyl-6,7-dihydro-5*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]-butylethylamine;

butyl-[7-(2-chloro-4-trifluoromethylphenyl)-2-methyl-6,7-dihydro-5*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]ethylamine;

[7-(2,4-bis-trifluoromethylphenyl)-2-methyl-6,7-dihydro-5*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]-butylethylamine;

[7-(2-chloro-4-trifluoromethylphenyl)-2-methyl-6,7-dihydro-5*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]cyclopropylmethylpropylamine;

[7-(2,4-bis-trifluoromethylphenyl)-2-methyl-6,7-dihydro-5*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]-cyclopropylmethylpropylamine;

[7-(2-bromo-4-isopropylphenyl)-2-methyl-6,7-dihydro-5*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]-cyclopropylmethylpropylamine;

cyclopropylmethyl[7-(2,4-dichlorophenyl)-2-methyl-6,7-dihydro-5*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]propylamine;

7-(2,4-dichlorophenyl)-4-(2-ethyl-piperidin-1-yl)-2-methyl-6,7-dihydro-5*H*-pyrrolo[2,3-*d*]pyrimidine;

7-(2,4-dichlorophenyl)-4-[(2*R*,5*R*)-2,5-dimethylpyrrolidin-1-yl]-2-methyl-6,7-dihydro-5*H*-pyrrolo[2,3-*d*]pyrimidine;

7-(2,4-dichlorophenyl)-2-methyl-4-(3-thiazol-2-yl-pyrazol-1-yl)-6,7-dihydro-5*H*-pyrrolo[2,3-*d*]pyrimidine;

- 7-(2,4-bis-trifluoromethylphenyl)-2-methyl-4-(3-thiazol-2-yl-pyrazol-1-yl)-6,7-dihydro-5H-pyrrolo[2,3-*d*]pyrimidine;
7-(2-bromo-4-isopropylphenyl)-2-methyl-4-(3-trifluoromethyl-pyrazol-1-yl)-6,7-dihydro-5H-pyrrolo[2,3-*d*]pyrimidine;
5 7-(2,4-dichlorophenyl)-4-(5-isopropyl-3-trifluoromethyl-pyrazol-1-yl)-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-*d*]pyrimidine and 7-(2,4-dichlorophenyl)-4-(3-isopropyl-5-trifluoromethyl-pyrazol-1-yl)-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-*d*]pyrimidine;
7-(2,4-dichlorophenyl)-4-(3-ethyl-5-trifluoromethylpyrazol-1-yl)-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-*d*]pyrimidine;
10 7-(2,4-dichlorophenyl)-4-(3,5-dimethylpyrazol-1-yl)-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-*d*]pyrimidine;
7-(2,4-dichlorophenyl)-4-(3-dimethoxymethyl-pyrazol-1-yl)-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-*d*]pyrimidine;
7-(2,4-dichlorophenyl)-4-(3-ethyl-5-trifluoromethylpyrazol-1-yl)-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-*d*]pyrimidine;
15 4-(4-bromo-3-methyl-pyrazol-1-yl)-7-(2,4-dichlorophenyl)-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-*d*]pyrimidine;
4-(4-bromopyrazol-1-yl)-7-(2,4-dichlorophenyl)-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-*d*]pyrimidine;
20 7-(2,4-dichlorophenyl)-4-[3-(4-chlorophenyl)-pyrazol-1-yl]-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-*d*]pyrimidine;
7-(2,4-dichlorophenyl)-4-[3-(2-nitrophenyl)-pyrazol-1-yl]-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-*d*]pyrimidine;
7-(2,6-dimethoxy-pyridin-3-yl)-2-methyl-4-(3-thiazol-2-yl-pyrazol-1-yl)-6,7-dihydro-5H-pyrrolo[(2,3-*d*)]pyrimidine;
25 7-(2,4-bis-trifluoromethyl-phenyl)-2-methyl-4-(3-morpholyn-4-yl-pyrazol-1-yl)-6,7-dihydro-5H-pyrrolo[(2,3-*d*)]pyrimidine;
7-(2,4-bis-trifluoromethyl-phenyl)-2-methyl-4-(3-pyridin-3-yl-pyrazol-1-yl)-6,7-dihydro-5H-pyrrolo[(2,3-*d*)]pyrimidine;
30 7-(2,4-bis-trifluoromethyl-phenyl)-2-methyl-4-(3-pyrazin-2-yl-pyrazol-1-yl)-6,7-dihydro-5H-pyrrolo[(2,3-*d*)]pyrimidine;
7-(2,4-bis-trifluoromethyl-phenyl)-2-methyl-4-(3-oxalol-5-yl-pyrazol-1-yl)-6,7-dihydro-5H-pyrrolo[(2,3-*d*)]pyrimidine;
7-(2,4-dichlorophenyl)-2-methyl-4-(3-trifluoromethyl-(1,2,4)triazol-1-yl)-6,7-dihydro-5H-pyrrolo(2,3-*d*)pyrimidine;
35 butyl-[7-(2,4-dichlorophenyl)-2-methyl-6,7-dihydro-5H-cyclopentapyrimidin-4-yl]-ethyl-amine;
cyclopropylmethyl[7-(2,4-dimethoxyphenyl)-2-methyl-6,7-dihydro-5H-cyclopentapyrimidin-4-yl]-propyl-amine;
40 cyclopropylmethyl[7-(2,4-dichlorophenyl)-2-methyl-6,7-dihydro-5H-cyclopentapyrimidin-4-yl]-propylamine;
7-(2,4-dichlorophenyl)-4-[(2R,5R)-2,5-dimethylpyrrolidin-1-yl]-2-methyl-6,7-dihydro-5H-cyclopentapyrimidine;


7-(2,4-dichlorophenyl)-4-[(2R,5R)-2,5-dimethylpyrrolidin-1-yl]-2-methyl-6,7-dihydro-5H-cyclopentapyrimidine;

[8-(2,4-bis-trifluoromethylphenyl)-2-methyl-5,6,7,8-tetrahydropyrido[2,3-*d*]pyrimidin-4-yl](1-propylbutyl)amine;

5 butyl-[8-(2,4-dichlorophenyl)-2-methyl-5,6,7,8-tetrahydropyrido[2,3-*d*]pyrimidin-4-yl]-ethylamine;


cyclopropylmethyl[8-(2,4-dichlorophenyl)-2-methyl-5,6,7,8-tetrahydropyrido[2,3-*d*]pyrimidin-4-yl]propylamine.

10 13. A process for the preparation of a compound of formula (I) as claimed in claim 1, which comprises the reaction of a compound of formula (II), wherein L is a leaving group,



15 with the amino compound R_2R_3NH (III), wherein R, R_2 and R_3 are defined as in claim 1, followed where necessary or desired by isolation of the compound as salt thereof.


14. A process, according to claim 13, for preparing compounds of formula (IIa),



20 which are equivalent to compounds of formula (II) wherein X is nitrogen, comprising the following steps:

- i) activation of the hydroxy group of compounds of formula (IV), wherein p is 1 or 2, R_a is a suitable protecting group for the amino group, R and R_1 are defined as in claim 1, by conversion into a suitable leaving group;
- 25 ii) deprotection of the amino protecting group ;
- iii) cyclisation.

15. A process, according to claim 13, for preparing compounds of formula (IIb),



which are equivalent to compounds of formula (II) in which X is carbon, comprising the conversion of the hydroxy group of compounds of formula (XIV) into a leaving group, wherein R and R₁ are defined as in claim 1.

5 16. The use of a compound according to any of claims from 1 to 12, in the preparation of a medicament for use in the treatment of conditions mediated by CRF (corticotropin-releasing factor).

10 17. The use of a compound according to claim 16, in the preparation of a medicament for use in the treatment of depression and anxiety.

18. The use of a compound according to claim 16, in the preparation of a medicament for use in the treatment of IBS (irritable bowel disease) and IBD (inflammatory bowel disease).

15 19. A compound according to any of claims 1 to 12, for use in the treatment of conditions mediated by CRF (corticotropin-releasing factor).

20 20. A compound according to claim 19, for use in the treatment of depression and anxiety.

21. A compound according to claim 19, for use in the treatment of IBS (irritable bowel disease) and IBD (inflammatory bowel disease).

25 22. A pharmaceutical composition comprising a compound according to any of claims from 1 to 12, in admixture with one or more physiologically acceptable carriers or excipients.

30 23. A method for the treatment of a mammal, including man, in particular in the treatment of conditions mediated by CRF (corticotropin-releasing factor), comprising administration of an effective amount of a compound according to any of claims from 1 to 12.

24. A method, according to claim 23, in the treatment of depression and anxiety, comprising administration of an effective amount of a compound according to any of claims 1 to 12.

35 25. A method, according to claim 23, in the treatment of IBS (irritable bowel disease) and IBD (inflammatory bowel disease), comprising administration of an effective amount of a compound according to any of claims 1 to 12.

INTERNATIONAL SEARCH REPORT

Internl I Application No
PCT/GB 02/02029

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D239/70 A61K31/517 C07D487/04 C07D471/04 A61K31/519
A61P25/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	EP 1 097 709 A (PFIZER PROD INC) 9 May 2001 (2001-05-09) claim 10 page 48, line 32 - line 46 ---	1-25
P, X	EP 1 149 583 A (PFIZER PROD INC) 31 October 2001 (2001-10-31) claim 9 page 52, line 10 - line 21 ---	1-25
X	EP 1 082 960 A (PFIZER PROD INC) 14 March 2001 (2001-03-14) see structure VIII on page 12/13 page 22, line 6 - line 19 --- -/--	1-25

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

4 July 2002

Date of mailing of the international search report

22/07/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5618 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Kollmannsberger, M

INTERNATIONAL SEARCH REPORT

Interr Application No
PCT/GB 02/02029

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 08846 A (PFIZER ;CHEN YUHPYNG LIANG (US)) 5 March 1998 (1998-03-05) cited in the application claim 1 ---	1-25
X	WO 95 33750 A (PFIZER ;CHEN YUHPYNG L (US)) 14 December 1995 (1995-12-14) cited in the application compounds of structure II, see claim 1 page 40; example 20 ---	1-25
A	MCCARTHY J R ET AL: "RECENT ADVANCES WITH THE CRF1 RECEPTOR: DESIGN OF SMALL MOLECULE INHIBITORS, RECEPTOR SUBTYPES AND CLINICAL INDICATIONS" CURRENT PHARMACEUTICAL DESIGN, BENTHAM SCIENCE PUBLISHERS, SCHIPHOL, NL, vol. 5, no. 5, 1999, pages 289-315, XP000882142 ISSN: 1381-6128 the whole document ---	1-25
A	CHRISTOS ET AL: "Corticotropin-releasing factor antagonists" EXPERT OPINION ON THERAPEUTIC PATENTS, ASHLEY PUBLICATIONS, GB, vol. 8, no. 2, February 1998 (1998-02), pages 143-152, XP002109498 ISSN: 1354-3776 the whole document -----	1-25

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB 02/02029

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 23-25 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: 1-25 (in part)
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-25 (in part)

The present claims partly relate to compounds defined by reference to a desirable characteristic or property, namely their ability of being metabolized in vivo to compounds structurally defined in the claims ("prodrugs") without giving technical (i. e. structural) information how to achieve this goal.

Since in-vivo-tests would have to be carried out to determine which compounds are included in this definition and it cannot be readily determined if e. g. existing compounds of the prior art may be metabolized in vivo to compounds structurally defined in the present claims, in this respect an unclarity results to such an extent (Art. 6 PCT) that a meaningful search and comparison with the prior art is impossible. The search has thus been limited to compounds structurally defined in the claims.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inter

Application No

PCT/GB 02/02029

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 1097709	A	09-05-2001	AU 6669500 A EP 1097709 A2 HU 0004194 A2	03-05-2001 09-05-2001 28-12-2001
EP 1149583	A	31-10-2001	BR 0101456 A EP 1149583 A2 US 2001041673 A1	04-12-2001 31-10-2001 15-11-2001
EP 1082960	A	14-03-2001	AU 5364400 A EP 1082960 A2 HU 0003386 A2 JP 2001097889 A	01-03-2001 14-03-2001 30-07-2001 10-04-2001
WO 9808846	A	05-03-1998	AU 726771 B2 AU 3355797 A BG 103192 A BR 9711262 A CN 1228091 A CZ 9900677 A3 EP 0925298 A1 HR 970452 A1 WO 9808846 A1 JP 2000502722 T NO 990892 A NZ 333728 A PL 331988 A1 SK 22599 A3 TR 9900408 T2 ZA 9707652 A	23-11-2000 19-03-1998 30-09-1999 17-08-1999 08-09-1999 17-11-1999 30-06-1999 31-08-1998 05-03-1998 07-03-2000 25-02-1999 24-11-2000 16-08-1999 11-07-2000 21-05-1999 26-02-1999
WO 9533750	A	14-12-1995	AT 196295 T AU 692548 B2 AU 2453095 A BR 9502708 A CA 2192354 A1 CN 1150428 A ,B CN 1246475 A CZ 9603608 A3 DE 69518841 D1 DE 69518841 T2 DK 764166 T3 EP 0764166 A1 ES 2150567 T3 FI 964894 A HR 950321 A1 HU 75774 A2 WO 9533750 A1 JP 2000001434 A JP 3223169 B2 JP 11246411 A JP 9507249 T JP 3193055 B2 NO 965237 A NO 2391 A NZ 285442 A PL 320631 A1 PT 764166 T SK 155596 A3	15-09-2000 11-06-1998 04-01-1996 30-04-1996 14-12-1995 21-05-1997 08-03-2000 14-07-1999 19-10-2000 11-01-2001 09-10-2000 26-03-1997 01-12-2000 05-12-1996 28-02-1998 28-05-1997 14-12-1995 07-01-2000 29-10-2001 14-09-1999 22-07-1997 30-07-2001 06-02-1997 06-02-1997 27-05-1998 13-10-1997 31-01-2001 11-12-2000

INTERNATIONAL SEARCH REPORT

information on patent family members

Internat^l Application No
PCT/GB 02/02029

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9533750	A	US 5962479 A ZA 9504677 A	05-10-1999 09-12-1996
<hr/>			